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1 Abstract 
Rhabdomyosarcoma (RMS) are the most common pediatric soft tissue sarcomas. RMS of 
the embryonal subtype (ERMS) are characterized by high expression of markers of an 
activated Hedgehog (HH) signaling cascade, i.e. they overexpress GLI1, GLI2 and PTCH. 
However, they very infrequently show pathway-activating mutations e.g. in PTCH, although 
inherited PTCH/Ptch mutations act as ERMS-drivers both in humans and mice. This is 
different for oncogenic mutations in the 3 RAS genes (H-, K-and NRAS; oncRAS), which are 
a very common in ERMS. Since the literature provides evidence for crosstalks between HH 
and RAS signaling in other tumor entities, this thesis aimed at a better understanding of a 
potential interaction of HH and RAS signaling in ERMS and of their roles in ERMS 
pathogenesis, growth and aggressiveness. This is particulary important for improvement of 
treatment strategies, which currently show only moderate efficiencies and sometimes cause 
severe side effects. 
First, the role of oncRAS isoforms in regulation of HH targets and associated cellular 
responses were studied in human cell lines derived from sporadic (full-blown) ERMS. The in 
vitro data from TE617.T, RUCH-2 and RD highlight that oncRAS isoforms decrease the 
expression of the major HH-target GLI1 in dependency of ERK. GLI1 downregulation was 
also seen on protein level in both the nucleus and cytoplasm. This indicates that 
oncRAS/ERK probably act on GLI1 transcription. In addition, oncRAS/ERK also regulate the 
expression of other HH pathway members e.g. of SHH, PTCH and GLI2, which however 
depends on the oncRAS isoform and the individual cell line. Although oncRAS mutations can 
modify the expression of SHH, the cell lines are in all likeliness not able to secrete 
HH ligands and are not HH-responsive. Together, this supports an oncRAS-mediated non-
canonical suppression of HH signaling, or at least of GLI1/GLI1 expression, in sporadic 
ERMS.  
Interestingly, oncRAS isoforms increase proliferation and tumorigenicity of ERMS cell lines 
despite downregulation of GLI1/GLI1. This indicates that proliferation of the cells is 
independent of HH signaling or at least of GLI1/GLI1. Since oncRAS-mediated GLI1-
downregulation is only moderate in xenografts, it is likely that the tumor microenvironment 
also influences HH signaling. 
OncKRas and oncHRas also aggravate formation of Hh/Ptch-driven ERMS from 
heterozygous Ptchdel/+ mice. This is in contrast to oncNRas, which induces expression of 
myogenic markers without otherwise affecting the tumor. This suggests that the 3 oncRas 
isoforms have divergent functions in ERMS, at least in Hh/Ptch-driven tumors. Interestingly, 
these oncRas-mediated changes are only seen when the oncRas genes are expressed at a 
2 | ABSTRACT 
very early ERMS stage, i.e. in ERMS precursor lesions. However, they do not occur when 
the mutations are induced at the full-blown tumor stage. Since, according to the literature, 
oncRas mutations themselves do not drive ERMS formation and since none of the oncRas 
genes significantly influence Hh signaling activity in Hh/Ptch-driven ERMS, these findings 
open the possibility that the mutational status of PTCH/Ptch may influence the importance of 
oncRAS mutations in ERMS. On the other hand it is possible that oncRAS mutations are 
rather passenger mutations, which only affect already initiated ERMS precursor cells and/or 
cancer stem cells (CSCs), but not the ERMS bulk populations. Indeed, a preliminary analysis 
shows that cell lines from sporadic (full-blown) ERMS have a subpopulation, which is positive 
for the CSC marker CD133. Of whether full-blown ERMS of heterozygous Ptchdel/+ mice lack 
this population is not clear at the moment and further experiments need to be done to shed 
light on these hypothesis. Together, these interesting results help to better understand the 
pathology of ERMS and hopefully will also be valuable to improve current therapies for this 
childhood sarcoma. 
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2 Introduction 
2.1 Rhabdomyosarcoma 
Soft tissue sarcomas are a very heterogeneous group of over 50 rare tumor entities that 
occur throughout the lifespan 1. They account for about 2 % of malignant tumors in adults 
and 7 % of pediatric malignancies 2,3. In children, rhabdomyosarcoma (RMS) account for 
approximately 50 % of all soft tissue tumors and thereby are the third most common 
extracranial solid tumor 3,4. RMS have an incidence of 4.5 cases per million children per year 
and most frequently occur in children younger than 10 years of age 5. 
Originally RMS were thought to develop from cells committed to the skeletal muscle lineage, 
because they frequently show aberrant muscle differentiation and develop in the skeletal 
muscle. However, since these tumors can also arise from other anatomic sites, such as the 
genitourinary region, it is thought that they rather are of mesenchymal origin 1,6-8. 
RMS represent a heterogeneous group of soft tissue sarcomas. They can be divided into 
several histopathological subtypes, which differ in their clinical and morphological phenotype 
and molecular features. The current classification from the World Health Organization (WHO) 
divides RMS into alveolar RMS (ARMS), which are characterized by tumor cells separated 
by thin fibrovascular septa and embryonal RMS (ERMS) with small round blue cells and 
partial rhabdomyoblastic differention. ERMS can also show botryoid and pleomorphic growth 
patterns. Other RMS variants are pleomorphic RMS (PRMS), and sclerosing/spindle cell 
RMS (SRMS) 5,9-11. The two major RMS subtypes in children are ARMS and ERMS and they 
differ in their prevalence, clinical features and outcome 6. 
ARMS account for approximately one-third of all RMS and frequently occur in adolescents. 
They are found most commonly in the deep tissue of the extremities and show an alveolar 
pattern in histology 5. On molecular level they can be divided into fusion-positive and fusion-
negative tumors. Fusion-positive ARMS (75 %) show chromosomal translocations 
[t(2;13)(q35,q14) or t(1;13)(p36;q14)] leading to Forkhead box protein O (FOXO)1-Paired box 
gene (PAX)3/PAX7 fusion proteins, which contribute to pathogenesis 12. Fusion-negative 
ARMS, lacking PAX-FOXO1 fusion proteins, are clinically and biologically similar to ERMS 13. 
ERMS account for approximately two-thirds of all RMS and occur mainly in young children. 
Histologically, they resemble undifferentiated embryonic mesenchyme with isolated immature 
myoblastic cells. They are often found in the head and neck region and in the genitourinary 
tract 5. Whole-genome sequence projects reveal that ERMS in general possess a higher 
background mutation rate than ARMS 14,15. On molecular level, ERMS frequently show loss 
of heterozygosity (LOH) at chromosome 11p15, which is the locus of Insulin-like growth 
factor 2 (IGF2) 4. In addition, mutations in the rat sarcoma (Ras) signaling pathway (NRAS, 
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KRAS, HRAS and Neurofibromin 1(NF1)) are frequently described for ERMS 5,6,15 (compare 
section 2.3.4). Moreover, they can carry mutations in Myogenic differentiation antigen 
(MYOD), Fibroblast growth factor receptor (FGFR)4, catalytic Phosphoinositide-3-kinase 
alpha polypeptide (PIK3CA), Catenin beta 1 (CTNNB1) genes and in the tumour suppressor 
genes tumor protein 53 (TP53) and Retinoblastoma (RB)1. However and in contrast to 
ARMS, they are always fusion-negative 6,8,16. 
RMS have been associated with several hereditary diseases. These include hereditary 
retinoblastoma, neurofibromatosis type 1, Li–Fraumeni syndrome, Rubinstein–Taybi 
syndrome, Beckwith–Wiedemann syndrome, Costello syndrome, Noonan syndrome and 
Gorlin (basal cell carcinoma nevus) syndrome 8,17-22. However, most cases of RMS are 
considered sporadic in their origin 8,20. 
2.1.1 Current prognostics and therapy strategies 
The tumor size, age at diagnosis, histological type, tumor stage and already conducted 
therapies are significantly associated with the overall survival of RMS. In general, patients 
with RMS show a 10-year overall survival rate of 62 %. More precisely, the rates range 
between 75 % for fusion-negative ARMS, 65 % for ERMS and 20 % for fusion-positive 
ARMS 13,23. This highlights that fusion-positive ARMS are associated with a poorer prognosis 
than ERMS and fusion-negative ARMS. 
RMS are considered a systemic disease with the possibility of micro- and macrometastasis, 
which are found in 46 % of fusion-positive RMS and 17 % of fusion-negative RMS 1,13,24. 
Thus an effective treatment should not only target the primary tumor but also distant tumor 
seeds. The currently available multimodal therapy, which encompasses surgery, radiation 
and chemotherapeutic drugs, leads to the recovery of 60 % of all RMS patients. However, 
less than 30 % of high-risk patients (metastatic or fusion-positive tumors, adults) are 
cured 13,25. In addition, many patients suffer from adverse side effects and treatment-related 
late effects 8. Thus, more effective and less harmful therapy options are needed, which 
requires a better understanding of biology and molecular mechanisms of RMS pathogenesis. 
2.2 The Hedgehog signaling pathway  
The Hedgehog (Hh) ligand and its receptor Patched (Ptch) were first discovered in a 
mutational screen in larvae of Drosophila melanogaster. The mutations in the respective 
genes lead to segmentation defects, which in case of Hh results in a surface reminding of 
hedgehog spines 26. A few years later, Hh was shown to influence pattern formation in 
surrounding cells in a paracrine manner 27-29.  
Today it is known, that the Hh signaling pathway is one of the most important signal 
transduction pathways during embryonic development. In general, Hh signaling is quiescent 
in the adult organism but it is implicated in cell differentiation, stem cell maintenance, 
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metabolic homeostasis, tissue homeostasis and repair 30,31. As a consequence, pathological 
activation of the pathway plays a crucial role in initiation and formation of various cancers 32. 
2.2.1 Canonical Hh signaling 
In mammals 3 Hh homologs, namely Indian Hedgehog (Ihh), Desert Hedgehog (Dhh) and 
Sonic Hedgehog (Shh), with distinct expression patterns were discovered 33. Shh, the best 
studied Hh ligand, has a high functional similarity to Hh of Drosophila. It affects cells of the 
developing embryo, especially during formation of the ventral neural tube, the anterior-
posterior limb axis and the ventral somites. Furthermore and as already said, it controls 
tissue homeostasis, stem cell maintenance and differentiation processes of mesenchymal 
cells in adults 33,34. Ihh is involved in chondrogenesis, whereas Dhh regulates germ-cell 
proliferation and development of peripheral nerves. Dhh is also expressed in adult 
nerves 33,35-37. Hh proteins are synthesized as precursors and are matured by autocatalytic 
cleavage and posttranslational modifications. Thus, a cholesterol moiety is attached to the N-
terminal product and thereby restricts the ligand to the cell surface. If required for signaling, 
the processed Hh ligands are secreted with the help of the transmembrane protein 
Dispatched (DISP) 32,38-40. 
Two Ptch homologs Patched1 (Ptch) and Patched 2 (Ptch2) are present in mammals. Ptch is 
a 12-pass transmembrane protein and the major Hh receptor. It has 2 extracellular loops, 
which are required for Hh binding, a cytoplasmic C-terminus that is involved in signal 
transduction and a sterol-sensing domain that mediates the intracellular trafficking of Ptch. It 
constitutively represses Hh signaling and thereby acts as a tumor suppressor 41-43. The 
binding of Hh ligands to Ptch is supported by its co-receptors Cell adhesion molecule-
related/downregulated by oncogenes (Cdo), Brother of Cdo (Boc) and Growth arrest specific 
1 (Gas1) 44. In its unbound state, Ptch is localized in the primary cilium und suppresses the 
activity of its interaction partner Smoothened (Smo) via a poorly understood mechanism 45. 
Smo is a seven transmembrane receptor of the G-protein-coupled receptor (GPCR) 
superfamily 46,47. Its activation triggers processing and modifications of glioma-associated 
oncogene (Gli) proteins (Cubitus interruptus in Drosophila melanogaster) and thereby the 
activity of the Hh signaling cascade 42. 
The Gli proteins act as activator or repressor of transcription, which is reliant on the 
availability of Hh ligands 48,49. Gli1 is a transcriptional target of Hh signaling and provides a 
positive feedback loop in the pathways activity, whereas Gli2 and Gli3 are the main 
mediators of Hh signaling 50. Gli2 and Gli3 are bifunctional transcription factors, which can 
act as full length activator forms (GliA) or truncated repressor forms (GliR). The activator 
forms are stabilized in the presence of Hh ligands. Gli proteins are processed into their 
truncated repressor forms when Hh ligands are absent. The balance between activator and 
repressor forms is very important for the regulation of Hh signaling activity 51-53. The 
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processing into truncated Gli proteins is triggered by phosphorylation of amino acids that are 
located N-terminally or C-terminally of the DNA binding domain. Strong phosphorylation of 
both regions promotes the processing into truncated GliR forms or triggers degradation. 
Partially phosphorylated Gli proteins are processed and act as weak GliA (phosphorylation C-
terminally of the DNA binding domain) or weak GliR (phosphorylation N-terminally of the DNA 
binding domain). Dephosphorylated Gli proteins are not processed and act as strong 
GliA 54,55. Since Gli1 misses the N-terminal region after the zinc-finger DNA binding domain, it 
is supposed to act only as a GliA form. Gli1 and Gli2 have strong activator functions when 
present as the full length GliA form. Gli2 can be processed into a GliR form with low efficiency 
in mouse embryos and it is therefore considered to have a weak repressor activity 56. In 
contrast, full-length Gli3 protein, which acts as a weak GliA form especially in early 
developmental processes like spinal cord patterning and sclerotome development 56-58, is 
efficiently processed into its truncated GliR form that acts as a strong transcriptional 
repressor. 
A simplified scheme of the Hh pathway is shown in Figure 1 (Fig. 1). Fig. 1A shows the 
pathway in its inactive state, whereas Fig. 1B shows the active pathway upon binding of the 
Hh ligand.  
In the absence of Hh ligands, Ptch is located in the primary cilium of the cell where it 
represses the activity of its interaction partner Smo 45. The Gli proteins are prevented from 
entering the nucleus through interactions with the serine/threonine kinase fused (Fu) and 
suppressor of fused (Sufu) 59. The Gli proteins are phosphorylated, which results in their 
proteolytic cleavage to truncated Gli3R proteins. GliR proteins, mainly Gli3R, translocate into 
the nucleus and repress target gene transcription. In addition, surplus Gli proteins are 
ubiquitinated and subsequently proteasomally degraded 60,61. 
Upon binding of Hh ligands, Ptch is inactivated and its inhibitory effect on Smo is abrogated. 
This results in enrichment of Smo in the primary cilium. As a consequence Sufu is degraded 
and releases Gli proteins 62,63. The Gli proteins are dephosphorylated and stabilized in their 
full length GliA form. Thereupon, GliA proteins, mainly Gli2A, translocate into the nucleus and 
activate the transcription of Hh target genes 42,49,64. Among others, the mammalian Hh target 
genes include Gli1, Ptch and Hh interacting protein (Hhip). Additionally, Gli proteins can 
regulate genes implicated in proliferation (Igf2, Platelet-derived growth factor receptor 
(Pdgfr), myelocytomatosis virus oncogene cellular homolog (Myc)), cell cycle progress and 
apoptosis (Cyclin D1, Cyclin D2, N-Myc, B-cell lymphoma (Bcl) 2), angiogenesis (Vascular 
endothelial growth factor (Vegf), Angiopoietin (Ang)1/2), epithelial-mesenchymal transition 
(Matrix metalloproteinase (Mmp)9, Snail) or in regulation of stem cells (Nanog, (sex 
determining region Y)-box 2 (Sox2)) 31,32,42,60,65-67. However, the most reliable and robust 
readout of an active Hh signaling pathway is considered to be Gli1 expression 46,68,69. The 
activity of the Hh signaling pathway is not only regulated by its ligands, but partly also 
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through its targets genes. Whereas expression of Gli1 amplifies the Hh signal, expression of 
Ptch and Hhip decreases the signal in a negative feed-back loop. 
 
Figure 1: The Hh signaling pathway 
(A) In the absence of its ligands the Hh signaling pathway is inactive. The transmembrane protein receptor 
Patched (Ptch) inhibits the activity of its interaction partner Smoothened (Smo). As a consequence, the glioma-
associated oncogene (Gli) transcription factors, which are downstream targets of Smo, are kept in the cytoplasm 
by interaction with suppressor of fused (Sufu). Gli proteins are processed and act in their truncated repressor 
forms (Gli
R
), which block target gene expression. Additionally, Gli proteins are proteasomally degraded. 
Consequently, transcription of Hh target genes is repressed. (B) Hh ligands bind to their receptor Ptch. This 




translocates into the nucleus and activates the transcription of Hh target genes. One of these targets is Gli1, 
which can amplify the Hh signal and provides a reliable marker of the pathway’s activity. Additionally, Hh siganling 
promotes proteasomal degradation of Gli inhibitor Sufu. For more details see text. Modified according to 
32
. 
2.2.2 Non-canonical Hh signaling 
Besides canonical regulation (see section 2.2.1), Hh signaling can be regulated in a non-
canonical manner. Non-canonical Hh signaling is divided into signaling processes, which do 
not require Smo (see section 2.2.2.1) and those which do not require Gli transcription factors 
(see section 2.2.2.2) 70. 
2.2.2.1 Smo-independent Hh signaling 
Smo-independent Hh signaling summarizes the regulation of expression, stability and 
transcriptional activity of Gli transcription factors by interaction with other signaling pathways 
or regulatory proteins. Smo-independent regulation of Gli proteins by other oncogenes and 
tumor suppressors is particularly involved in cancers 51,52,69,71. 
The tumor suppressor p53 can inhibit Gli transcriptional activity because it can hamper the 
nuclear localisation of Gli1. This has been shown in melanoma 72. Vice versa, Gli1 can also 
repress the activity of p53 in mouse embryonic fibroblasts by upregulation of the p53 inhibitor 
Mouse double minute 2 homolog (Mdm2). This results in degradation of p53 73. 
The transforming growth factor β (Tgfβ) can indirectly induce Gli1 and Gli2 expression in 
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different cell lines without involving the Ptch/Smo axis. Thus, activation of Tgfβ can 
cooperate with Smad3 or β-catenin, which in turn bind to the Gli2 promotor and thereby 
regulate the activation of Gli2 and Gli1 74. 
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ protein kinase B (Akt)/ 
mammalian target of rapamycin (mTOR) signaling cascade can enhance nuclear localization 
and transcriptional activity of Gli1 and Gli2 in different human an murine model systems 75-78. 
Thus, activated mTOR/Small subunit ribosomal protein S6 kinase beta (S6K1) signaling 
downstream of PI3K/Akt can modify phosphorylation and enhance activity of Gli1 79. 
Additionaly, AKT1 itself is a transcriptonal target of the HH signaling cascade in B-cell 
lymphoma. This connection is a hint for a regulatory feed-back mechanism between Akt and 
Hh signaling 80. 
Furthermore, the dual-specificity tyrosine-(Y)-phosphorylation-regulated kinases (Dyrk) 1A 
and 1B and also Dyrk2 can regulate Gli1 and Gli2 activity by phosphorylation 81-83. As already 
mentioned above, phosphorylation of Gli proteins leads to processing into the respective GliA 
or GliR forms 54. Dyrk1A can phosphorylate GLI1, which promotes its nuclear localization 81,82. 
Dyrk1B was reported to either inhibit or stimulate Hh signaling, dependent on the Dyrk1B 
expression level and the used model systems 84-87. It was suggested that Dyrk1B activates 
mTOR/Akt, which promotes Gli1 stabilization 87. Finally, Dyrk2 can phosphorylate Gli2, 
thereby inducing its degradation in mouse embryonic fibroblasts and COS1 cells 83. 
Finally, oncogenic Ras (oncRas) isoforms can directly influence Gli transcription factors with 
diverse outcomes in different tumor entities. This is reviewed in detail in section 2.4. 
2.2.2.2 Gli-independent Hh signaling 
The Hh receptor Ptch can regulate cell survival through apoptosis induction. This does not 
involve Hh ligands, Smo or Gli, but the formation of a caspase-activating complex 88,89. 
Furthermore, Ptch can regulate cell cycle progression through interaction with Cyclin B1 
without the involvement of the Smo/Gli axis 90,91. 
In addition, Hh ligands can alter cell morphology and migratory capacity without Gli 
transcription activity in murine and human cells. However, this requires Smo activity, which in 
turn can activate PI3K or small guanosine triphosphate (GTP)ases like RhoA resulting in 
cytoskeletal changes 89,92. The Smo-mediated cytoskeletal rearrangements and migration 
requires the metabolism of arachidonic acid through the 5-lipoxygenase pathway 92,93. 
Moreover, Shh can stimulate Src kinases to control guidance of murine commissural axons. 
This also requires Smo, but not Gli proteins 94. Additionally, Shh stimulates intracellular Ca2+ 
spike activity in neurodevelopment 95. Vice versa, intracellular Ca2+ release and Protein 
kinase c (Pkc) activation can stimulate Shh gene expression 96 and these activities do not 
require Gli proteins. Finally, Smo can trigger intracellular signaling via second messengers 
like Ca2+ and cyclic adenosine monophosphate (cAMP) 97. Indeed, Smo is supposed to 
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influence physiological Ca2+ fluctuation and Ca2+-dependent signaling pathways in a Gli-
independent manner 96. Moreover, Smo, Ca2+ and cAMP are involved in Warburg-like 
metabolic reprogramming in muscles and brown fat 98. 
2.2.3 Canonical HH signaling in human cancer 
Several cancers are caused by pathological activation of the Hh signaling pathway. Indeed, 
the first link between a predisposition to tumors and mutations within the HH signaling 
pathway was the discovery of PTCH mutations in patients with Gorlin syndrome 99-102. 
Besides developmental defects, patients with Gorlin syndrome develop basal cell carcinoma 
(BCC) and have an increased risk of developing other cancers such as medulloblastomas 
(MB), RMS, fibromas, glioma and meningioma 21,66,102-107. 
Subsequently, aberrant activation of the HH signaling cascade due to inactivating mutations 
in PTCH or SUFU, activating mutations in SMO or mutations of other HH pathway molecules 
have been shown in the majority of both familial and sporadic forms of BCC and a subset of 
MB 108-117. In the latter cancer entity a signature of the HH pathway activation status (GLI1, 
SPHK1, SHROOM2, PDLIM3, OTX2) has been established and serves as a diagnostic tool 
in the treatment of these tumors with HH inhibitors 118. In addition, mutations in members of 
the HH signaling pathway have also been reported in other cancers associated with Gorlin 
syndrome, including RMS (see section 2.2.4) and meningiomas 119,120. 
Thereupon, pathological activation of HH signaling was detected in a huge variety of other 
cancer types. As in BCC and MB, the dysregulation of the signaling pathway can be 
mutation-driven (Fig. 2A). However, it also can be ligand-driven (Fig. 2B) or can be 
dysregulated due to amplification of GLI (Fig. 2C). This dysregulation can occur 
tumorintrinsically or in the surrounding stromal tissue, or in both. 
Examples for mutation-driven HH-associated tumors are BCC and MB, as already said. In 
contrast, lymphomas are ligand-driven tumors and show constitutive activation of the HH 
pathway due to overexpression of SHH 121. Similarly, the expression of SHH and GLI1 is 
increased in a subset of small lung cell carcinoma 122. An amplification of GLI transcription 
factors has been described in glioblastoma, BCC and bladder cancer 123-125.  
However, in the majority of tumor entities showing HH signaling activity, both mutations and 
overexpression of the ligands can be responsible for pathological activation of the pathway. 
For example tumors of the foregut, oesophagus, stomach and biliary tract can either show an 
increased level of SHH or IHH or genetic alterations in PTCH, SMO or SUFU 126,127. In a 
subgroup of pancreatic adenocarcinoma and its precursor lesions, HH ligands are 
abnormally expressed or the HH signaling cascade is deregulated due to overexpression of 
PTCH 128. Overexpression of HH ligands is also frequently observed in bladder cancer, which 
also can show amplification of GLI1 or overexpression of GLI2 129,130. A subset of melanoma 
has mutations in PTCH, SMO, SUFU, GLI1 or GLI2. In addition, the vascularization of these 
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tumors is regulated by SHH 75,131-133. In a subset of advanced human prostate cancers, 
activation of the HH pathway occurs due to HH ligands that act in an autocrine or paracrine 
manner. In another subset this is due to mutations in PTCH and HHIP 125,134. Similarly, the 
HH signaling pathway is activated due to mutations in PTCH or SUFU in a subset of breast 
cancer patients 135 and overexpression of SHH, GLI1 or PTCH 136 is associated with poor 
prognosis 136. 
 
Figure 2: Canonical HH signaling in human cancer 
Pathological activation of the HH signaling pathway plays a role in initiation, formation and progression of tumors 
(for details, see text). (A) Mutation-driven activation of the HH signaling pathway can be due to loss of function 
mutation in PTCH or gain of function mutations in SMO, which results in a permanent activation of the pathway. 
(B) Ligand-dependent dysregulation of the HH signaling pathway occurs due to overexpression of HH ligands. (C) 
Amplification-driven activation of the HH signaling pathway occurs due to amplification of GLI, which results in 
higher level of the respective proteins. 
Taken together, a pathological activation of the canonical Hh signaling pathway can be 
caused by several mechanisms. These include mutations in members of the Hh signaling 
pathway (Fig. 2A), overexpression of Hh ligands (Fig. 2B) or amplification of Glis (Fig. 2C). 
Besides these modifications, Gli activity and thus Hh signaling can also be regulated in a 
non-canonical manner (see section 2.2.2). 
2.2.4 Hh signaling and RMS 
The spectrum of tumors found in Gorlin patients includes RMS, showing that germline 
mutations in PTCH enhance the susceptibility to this tumor entity (see section 2.2.3). This is 
similar in Ptch-heterozygous mice that develop RMS-like tumors 21. These murine tumors 
resemble the embryonal RMS subtype in humans and as human ERMS, they show a strong 
expression of the Hh targets Gli1 and Igf2. In addition, they express terminal myogenic 
differentiation markers, like Desmin and MyoD 66,137,138. Moreover, a heterozygous deletion of 
Sufu in combination with loss of p53 or a constitutive activation of Smo leads to ERMS 
formation in mice 139,140. 
Besides GLI1, the average expression level of GLI2, GLI3 and PTCH are consistently 
elevated in human ERMS compared to normal skeletal muscle 141,142. In addition, the level of 
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these genes is higher in ERMS and fusion-negative ARMS compared to fusion-positive 
ARMS. It also seems to correlate with a worse outcome and survival rate 143. However, 
mutations in the coding regions of the HH pathway genes that can activate HH signaling, are 
very rare in RMS 15,144,145. 
Nevertheless, genomic loss of the PTCH locus on 9q22 has been identified in 30 % (4/12) of 
ERMS cases 146,147. In other studies, LOH of the PTCH or SUFU loci has also been detected 
in ERMS (3/8 tumors showed LOH of the PTCH and 2/4 tumors of the SUFU locus; in a 
different RMS subset 1/14 tumors showed LOH of the PTCH locus) 142,148. 
On the other hand, genomic gain of 12q13.3 and 2q14.2, which contain the GLI1 and GLI2 
loci, respectively, have been reported in up to 54 % (GLI1) and 92 % (GLI2) of ERMS 141,149. 
Consequently, multiple copies of GLI1 or GLI2 have been detected in the tumor samples 141. 
Additionally, increased protein level of GLI1 were observed 149. However, there are also 
studies, which describe no mutations in RMS 15,144. 
In addition, HH ligands were investigated in human RMS. Interestingly, SHH levels are not 
increased in ERMS 141. However, DHH and IHH are expressed, which implicates a role of 
these ligands in this tumor entity 150-152. 
Taken together, these data show that the Hh pathway plays an important role in RMS. 
However, its activation in RMS on molecular level is not fully understood. Nevertheless, 
inhibitors of the HH signaling pathway are under investigation for targeted therapy of RMS. 
The Gli1/2 inhibitor GANT61 shows promising results in cultured RMS cells 153-155. 
Unfortunately, this inhibitor is unstable under acetic conditions and thus cannot be used in 
the clinics 156. In addition, small molecule inhibitors for Smo are under investigation for RMS 
treatment. Cyclopamine, the first discovered natural Smo inhibitor, effectively reduces growth 
of different RMS cell lines 157. However, in full-blown murine ERMS, application of 
cyclopamine does not inhibit tumor growth despite effectively inhibiting Hh signaling. In fact, 
cyclopamine rather induces tumor growth 158. Recent analyses by our group with the Smo 
inhibitors cyclopamine, vismodegib, sonidegib and HhAntag (HhA) revealed that Smo 
inhibitors induce strong antitumoral effects in murine ERMS with a Ptch mutation, whereas 
cell lines derived from ERMS without Ptch mutation responded heterogeneously to Smo 
inhibition159,160. Therefore, Smo inhibitors are considered a good treatment option for ERMS 
that are caused by mutations upstream of Smo 159,160. 
2.3 The Ras signaling pathway 
The Ras genes were originally discovered in the genome of Harvey and Kirsten rat sarcoma 
viruses in the 1960/70s. In 1982, different research groups described mutated RAS alleles in 
human tumors, which resulted in an enormous interest in these genes 161. Today, 3 Ras 
isoforms have been identified in mammals, which are H-ras-l (HRas), K-ras-2 (KRas) with 
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2 splice variants (K-ras-4a and the predominant splice variant K-ras-4b) and N-ras (NRas). 
Additionally, 2 pseudogenes, H-ras-2 and K-ras-l, have been characterized. All Ras genes 
are highly conserved during evolution 162. The Ras proteins are low-molecular-weight GTP-
binding proteins (21 kDa), which are activated in response to different extracellular stimuli 
through their receptors. To deploy their biological activity the Ras proteins need to be 
localized at the inner plasma membrane. In addition, they need to be posttranscriptionally 
modified by farnesyltransferases. Then they interact with lipid groups, which stabilizes their 
position at the plasma membrane 163-166. 
Ras proteins control diverse cellular signaling pathways, which are involved in transcriptional 
regulation, translation, posttranslational modification and cellular processes, like growth, 
differentiation, survival, cell cycle progression, cytoskeletal remodeling, endocytosis and 
calcium signaling 167. A simplified overview of Ras signaling and its different downstream 
axes is depicted in Fig. 3. 
 
Figure 3: Activation of RAS and its downstream effector pathways 
(A) RAS proteins are activated by various extracellular stimuli, which are mediated by receptor tyrosine kinases, 
G-Proteins or others. Consequently, guanine nucleotide exchange factors (GEF) promote the formation of active, 
GTP bound RAS. The return to the inactive state is controlled by GTPase activating proteins (GAP), which 
promote the hydrolysis of RAS-bound GTP. Active RAS controls the activity of several downstream signaling 
pathways. (B) The major effector pathway of active RAS is the RAF/MEK/ERK pathway. It predominantly controls 
transcription, posttranslational modifications, cellular proliferation and growth, as well as cell survival, 
differentiation and cell cycle progression. The signal is transmitted by sequential phosphorylation of the RAF, 
MEK and ERK kinases. (C) Another prominent effector pathway, which interacts with RAS, is the 
PI3K/AKT/mTOR signaling pathway. This effector pathway controls transcription, translation, proliferation and 
survival. The signal is transmitted by sequential phosphorylation of the kinases AKT, mTOR, S6K and of S6. (D) 
Other downstream effector pathways of the RAS signaling cascade control calcium signaling, cytoskeletal 
remodeling and endocytosis. For more details, see text. Modified according to 
167
. 
As shown in Fig. 3A, the activity of Ras proteins is regulated by guanosine di- or triphosphate 
(GDP/GTP) binding, whereby GDP-bound Ras is inactive and GTP-bound Ras is active. The 
hydrolysis of GTP into GDP is catalyzed by GTPase activating proteins (GAPs) and the 
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exchange of GDP by GTP is catalyzed by guanine nucleotide exchange factors (GEFs) 168-
171. Ras is activated through GEFs in response to activation of different receptor tyorsine 
kinases (RTK) or GCPRs 172. Under physiological conditions, Ras activation is transient and 
strictly regulated. However, mutations in codon 12, 13, or 61 convert the Ras genes into 
active oncogenes. This is due to the fact that mutations at these conserved sites prevent the 
hydrolysis of GTP to GDP and are thereby promote constitutive activation of Ras 173. Besides 
activating mutations errors in GDP/GTP regulation, loss of GAPs or persistent RTK activation 
of GEFs are additional mechanisms of Ras activation in cancer 174. Activated Ras binds 
preferentially to its downstream Ras-binding-domain (RBD)- or Ras-association-domain-
containing targets and triggers the activity of other downstream effectors 175. 
The major target of Ras is rat fibrosarcoma (Raf), which in turn triggers the phosphorylation 
and activation of the downstream mitogen-activated protein kinase (Mapk) signaling pathway 
(Fig. 3B). In mammalian cells, 4 major Mapk kinases have been characterized, which are 
extracellular-signal regulated kinase (Erk) 1/2, c-Jun N-terminal kinase (Jnk), p38 and 
Erk5 176. Ras activates Raf by recruiting it to the plasma membrane. Three Raf isoforms 
exist, which are called Raf-1, A-Raf and B-Raf. B-Raf has a higher intrinsic kinase activity 
than Raf-1 and A-Raf. Nevertheless, all Rafs are activated by multiple dephosphorylation and 
phosphorylation processes by Ras when recruited to the membrane 177,178. Activated Raf in 
turn triggers serine phosphorylation of several proteins 179,180. Main targets of Raf are the 
mitogen-activated kinases (Mek)1 and Mek2. Activated Mek in turn phosphorylates and 
activates the Erk, which itself has several substrates 180,181. This signaling cascade controls 
cellular growth, differentiation, proliferation and migration of cells. Moreover, it regulates cell 
cycle progression and cellular differentiation processes 167,176,182-184. Additionally, this cascade 
can have tumor suppressor properties by promoting selective protein stabilization or 
degradation and cellular senescence 185-188. 
Ras signaling can also activate the PI3K/Akt/mTOR pathway 189 (Fig. 3C). PI3K converts 
phosphatidylinositol (4,5)-bisphosphate into phosphatidylinositol(3,4,5)-trisphosphate and 
thereby stimulates the activity of Akt by phosphorylation at Thr308. For full activation Akt 
must also be phosphorylated at Ser473 in its C-terminal region. Akt can trigger various 
cellular responses and is embedded in a complex network of activators, inhibitors and 
second messengers 190. For example, Akt can phosphorylate different kinases such as 
mTOR that in turn activates S6 kinase. This affects cell proliferation and survial, as well as 
transcriptional and translational events 167,191-193. Ras can interact with PI3K in a direct 
manner through its RBD without involving any other proteins. Depending on the cellular 
context, activation of the PI3K signaling pathway can lead to an activation or inhibition in 
Raf/Mek/Erk signaling at the level of Raf. Vice versa, Raf can activate or inhibit the 
PI3K/Akt/mTOR at the level of Akt (not visualized in Fig. 3) 189,194. 
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In addition to these two main effector pathways, Ras also regulates a large amount of other 
pathways (Fig. 3D). For example, Ras phosphorylates and thus activates phospholipases 
(PL), i.e. PLCɛ. Activation of PLs influences the generation of bioactive lipid mediators and 
leads to the mobilization of calcium, generation of diacylglycerol and activation of PKC 195-197. 
Additionally, RAS can stimulate endocytosis and hence influence cellular trafficking of 
specific molecules 198,199. Moreover, Ras signaling can regulate actin cytoskeleton dynamics 
in cells. This remodeling process is required for cellular growth 200,201. 
2.3.1 Specific features of different Ras isoforms 
The Ras genes show high homology and are co-expressed in most of mammalian tissues. 
However, whereas HRas level are high in brain, muscle and skin and low in liver of mice, 
KRas transcripts are most abundant in gut, lung and thymus and low in skin and skeletal 
muscle. NRas transcripts are elevated in testis and thymus. Additionally, the highest NRas 
level is observed at day 10 of gestation in mice, whereas KRas expression is highest at the 
beginning of gestation 202,203. In general, the translation and protein expression of KRas 
messenger RNA (mRNA) is reduced relative to that of other Ras isoforms due to a high 
frequency of rare codons in KRas. These rare codons apparently enhance oncRas-driven 
tumorigenesis, because their conversion into common codons results in fewer tumors after 
carcinogen exposure in mice. 204,205. 
The 3 Ras proteins share 85 % of their amino acid sequence, are activated through the same 
receptors and can exhibit functional redundancy. Nevertheless, activation of the Ras isoform 
can also have non-redundant functions 206-208. 
The 3 Ras proteins differ in their N-terminal amino acids, which contain membrane binding 
and trafficking informations 209. They are differently lipidated and show a different intracellular 
distribution 174,208. For example, at an inactive state, HRas and NRas are localized at the 
plasma membrane and Golgi membranes, whereas KRas is preferentially present at the 
plasma membrane 210. Within the plasma membrane, Ras isoforms are located in different 
microdomains. KRas is located within non-lipid-raft plasma membrane, irrespective of its 
activation state. In contrast, HRas is distributed equally between the raft and non-raft 
regions, but GTP-loading increases its localization within the non-lipid-raft plasma 
membrane 165,210. Besides this differential compartmentalization, ubiquitination can influence 
the ability of Ras proteins to activate their downstream effectors 206. 
In vitro experiments indicate that oncHRas might be a better activator of PI3K, whereas 
oncKRas and oncNRas activate predominantly Raf and Rac. This could result in different 
biological responses 211-215. Additionally, the expression of oncHRas, but not oncKRas, can 
induce senescence 174. On the other hand, oncNRas exerts anti-apoptotic effects, which are 
suppressed by oncKRas 216,217. 
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Furthermore, the biological outcome of a Ras mutation is strongly dependent upon the 
cellular context. For example, NRAS mutations are common in leukemia. Indeed, 
hematopoetic cells are easier transformed by oncNRas than by oncKRas or oncHRas. 
However, fibroblasts are more efficiently transformed by oncHRas than by oncKRas or 
oncNRas 218. In addition, oncNRAS, but not oncKRAS, is able to transform melanocytes 219. 
On the other hand, oncKRAS transforms colonic epithelial cell lines, whereas oncNRAS does 
not 216. Similarly, oncKRas suppresses differentiation and promotes proliferation of murine 
colonic tumors. However, oncNRas does not promote proliferation, but rather suppresses 
apoptosis in this model (the effect of oncHRas was not investigated) 220. Moreover, oncKRas 
promotes proliferation and maintains stem cell characteristics of endodermal progenitors. In 
contrast, oncHRas promotes differentiation and growth arrest of these cells, whereas 
oncNRas has no impact on none of these parameters 221. 
Finally, besides overlapping and redundant functions, isoform-specific differences of the Ras 
genes are also obvious during developmental processes in mice. Thus, a KRas knockout in 
the germline is embryonic lethal at day 12 to 14 of gestation 222,223. In contrast, mice with a 
HRas or an NRas knockout in the germline are viable 222,224. This could be due to the fact that 
KRas is essential for normal fetal liver erythropoiesis 225. However, HRas can replace the 
function of KRas when it is expressed from the KRas locus. The resulting mice are viable 
despite a dilated cardiomyopathy associated with arterial hypertension 226,227. This suggests 
that HRas can functionally substitute for KRas during development. However, a homozygous 
deletion of NRas is lethal in developing KRas+/- mice, because of severe anemia and growth 
delays of the embryos 222. This suggest, that NRas and KRas have partly overlapping 
functions in fetal liver erythropoiesis and other developmental processes. 
As already mentioned, HRas knockout mice grow normally and are fertile. Most interestingly, 
they show a decreased tumor load after carcinogenic (1,3-Dimethylbutylamine (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA)) treatment. Thus, HRas knockout mice develop 
approximately six times less papillomas compared with wildtype (wt) mice after 20 weeks of 
treatment. In addition, 40 % of the tumors of HRas-deficient mice show oncKRas mutations, 
which are not common in papilloma. This indicates that oncKRas can replace HRas in the 
initiation of papilloma 224,228. 
NRas knockout mice are viable, fertile and show no gross morphological or histological 
abnormalities. Nevertheless, these mice have an impaired immune response as measured 
by decreased thymocyte proliferation and lower numbers of CD8+ thymocytes upon an 
infection with influenza virus 229,230. However, this immune defect was not seen in another 
model, in which NRas was knocked-out together with HRas 224. Thus it remains open 
whether NRas is involved in a normal immune response. 
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2.3.2 Ras signaling in cancer 
Approximately 25 % of all human tumors harbor oncogenic RAS mutations (HRAS: 2 %, 
KRAS: 18 %, NRAS: 5 %; according to COSMIC v86). These mutations create active Ras 
proteins and result in abberant proliferation or survival of tumor cells 231,232. In the majority of 
cases (98 %), oncRas mutations are single base missense mutations at the residues G12, 
G13 or Q61. Interestingly, the predominant mutated Ras isoform and the respective mutated 
residue are specific for individual cancer types. However, in general G12 mutations occur 
more often in KRAS and HRAS, whereas Q61 mutations are predominant in NRAS 233. 
In pancreatic ductal adenocarcinoma (90 % of all pancreatic cancers) and lung 
adenocarcinoma (35 % of all lung adenocarcinoma) KRAS is the predominantly mutated 
RAS isoform whereas mutations in HRAS or NRAS are very rare. This is similar in colorectal 
cancers, in which KRAS is also the primarily mutated isoform (45 % of all colorectal cancers) 
and in which HRAS and NRAS mutations are infrequent. In melanomas (15 % of all 
melanomas), liver cancer (30 % of all liver cancers) and acute myelogenous leukaemias 
(30 % of all acute myelogenous leukaemias), NRAS is the predominant oncRAS isoform and 
mutations within HRAS or KRAS are rarely observed. HRAS mutations are more common 
than NRAS or KRAS mutations in bladder cancer (10 % of all bladder cancers show HRAS 
mutations) and in head and neck squamous cell carcinomas (4 % of these cancers have 
HRAS mutations) 167,233,234. Conversely, oncogenic KRAS and NRAS are observed at 
equivalent frequencies in multiple myeloma and seminoma, whereas mutations in HRAS are 
barely observed. In thyroid carcinomas, all 3 RAS isoforms are mutated at a similar 
frequency 167. The impact of oncRAS mutations in RMS is described in detail in 
sections 2.3.4 and 2.4.1. 
This highlights that most cancer types show mutations in a specific Ras isoform. As 
described above, differen Ras isoforms can regulate distinct signaling pathways 212-214. In 
addition, a completive function of different Ras isoforms due to none-overlapping functions 
are described. For example, both wtKRas and wtNRas are required for transformation of 
mouse fibroblast. Whereas wtNRas regulates adhesion, wtKRas coordinates the motility of 
the cells 235. However, recent studies also suggest collaborative effects between oncRas and 
different wtRas proteins, which supposedly is specific for individual cancer phenotypes. For 
example, in colorectal cancer cell lines an oncogenic KRas allele results in elevated levels of 
GTP-bound wtNRas 216. In pancreatic cancer cell lines or colon cancer cells oncKRas 
activates wtHRas via the GEF Son of sevenless (Sos) and thereby stimulates cancer cell 
growth and tumor growth in xenografts 236. Downregulation of wtHRas or wtNRas in 
pancreatic cancer cell lines or colon cancer cells expressing oncKRas leads to overactivation 
of the Erk and PI3K/Akt pathways 237. In cancer cell lines (oncHRAS: T24 bladder cancer cell 
line, oncKRAS: MIA PaCa-2 pancreatic cancer cell line, oncNRAS: RD RMS cell line) 
expressing oncRas, oncRas activates basal Mapk signaling despite negatively regulating 
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RTK signaling on receptor level, whereas wtRas activates RTK signaling and acts as a driver 
of cell survival and proliferation 238. In murine papilloma development, wtKRas acts 
cooperatively with oncHRas to promote papilloma development. Additionally, loss of wtNRas 
decreases the number of oncHRas-dependent papilloma 239. 
Beside this tumorpromoting role of wtRas in oncRas-expressing cancers, other studies 
suggest that wtRas can act as a tumor suppressor. For example, tumorigenesis in the mouse 
skin is associated with an elevated copy number of oncHRas and/or a loss of wtHRas, 
indicating a tumor suppressive function of wtHRas 240. Similar, loss of wtHRas increases the 
tumor load and reduces survival in murine pancreatic adenocarcinoma expressing 
oncKRas 241. In addition, wtHRas inhibits oncKRas-dependent progression of murine lung 
cancers. Finally, loss of wtNRas increases the number of oncKRas-induced lung tumors 239. 
2.3.3 RASopathies 
Oncogenic mutations in RAS (or in other regulators of RAS signaling) are not only found in 
sporadic cancers. As germline mutations, they also can cause autosomal dominant genetic 
syndromes. These diseases are called RASopathies and are frequently associated with 
RMS 242,243. Examples are Neurofibromatosis type 1, which is caused by germline mutations 
in NF1, which is a GAP that regulates GDP/GTP exchange of RAS 242,244,245. Other examples 
are the capillary malformation–arteriovenous malformation syndrome, which is caused by 
haploinsufficiency of the RAS signaling regulator gene RASA1 246, the cardio-facio-cutaneous 
syndrome, which is caused by germline mutations in BRAF, MAP2K1, MAP2K2 247,248 and 
the Legius syndrome, which is caused by inactivating mutations in SPRED1 that regulates 
the activation of the MAPK cascade 249. Interestingly, 2 of the RASopathies, namely Noonan 
and Costello syndrome, can be caused by mutations in RAS and are associated with an 
increased susceptibility to RMS. Thus, patients with Costello syndrome have a dominant 
HRAS germline mutation 17,250, whereas Noonan syndrome can be caused by germline 
mutations in KRAS or NRAS. The latter disease also can show germline mutations in 
PTPN11, SOS1, RAF1, SHOC2 and CBL, that, with the exception of CBL (E3 ubiquitin 
ligase), are all implicated in RAS signaling 251-258.  
2.3.4 RAS signaling and RMS 
As already mentioned, patients with Costello syndrome or Noonan syndrome are 
predisposed to the development of RMS, which are predominantly of the embryonal 
subtype 19,242,259-262. Additionally, a few cases of RMS have also been described in patients 
suffering from Neurofibromatosis type 1 or from cardio-facio-cutaneous syndrome 263-265. 
Interestingly, oncRAS mutations are also frequently found in sporadic RMS and are detected 
predominantly in the ERMS subtype 14,15. Dependent on the analyzed tumor subset, 12 % 16, 
22 % 266, 35 % 267 or even 46 % 141 of RMS show oncRAS mutations. Although these 
mutations can occur in all 3 RAS genes, NRAS mutations are the most common 
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ones 14,15,141,266,267. With regard to the analyzed tumor subset, oncRAS mutations can 
positivity or negatively influence the outcome for patients with ERMS. On the one hand, 
activating mutations in HRAS, KRAS, NRAS or NF-1 genes were described in 75 % of high-
risk ERMS tumors 5,6,15. On the other hand, gain-of-function mutations within the RAS genes 
were described to occur more frequently in ERMS patients with a better outcome 267. 
Nevertheless mutations within the RAS genes at positions G12 and Q61 are more frequent 
than G13 mutations 15,141,231,232,267 (and according to COSMIC v86). Furthermore, whole-
exome/-transcriptome sequencing, copy number and DNA methylome analyses of 60 RMS 
revealed activation of the FGFR4/RAS/AKT axis in up to 40 % of the tumors (24/60 tumors, 
with 10/60 tumors showing mutations in HRAS, KRAS or NRAS), which was predominantly 
detected in ERMS. However, mutations affecting PI3K directly are very rare 14,268. Together, 
these results led to the conclusion that the RAS signaling pathway could be a druggable 
target in RMS. Indeed, inhibition of MEK or combined inhibiton of MEK and PI3K/mTOR 
block proliferation and trigger apoptosis of RMS cells 269-272. 
Finally, it was proposed that oncRas mutations can either act as RMS-driver or as RMS-
modifiers. However, this point is still a matter of debate 273-277. Precisely, oncRas mutations 
were proposed to be necessary to convert normal primary human skeletal muscle myoblasts 
into tumorigenic cells mimicking ERMS 278. This was shown by activation of oncKRas under 
the control of the recombination activating gene 2 (rag2) promotor, which is active in 
myoblasts in zebrafish 274. On the other hand, microarray-based data of RMS samples 
suggest, that a RAS signature occurs only in combination with signatures of other activated 
pathways 275. In support of an RMS-modifier is also the observation that oncKRas in 
combination with heterozygous p53 mutations induces pleomorphic RMS, whereas p53 
mutations alone induce an other RMS subtype. RMS in oncKRas mice have not been 
described so far 279-283. Similarly, xenografts from murine satellite cells with oncKRas result in 
a pleomorphic RMS phenotype, but only in combination with a Cyclin-dependent kinase 
inhibitior (Cdkn) 2a knockout 273. 
To sum up, these results show that active Ras signaling plays an extraordinarily important 
role in RMS pathogenesis. However, the precise role of oncRas mutations in ERMS 
pathogenesis is not well understood. 
2.4 Interaction of Hh and Ras signaling 
A non-canonical interaction between the Hh and Ras signaling pathways has been described 
frequently 284. For example, the Shh/Ptch axis can stimulate activation of Erk in human 
mammary epithelial cells and in Shh Light II fibroblasts, which however does not require 
Smo 285. Vice versa, Mek influences the transcriptional activity of Gli1 in murine fibroblasts. In 
this setting, the N-terminal domain of Gli1 is phosphorylated in a Mek-dependent manner, 
which however does not involve Erk2 286. Additionally, Gli1 and Gli3 have been identified as 
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potential substrates of the Mapks Jnk and Erk in computational prediction and peptide 
binding arrays 287. Indeed, Mapks can phosphorylate Gli1, Gli2 and Gli3 on residues located 
near the binding site for Sufu 288. Furthermore, Gli proteins are stabilized by Epidermal 
growth factor receptor (EGFR)-mediated inhibition of proteasomal degradation in 
keratinocytes 289. Therefore, it is speculated that Mapks can activate Gli transcription factors 
in a Hh/Ptch/Smo-independent manner. 
Activated Hh signaling and simultaneous oncRas mutations are found in several tumor 
entities 284. This suggests a cooperation of both signaling pathways in tumor development, 
maintenance or progression. An overview of known interactions between Hh and Ras 
signaling in different tumor entities is depicted in Fig. 4. 
 
Figure 4: Interactions of HH and RAS signaling in cancer 
HH signaling activity can be modified by RAS signaling in a non-canonical manner. In this setting, oncgenic 
actiovation of members of the RAS pathway induce or inhibit GLI transcription factors. In addition, oncRAS can 
induce secretion of HH ligands. The MEK/ERK casacde was shown to regulate GLI transcription factors. For more 
details, see text. 
Hh/Ras interaction occurs for example in BCC, in which Hh and Egfr signaling synergistically 
contribute to oncogenic transformation via the Raf/Mek/Erk axis 290,291 and synergistically 
regulate the expression of genes necessary for tumor growth (Sox2, Sox9, Jun, C-X-C motif 
chemokine receptor (Cxcr)4 and Fgf19) 292. Additionally, Egfr/ADP ribosylation factor (Arf)6 
signaling triggers Hh signaling and tumor growth in a Drosophila oncRas-driven tumor model. 
Tumor growth in this model depends on oncRas and oncRas in turn induces the expression 
of Egfr ligands 293. 
In addition, oncRas-mediated modulation of Gli transcription factor can have oppositional 
outcomes in different tumor entities. Examples for activation of Hh signaling by oncRas are 
e.g. melanoma. In this tumor entity oncNRAS or oncHRAS can stimulate nuclear localization 
and transcriptional activity of GLI1 75. In gastric cancer cells an active MEK/ERK cascade has 
a positive regulatory role in GLI1 transcriptional activity 294. Another example is pancreatic 
cancer, in which GLI1 is required for oncKRAS-induced tumorgenesis 295,296. Moreover, 
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oncKRAS blocks proteasome-mediated GLI1 degradation and thereby activates the HH 
signaling cascade in pancreatic cancer cells 297. OncRAS also triggers ligand-independent 
HH signaling activation in thyroid cancer cells via the MEK/ERK axis 298. However, in 
contrast, Lauth and colleagues observed that oncKRAS can also abrogate HH signaling 
activity in pancreatic cancer cells by inhibition of GLI2 function and promotion of the 
formation of the GLI3 repressor form. Thus, oncRAS tumor-intrinsically blocks HH signaling. 
However, since oncKRAS tumorintrinsically also induces SHH expression and secretion, HH 
signaling activity is induced in neighboring stromal cells 84. 
In addition to the Ras/Mek/Erk axis, the PI3K/Akt/mTOR axis (which can also be regulated by 
Ras) can regulate Gli proteins and thus Hh signaling activity. For example, AKT enhances 
nuclear localization and activity of GLI1 in melanoma model systems 75. In murine fibroblasts, 
PI3K/Akt/ signaling is required for Shh signal transduction and subsequent Gli activation 76. 
In summary, the literature provides evidence for both, positive and negative crosstalks 
between Hh and Ras signaling in that oncRas either positively or negatively influences 
transcriptional activity of Gli transcription factors. The outcome of regulation depends on the 
experimental setting and on the tumor entity. Vice versa, Shh can regulate Erk activity in 
non-cancerous epithelial cells. 
2.4.1 HH and RAS signaling in RMS 
As described in sections 2.2.4 and 2.3.4, Hh and Ras signaling play crucial roles in RMS. 
Although interactions of these pathways have been described for several tumor entities, 
almost nothing is known about an interaction in RMS. Preliminary work from our group 
indicates that there is indeed a crosstalk between both pathways in RMS. Thus, the 
expression of any oncRAS isoform decreases GLI1 expression in the ERMS cell line RUCH-
2 and in the ARMS cell line RMS-13. However, the mechanism behind this downregulation is 
different. Whereas the oncRAS-dependent decrease in GLI1 expression is mediated by MEK 
in RUCH-2 cells, MEK is not involved in GLI1-suppression in RMS-13 cells. Moreover, 
preliminary xenotransplantation studies and a genetic approach in the mouse indicate that 
oncRas isoforms change the growth behavior of Hh-associated RMS precursor lesions 299. 
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3 Aim of this study 
RMS is the most common malignant soft tissue sarcoma in children. The efficiency of 
currently available multimodal therapies is limited and many patients suffer from severe 
adverse side effects and fatal long-term consequences. This indicates that it is of uttermost 
importance to better understand the tumor’s pathology and to establish new therapeutic 
approaches. 
The Hh signaling cascade and the Ras signaling pathway are frequently activated in RMS. 
This is in the first instance obvious in human ERMS that strongly express HH target genes 
and concurrently can show oncogenic H-, K- or NRAS (collectively named oncRAS) 
mutations. Surprisingly, and as already mentioned, preliminary work from our group indicates 
that all oncRAS isoforms decrease the expression of the major HH-target GLI1 in an ERMS 
and also in an ARMS cell line. In ERMS the decrease apparently is mediated via MEK. 
The main focus of this thesis was to investigate the role of oncRAS isoforms in regulation of 
HH targets and associated cellular responses of ERMS in more depth and thereby to validate 
the already gained results. Additionally, the consequences of a crosstalk between RAS and 
HH signaling for ERMS pathogenesis, growth and aggressiveness were analyzed. 
For this purpose, the proliferation status and the activity of RAS and HH signaling were 
investigated in 3 different ERMS cell lines expressing oncRAS isoforms. In addition, it was 
examined whether the oncRAS-mediated decrease in GLI1 was caused downstream of MEK 
at the level of ERK. Moreover, the subcellular localization and the protein level of all 3 GLI 
transcription factors were investigated. Finally, the cell lines were transplanted into 
immunosuppressed mice and the impact of oncRAS and the concomitant downregulation of 
GLI1 on tumor growth and HH signaling activity was analyzed. 
In a second approach, the impact of oncRas signaling on growth, differentiation status and 
on Hh signaling genes was analyzed in genetically engineered Hh/Ptch-driven ERMS mouse 
models. For this purpose, Ptchdel/+oncRasfl/+Myf5CreER/+ mice were generated. In these mice, 
the expression of either oncHRas, oncKRas or oncNRas can be induced at different stages 
of tumor development. Using this model, the impact of the respective oncRas mutation on 
tumor incidence, tumor latency time or multiplicity and on proliferation, Hh signaling activity 
and myyogenic differentiation was investigated. The experiments were perfomed in mice, in 
which the mutation was induced either in tumor precursor lesions or in full-blown ERMS. The 
aim of this study was to analyze the impact of oncRas mutations on different developmental 
stages of ERMS.
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4 Material 
4.1 Technical equipment 
Table 1: Technical equipment 
Technical equipment Supplier 
7900HT Fast Real-Time PCR System Applied Biosystems, Waltham, MA, USA 
Agarose gel electrophoresis chamber 
Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Autoclave (9216E) Fedegari Autoclavi SpA, Albuzzano, Italy 
Autoclave (Systec DX-150) Systec GmbH & Co. KG, Linden, Germany 
Centrifuges  
(Biofuge pico, fresco, primo, Multifuge 3LR) 
Heraeus Holding GmbH, Hanau, Germany 
Centrifuge (5427 R) Eppendorf AG, Hamburg, Germany 
CO2-Incubator (CB220-230V-G) Binder GmbH, Tuttlingen, Germany 
CO2-Incubator (6000, BBD, 6220) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Cooling plate (EG1150 C) 
Leica Microsystems GmbH, Wetzlar, 
Germany 
Digital monochrome thermal video printer 
(P91D) 
Mitsubishi Electric Co., Tokyo, Japan 
Digital photocamera (PowerShot G2) 
Canon Deutschland GmbH, Krefeld, 
Germany 
Dispersing tool for homogenizer (DS-8/P) Miccra GmBH, Heitersheim, Germany 
Dissection tools 
Karl Hammacher GmbH, Solingen, 
Germany 
Flow cytometer (BD LSR II) BD Biosciences, San Jose, CA, USA 
Flow cytometer (FACS Calibur) BD Biosciences, San Jose, CA, USA 
Freezer (-20 °C) Liebherr GmbH, Bulle, Switzerland 
Freezer (-80 °C) Sanyo Electric Co., Ltd., Osaka, Japan 
Freezing container (Mr. Frosty™) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Fridge (4 °C) Robert Bosch GmbH, Stuttgart, Germany 
Heating block shaker (ThermoMixer©) Eppendorf AG, Hamburg, Germany 
High-precision scales (Sartorius Basic plus 
2100) 
Sartorius AG, Göttingen, Germany 
Homogenizer (Miccra D-1) Miccra GmBH, Heitersheim, Germany 
Hybridization oven (HB-1000 Hybridizer) Analytik Jena US, Upland, CA, USA 
Gas burner Campingaz, Hattersheim, Germany 
Inverted fluorescence microscope  
(Axiovert 25) 
Carl Zeiss GmbH, Jena, Germany 
Inverted research microscope (IX71) Olympus Optical Co., Ltd., Tokyo, Japan 
Cryostat (CM 1900-1-1)  
Leica Microsystems GmbH, Wetzlar, 
Germany 
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Liquid nitrogen tank L’air liquid S.A., Paris, France 
Magnetic stirrer (MR3000/3001) 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Micro computed tomography (µCT) system 
(QuantumFX)  
PerkinElmer Health Sciences, Hopkinton, 
MA, USA  
Microplate reader (SynergyMx) 
BioTek Instruments GmbH, Bad 
Friedrichshall, Germany 
Microscope (Olympus BX 60) Olympus Optical Co., Ltd., Tokyo, Japan 
Microtome (HN 40) 
Leica Microsystems GmbH, Wetzlar, 
Germany 
Microwave oven (Dimension 4) Panasonic Corp., Kadoma, Japan 
Neubauer counting chamber  Brand GmbH & Co KG, Wertheim, 
Germany 
Neon™ Transfection system 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Paraffin dispenser (PAG12) 
Medite Medizintechnik GmbH, Burgdorf, 
Germany 
Paraffin tissue floating bath 
Medax GmbH & Co. KG, Rendburg, 
Germany 
PCR Thermocycler (Mastercycler®) Eppendorf AG, Hamburg, Germany 
PCR Thermocycler (Labcycler Basic, 
Labcycler Gradient) 
SensoQuest GmbH, Göttingen, Germany 
pH-meter (inoLab, pH Level 1) and 
electrode (SenTix 91) 
WTW, Weilheim, Germany 
Pipette controller (accu-jet® pro) 
Brand GmbH & Co. KG, Wertheim, 
Germany 
Pipettes (Multi- and single-channel pipettes) Eppendorf AG, Hamburg, Germany 
Platform shaker (Unimax1010) 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Precision weighing balance (ALC-210.4) Sartorius AG, Göttingen, Germany 
Power supply for agarose gel 
electrophoresis 
Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Power supply for Western Blot transfer 
Cleaver Scientific ltd., Rugby, United 
Kingdom 
Spectrophotometer (NanoDrop 8000) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Stereo microscope (Stemi 2000) Carl Zeiss GmbH, Jena, Germany 
Sterile workbench (Euroflow EF/A 5) Clean Air Techniek, Woerden, Netherlands 
Tab. centrifuge (Micro Centrifuge SD) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Tissue processor (TP1020) 
Leica Microsystems GmbH, Wetzlar, 
Germany 
Ultraviolet (UV) light -Transilluminator 
INTAS Science Imaging Instruments 
GmbH, Göttingen, Germany 
Vacuum pump (EcoVac) Schuett-biotec GmbH, Göttingen, Germany 
Vortex mixer (Vortex-Genie2®) Scientific Industries Inc, Bohemia, NY, USA 
Water bath (1083) GFL mbH, Burgwedel, Germany 
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Water purification system (Arium® 611 VF) Sartorius AG, Göttingen, Germany 
Western Blot imaging system 
(FluorChem™Q) 
Bio-Techne Corp., Minneapolis, MN, USA 
Western Blot transfer system (Trans-Blot® 
SD semi-dry electroblotting system) 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Western Blot transfer system (Tank 
electroblotting system OwlTM VEP-2 Mini) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
4.2 Consumables 
Table 2: Consumable materials 
Consumable Supplier 
6 well cell culture plate Sarstedt AG & Co., Nürnberg , Germany 
24 well cell culture plate  
Corning Incorporated, New York City, NY, 
USA 
96 well assay plate (black plate, clear 
bottom) 
Corning Incorporated, New York City, NY, 
USA 
384 well plate black & adhesive seal sheet 4titude® Ltd., Surrey, UK 
Cell scraper Sarstedt AG & Co., Nürnberg , Germany 
Centrifuge tubes (15 ml, 50 ml) 
Greiner Bio-One International GmbH, 
Kremsmünster, Austria 
Coverslips  
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Disposable needles (Sterican Ø 0.45 x 
12 mm or Ø 0.30 x 12 mm)  
B.Braun AG, Melsungen, Germany 
Disposable syringes (BD DiscarditTM II 2, 
10, 20, 50 ml) 
BD Biosciences, San Jose, CA, USA 
Combitips advanced® (0.2 ml, 0.5 ml, 
2.5 ml, 5 ml, 10 ml) 
Eppendorf AG, Hamburg, Germany 
CryoPure tubes Sarstedt AG & Co., Nürnberg, Germany 
Delicate task wipes Kimberly-Clark Europe Ltd., Surrey, UK 
Disposable cups (100 ml) Sarstedt AG & Co., Nürnberg, Germany 
Filter tips (Biosphere® 20 µl, 100 µl, 200 µl, 
1000 µl) 
Sarstedt AG & Co., Nürnberg , Germany 
Flow cytometry tube  Sarstedt AG & Co., Nürnberg , Germany 
Fluted filters  Sartorius AG, Göttingen , Germany 
Glassware Schott AG, Mainz, Germany 
Insulin syringe (BD Microfine + Demi) BD Biosciences, San Jose, CA, USA 
Microscope slides & Superfrost® plus 
microscope slides  
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Nitrocellulose membrane (Hybond ECL), 
0.2 µM and 0.45 µM pore size 
GE Healthcare Europe GmbH, Freiburg, 
Germany  
Nunclon™ disposables for cell culture 
(10 cm cell culture dish, 96-well plate) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
NuPAGE Novex 3-8 % Tris-Acetate Gel Invitrogen, Carlsbad, CA, USA 
NuPAGE Novex 4-12 % Bis-Tris Gel  Invitrogen, Carlsbad, CA, USA 
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Parafilm® laboratory film Bemis Company, Inc., Neenah, WI, USA 
Pasteur pipettes 
TH. Geyer GmbH & Co. KG, Renningen, 
Germany 
PCR tear-a-way plates & cap strips 4titude® Ltd., Surrey, UK 
Petri dishes  Ochs GmbH, Bovenden/Lenglern, Germany 
Pipette tips (20 μl, 200 µl, 1000 μl)  Sarstedt AG & Co., Nürnberg, Germany 
Reaction tubes (1.5 ml, 2 ml, 5 ml) Sarstedt AG & Co., Nürnberg, Germany 
Safeseal microtubes (1.5 ml, 2 ml) Sarstedt AG & Co., Nürnberg, Germany 
Serological pipettes (2 ml, 5 ml, 10 ml, 
25 ml) 
Sarstedt AG & Co., Nürnberg , Germany 
Softa-Man® hand disinfectant B.Braun AG, Melsungen, Germany 
Sterile filters (0.2 µm, 0.45 µm) Sartorius AG, Göttingen, Germany 
Surgical blades Aesculap AG, Tuttlingen, Germany 
Whatman® Blotting paper (GB 33 B003) 
Heinemann Labortechnik GmbH, 
Duderstadt, Germany 
Weighing paper  
Macherey-Nagel GmbH & Co. KG, Düren, 
Germany 
4.3 Reagents and chemicals 
All chemicals, which are not listed in Table 3 (Tab. 3) were purchased from Merck KGaA, 
Darmstadt, Germany or Carl Roth GmbH & Co. KG, Karlsruhe, Germany. 
Table 3: Reagents and chemicals 
Reagent or chemical Supplier 
3-Amino-9-ethylcarbazole (AEC) Sigma-Aldrich Co., St. Louis, MO, USA 
Acetic acid 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Agarose 
VWR International GmbH, Erlangen, 
Germany 
Aluminium potassium sulfate 
dodecanhydrate 
Merck KGaA, Darmstadt, Germany 
Ampicillin sodium salt 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Boric acid 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Bovine serum albumin fraction V (BSA), 
protease free 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Chloroform  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Citric acid monohydrate 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Contrast reagent Imeron 300 Bracco Imaging GmbH, Konstanz, Germany 
Cresol red, sodium salt 
Aldrich Chemical Company Inc., Milwaukee, 
WI, USA 
Cryoblock embedding medium 
Medite Medizintechnik GmbH, Burgdorf, 
Germany 
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Dimethylformamide (DMF) Sigma-Aldrich Co., St. Louis, MO, USA 
Dimethylsulfoxide (DMSO) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Dithiothreitol (DTT) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Deoxyribonucleotide triphosphates (dNTPs) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Loading dye solution for DNA (6x) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
DNase/RNase-free distilled H2O 
(ultrapure H2O)  
Invitrogen, Carlsbad, CA, USA 
Eosin Y Merck KGaA, Darmstadt, Germany 
Ethanol (EtOH) 99 % J.T. Baker B.V., Deventer, Netherlands 
Ethanol 99%, denatured 
TH. Geyer GmbH & Co. KG, Renningen, 
Germany 
Ethidium bromide (EtBr) 0.07%  
Inno-Train Diagnostik GmbH, Kronberg im 
Taunus, Germany 
Ethylenediamine tetraacetic acid (EDTA) 
disodium salt dihydrate 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
GeneRuler DNA ladder (50 base pairs (bp), 
100 bp plus, 1 kilobase (kb)) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Glutaraldehyde Sigma-Aldrich Co., St. Louis, MO, USA 
Glycergel mounting medium  
Dako North America Inc., Carpinteria, CA, 
USA  
Haematoxylin crystalline, Mayer’s Merck KGaA, Darmstadt, Germany 
Hydrochloric acid (37 %) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Hydrogen peroxide (35 %) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Immersion oil for microscopy (Immersion™ 
518 N) 
Carl Zeiss GmbH, Jena, Germany 
Isoflurane (FORENE) 
Abbott Laboratories Inc, Santa Clara, CA, 
USA 
Isopropanol 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Kanamycin A Sigma-Aldrich Co., St. Louis, MO, USA 
Liquid barrier marker 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Matrigel basement membrane matrix 
phenol red free 
Corning Incorporated, New York City, NY, 
USA 
Methanol (MeOH)  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
NuPAGE MES SDS running buffer, 20 x  Invitrogen, Carlsbad, CA, USA 
NuPAGE Tris acetate SDS running buffer, 
20 x 
Invitrogen, Carlsbad, CA, USA 
Paraformaldehyde (PFA) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
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Pertex mounting medium  
Medite Medizintechnik GmbH, Burgdorf, 
Germany 
Phosphatase inhibitor cocktail Tab.ts 
(PhosSTOP)  
Roche Diagnostics GmbH, Mannheim, 
Germany 
Phosphate buffered saline (PBS) Tab.ts  Invitrogen, Carlsbad, CA, USA 
Powdered milk  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Protease inhibitor cocktail (cOmplete Mini) 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Primer “random” p(dN)6 Hexamer-
oligonucleotides 
Roche Diagnostics GmbH, Mannheim, 
Germany 
ProLong Gold antifade mountant with 4′,6-
diamidino-2-phenylindole (DAPI) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
RNaseZAP Sigma-Aldrich Co., St. Louis, MO, USA 
SeeBlue Plus2 Pre-Stained Protein 
Standard  
Invitrogen, Carlsbad, CA, USA 
S.O.C. (Super optimal broth with catabolite 
repression) medium 
Invitrogen, Carlsbad, CA, USA 
Sodium chloride AppliChem GmbH, Darmstadt, Germany 
Sodiumdodecylsulfate (SDS) AppliChem GmbH, Darmstadt, Germany 
Sodium hydroxide 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Spectra multicolor high range protein ladder 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Sucrose Sigma-Aldrich Co., St. Louis, MO, USA 
Tamoxifen Sigma-Aldrich Co., St. Louis, MO, USA 
Triethanolamine (TEA) hydrochloride Sigma-Aldrich Co., St. Louis, MO, USA 
Tris(hydroxymethyl)aminomethane (TRIS) 
base 
AppliChem GmbH, Darmstadt, Germany 
Triton™ X-100 Sigma-Aldrich Co., St. Louis, MO, USA 
Tropix® I-BLOCK™  Applied Biosystems, Waltham, MA, USA 
Tryptone (peptone ex casein) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
TWEEN® 20 Sigma-Aldrich Co., St. Louis, MO, USA 
X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Xylene J.T. Baker B.V., Deventer, Netherlands 
Yeast extract 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
4.4 Buffers and solutions 
If not indicated otherwise all buffers and solutions were prepared using double-distilled H2O 
(ddH2O). 
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Table 4: Buffers and solutions and their components 
Buffer Composition 
2 x Laemmli buffer 
65 mM Tris-HCl, pH 6.8 
25 % (w/v) Glycerol  
2 % (w/v) SDS 
0.01 % (w/v) Bromophenol blue 
6 x SDS loading buffer 
375 mM Tris, pH 6.8 
12 % (w/v) SDS 
60 % (v/v) Glycerol  
0.6 M DTT 
0.01 % (w/v) Bromophenol blue 
10 x PBS 
pH 7.4  
1.4 M NaCl 
65 mM Na2HPO4 
27 mM KCl 
15 mM KH2PO4 
10 x Tris-boric acid-EDTA solution (TBE) 
pH 8.0 
890 mM Tris/HCl, pH 8.0 
730 mM boric acid 
12.5 mM EDTA 
10 x Tris-buffered saline (TBS)  
pH 7.4 
150 mM NaCl  
10 mM Tris/HCl, pH 8.0 
AEC chromogen 
pH 5.2  
70 mM Sodium acetate trihydrate  
30 mM Acetic acid  
16 mM 3-Amino-9 Ethylcarbazole  
Dissolved in DMF 
Blotting buffer for semi-dry blotting 
50 mM Tris  
40 mM Glycine  
20 % (v/v) Methanol  
0.0325 % (w/v) SDS 
Blotting buffer for tank blotting 
pH 8.3 
200 mM Glycin 
25 mM Tris 
20 % (v/v) Methanol 
0.1 % (w/v) SDS 
BSA-azide 
3 mM Sodium azide  
2 % (w/v) BSA 
Dissolved in PBST 
Casein 
0.2 % (w/v) I-Block 
Dissolved in TBS 
Citric acid buffer 
pH 3.0 or pH 6.0 
10 mM Sodium Citrate  
Cresol 
0.1 % (w/v) Cresol red 
Dissolved in saturated sucrose-solution  
dNTP-Mix 
 
10 mM dATP 
10 mM dCTP 
10 mM dGTP 
10 mM dTTP 
Eosin solution 
80 % (v/v) EtOH  
1 % (w/v) Eosin y (water soluble) 
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Haematoxylin solution, Mayer’s 
300 mM Trichloro acetaldehyde hydrate  
100 mM Potassium aluminum sulfate  
50 mM Citric acid  
35 mM Haematoxylin  
75 nM Sodium iodate 
Lysis buffer 
pH 8.8 
150 mM NaCl  
30 mM Tris/HCl, pH 7.5  
10 % (v/v) Glycerol  
1 % (v/v) Triton X-100  
1 Tab.t/ 10 ml phosphatase inhibitor and 
protease inhibitor 
added before use: 2 mM DTT,  
500 μM Phenylmethanesulfonylfluoride  
LacZ buffer 
2 mM MgCl2  
0,02 % (v/v) NP-40 
0,01 % (w/v) Natrium Deoxycholat 
Dissolved in PBS 
LacZ-staining buffer 
5 mM K3Fe(CN)6  
5 mM K4Fe(CN)6  
2 mM MgCl2  
0.02 % (v/v) NP-40  
0.01 % (w/v) Natrium Deoxycholat  
500 μg/ml X-Gal  
Dissolved in PBS 
Lysogeny broth medium (LB medium) 
1 % (w/v) Bacto-tryptone 
1 % (w/v) NaCl (pH7.0) 
0.5 % (w/v) Yeast extract 
Lysogeny broth agar (LB agar) 
1.5 % (w/v) Agar 
Dissolved in LB medium 
Modified radioimmunoprecipitation assay 
buffer (RIPA) 
50 nM Tris/HCl, pH 7.4  
1 % (v/v) NP-40  
0.25% (v/v) Na-Deoxycholat  
150 mM NaCl  
1 mM EDTA  
1 Tab.t/ 10 ml phosphatase inhibitor and 
protease inhibitor 
Nuclear lysis buffer (NL buffer) 
50 mM Tris-HCl, pH 8 
150 mM NaCl 
1 % (v/v) NP-40  
0.5 M sodium deoxycholate 
0.1 % (w/v) SDS 
1 Tab.t/ 10 ml phosphatase inhibitor and 
protease inhibitor 
added before use: 10 % (v/v) Glycerol 
Paraformaldehyde 
4% (w/v) Paraformaldehyde 
Dissolved in PBS 
PBS-Tween 20 (PBST)  
0.1 % (v/v) Tween-20 
Dissolved in PBS  
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Propidium iodide (PI) staining solution 
10 µg/ml PI 
100 µg/ml RNase A 
Dissolved in PBS 
Proteinase K  
pH 8.0  
50 mM Tris/HCl  
5 mM EDTA  
10 mg/ml Proteinase K 
Subcellular fractionation buffer (SF buffer) 
250 mM Sucrose 
20 mM HEPES, pH 7.4 
10 mM KCl 
1.5 mM MgCl2 
1 mM EDTA 
1 mM Ethyleneglycol etraaceticacid (EGTA) 
1 Tab.t/ 10 ml phosphatase inhibitor and 
protease inhibitor 
added before use: 2 mM DTT  
Sodium Chloride-Tris-EDTA (STE) buffer 
100 mM NaCl 
50 mM Tris/HCl 
1 mM EDTA 
1 % (w/v) SDS 
Stripping buffer 
62.5 mM Tris, pH 6.7 
2 % (w/v) SDS 
100 mM ß-Mercaptoethanol 
TBS-Triton X-100 
0.1% Triton X-100 
Dissolved in TBS  
TBS-Tween 20 (TBST) 
0.5 % (v/v) Tween-20  
Dissolved in TBS 
Tris-EDTA (TE) buffer 
pH 8.0 
10 mM Tris  
1 mM EDTA 
Trypan blue staining solution 
0.4 % (w/v) Trypan blue  
Dissolved in PBS 
X-Gal stock solution 
4 % (w/v) X-Gal 
Dissolved in DMSO 
4.5 Kits and ready-to-use reaction systems 
Unless indicated otherwise, all commercially available kits and ready-to-use reaction systems 
listed in Tab. 5 were used according to the manufacturer’s instructions. 
Table 5: Commercially available kits and ready-to-use reaction systems 
Reaction system Supplier 
Amersham enhanced chemiluminescence 
(ECL) Western Blotting detection reagents  
GE Healthcare Europe GmbH, Freiburg, 
Germany 
Cell proliferation Enzyme-linked 
immunosorbent assay (ELISA), BrdU 
chemiluminescent 
Roche Diagnostics GmbH, Mannheim, 
Germany  
Dako REAL™ EnVision™ detection system, 
Peroxidase/3,3'-Diaminobenzidine (DAB) +, 
Rabbit/Mouse 
Dako North America Inc., Carpinteria, CA, 
USA 
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Dual-Luciferase® Reporter assay system Promega GmbH, Mannheim, Germany 
NEON Transfection kit 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Pierce BCA Protein assay kit  
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Platinum™ SYBR™ Green qPCR 
SuperMix-UDG w/ROX 
Invitrogen, Carlsbad, CA, USA 
PureLink®HiPure Plasmid Midiprep Kit Invitrogen, Carlsbad, CA, USA 
QIAamp DNA FFPE Tissue Kit Qiagen GmbH, Hilden, Germany 
QuantiTect SYBR® Green RT-PCR Kit Qiagen GmbH, Hilden, Germany 
Ras Pull-down activation assay biochem kit 
(bead pull-down format) 
Cytoskeleton Inc, Denver, CO, USA 
RevertAid™ H Minus First Strand cDNA 
Synthesis Kit 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
TRIzol® Reagent Life Technologies Co., Camarillo, CA, USA 
Water soluble tetrazolium salt (WST-1) 
reagent 
Roche Diagnostics GmbH, Mannheim, 
Germany 
4.6 Enzymes 
All enzymes were stored at -20 °C. Enzymatic reactions were performed according to the 
manufacturer’s recommendations. 
Table 6: Enzymes 
Enzyme Supplier 
BamH1 New England Biolabs, Ipswich, MA, USA 
BpmI New England Biolabs, Ipswich, MA, USA 
EcoRI New England Biolabs, Ipswich, MA, USA 
Hind III New England Biolabs, Ipswich, MA, USA 
KpnI New England Biolabs, Ipswich, MA, USA 
NheI New England Biolabs, Ipswich, MA, USA 
Not1 New England Biolabs, Ipswich, MA, USA 
Proteinase K  
Carl Roth GmbH & Co. KG, Karlsruhe, Ger-
many 
RNase A  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
SuperScript™ II Reverse Transcriptase 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Taq-Polymerase (MolTaq)  
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4.7 Small molecule inhibitors 





HhAntag (HhA) DMSO 30 µM 
Genentech, San 
Francisco, CA, USA 
PI-103 DMSO 3 µM 
Alexis Biochemicals, San 
Diego, CA, USA 





DMSO 100 - 150 nM 
Cayman chemicals, Ann 
Arbor, MI, USA 
U0126 DMSO 10 µM 
InvivoGen, San Diego, 
CA, USA 
4.8 Plasmids 
Table 8: Plasmids and their application 




CLONTECH Laboratories Inc., 
















CLONTECH Laboratories Inc., 
Mountain View, CA, USA 
pGL3 9×Gli-BS Gli reporter assay 300 
pCR3.1 Gli reporter assay Invitrogen, Carlsbad, CA, USA 
pCR3.1-mGli1 Gli reporter assay 301 
pRL-CMV Gli reporter assay 
Promega GmbH, Mannheim, 
Germany 
4.9 Antibodies 
The primary antibodies (Ab) were monoclonal (mAb) or polyclonal (pAb) against their target. 
For Western Blot analyses horseradish peroxidase (HRP) conjugated IgG 
(immunoglobulin G) secondary antibodies were used. Antibodies for immunohistochemically 
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Table 9: Primary antibodies 
Primary antibody Dilution Readout Supplier 
mAb mouse anti-α-
Tubulin (Clone DM1A) 
1:10,000 




mAb mouse anti-AKT 
(Clone 55/PKBa/Akt) 
1:1,000 
WB band size:  
60 kDa 
BD Biosciences, San 
Jose, CA, USA 
mAb mouse anti-Heat 
shock cognate 71 kDa 
protein (HSC70) (B-6)  
1:10,000  




Cruz, CA, USA  
mAb mouse anti-Ki67  1:50  
IHC: Nuclear staining 
of dividing cells 
BD Biosciences, San 




WB band size:  
21 kDa 
Cytoskeleton Inc, 
Denver, CO, USA 
mAb mouse anti-S6 
(54D2)  
1:1,000  




MA, USA  
mAb rabbit anti-pAKT 
(Ser473) (193H12)  
1:1,000  





pAb goat anti-GLI3 1:200 
WB band size: 
190 kDa: full length 
form 
85 kDa: truncated 
repressor form 
R&D Systems, 
Minneapolis, MN, USA 
pAb rabbit anti-
Caspase 3  
1:1,000  
WB band size: 35 kDa 




pAb rabbit anti-GLI1 
(V812) 
1:750 
WB band size:  




pAb rabbit anti-GLI2 
(aa46-60) 
1:1,000 





pAb rabbit anti-ERK  1:1,000  




pAb rabbit anti-pERK 
(Thr202/Tyr204)  
1:1,000  





pAB rabbit anti-Lamin 
B1 
1:1,000 





pAb rabbit anti-pS6 
(Ser240/244)  
1:1,000  





pAB rabbit anti-Ras 1:1,000 





WB: Western Blot, IHC: Immunohistochemistry 
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Table 10: Secondary antibodies 
Secondary antibody Conjugation Dilution Supplier 
















4.10 Synthetic Oligonucleotides 
All synthetic deoxyribonucleic acid (DNA) oligonucleotides were obtained from Eurofins 
Scientific SE (Luxemburg, Luxembourg). For polymerase chain reactions (PCR) and 
quantitative real-time PCR (qRT-PCR) a 10 µM working solution of each primer was used. 
The appropriate dilutions and concentrations are described in sections 5.2.3 and 5.2.8. 
 
Table 11: Oligonucleotides for PCR approaches 
Primer name 






Primers for genotyping 


















622 bp  
(wt Hras) 









270 bp  
(wt Kras) 














































302 bp  
(Hras fragment) 
299 





270 bp  













































HsaGli1 tq F 






















































































































































MHC tq F 








mTropo tq F 







mp21 tq F 







mp27 tq F 































4.11.1 Media for cultivation of prokaryotic cells 
Bacterial cells were cultured in LB medium or on LB medium agar plates. To erase 
untransformed cells appropriate antibiotics, namely ampicillin (100 µg/ml) or kanamycin 
(50 µg/ml), were added to the autoclaved and cooled media. Both, media and plates, were 
stored at 4 °C until use. 
4.11.2 Media and reagents for cultivation of eukaryotic cells 
Eukaryotic cell lines were cultured in medium according to Tab. 13. All media and reagents 
were sterile or were autoclaved. All reagents were stored at -20 °C or 4 °C until use. 
Table 13: Media and reagents 
Medium or reagent Supplier 
Accutase GE Healthcare Europe, Freiburg, Germany 
DMSO Sigma-Aldrich Co., St. Louis, MO, USA 
Dulbecco’s Modified Eagle Medium 
supplemented with 4.5 g/L Glucose, L-
Glutamine, Sodium Pyruvate (DMEM+++) 
Invitrogen, Carlsbad, CA, USA 
Dulbecco’s Modified Eagle Medium 
supplemented with 4.5 g/L Glucose, L-
Glutamine (DMEM++-) 
Invitrogen, Carlsbad, CA, USA 
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Fetal calf serum (FCS) Invitrogen, Carlsbad, CA, USA 
G 418 disulfate salt solution (50 mg/ml) Sigma-Aldrich Co., St. Louis, MO, USA 
PBS Tab.ts for cell culture 
(1 Tab.t dissolved in 500 ml ddH20, 
autoclaved before use) 
Invitrogen, Carlsbad, CA, USA 
Penicillin (10.000 U/ml) and Streptomycin 
(10 mg/ml) (P/S) 
PAN Biotech GmbH, Aidenbach, Germany 
Puromycin dihydrochloride (10 mg/ml) Sigma-Aldrich Co., St. Louis, MO, USA 
RPMI 1640 (RPMI) Invitrogen, Carlsbad, CA, USA 
TrypLE Express Invitrogen, Carlsbad, CA, USA 
Zeocin™ (100 mg/ml) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
 
4.12 Biological Material 
4.12.1 Bacterial Strains 
Chemical competent Escherichia coli DH5α cells were used for transformation and 
amplification of plasmid DNA (pDNA). The bacteria were stored at - 80 °C until use. 
 
4.12.2 Eukaryotic cell lines 
Different eukaryotic cell lines were used to perform cell culture experiments. If not indicated 
otherwise, the cells were obtained from the American type culture collection (ATCC). All cells 
were adeherent and they were cultured in appropriate cell culture media under constant 
conditions (37 °C, 5 % CO2, humidified atmosphere) in a CO2-incubator. 
Table 14: Eukaryotic cell lines 







fibroblast cell line 
responsive to SHH 
DMEM +++ 
10 % FCS 







10 % FCS 
1 % P/S 
308, 
kindly provided by 








10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 
5 µg/µl Puromycin 
This work 
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Daoy KRAS 
DAOY stably 




10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 




kidney cell line 
DMEM +++ 
10 % FCS 







kidney cell line, 
secreting Shh-N 
DMEM +++ 
10 % FCS 
1 % P/S 




fibroblast cell line 
DMEM +++ 
10 % FCS 





Human ERMS cell 
line 
DMEM +++ 
10 % FCS 





Human ARMS cell 
line 
RPMI 1640 
10 % FCS 










10 % FCS 
1 % P/S 




transduced with a 
pMSCVpuro-
HRASG12V vector  
RPMI 1640 
10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 
0.5 µg/µl Puromycin 
299 
RUCH-2 
Human ERMS cell 
line 
DMEM +++ 
10 % FCS 










10 % FCS 
1 % P/S 
8 µg/µl Puromycin 
299 
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RUCH-2 HRAS 
RUCH-2 stably 




10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 
8 µg/µl Puromycin 
299 
SHH light II 
NIH/3T3 stably 




10 % FCS 
1 % P/S 
0,4 µg/ml G-418 
0,15 mg/ml Zeocin 
310 
TE617.T 
Human ERMS cell 
line 
DMEM ++- 
10 % FCS 








10 % FCS 
1 % P/S 








NRASG12V vectors  
DMEM ++- 
10 % FCS 
1 % P/S 








10 % FCS 
1 % P/S 




4.12.3 Genetically modified mouse lines 
All experiments using animals were performed in agreement with the legal and ethical 
requirements and have been approved by the Lower Saxony State Office for Consumer 
Protection and Food Safety (file numbers 33.9-42502-04-12/0805, 33.9-42502-04-17/2534, 
33.9-42502-04-13/1284). All used mouse lines are listed in Tab. 15. Breeding, genotyping 
and experimental procedure are described in sections 5.5 and 5.2.3.1. 
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Ptchdel/+ Balb - BALB/c 
Heterozygous 
deletion of exon 8 
and 9 within the 
Ptch gene 
316 
HRasflox_B6 Hrastm1Jaf C57BL/6 
Tandemly-arrayed 
murine HRas1 
genes with a wt 
copy flanked by 
loxP sites followed 










KRasflox_B6 Krastm4Tyj C57BL/6 
A Lox-Stop-Lox 
behind exon 1 of wt 
KRas is followed by 
the KRasG12D point 






NRasflox_B6 Nrastm1Tyj C57BL/6 
A Lox-Stop-Lox 
behind exon 1 of wt 
NRas is followed by 
the NRasG12D point 












expression of the 
cyclization 
recombination 
(Cre) ERTM fusion 
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Myf5CreER/+_Balbc Myf5tm1(cre/Esr1*)Trdo BALB/c 
Tamoxifen-
inducible 
expression of the 
CreERTM fusion 











deletion of exon 3 
of the Foxn1 gene 
(causes thymic 
aplasia resulting in 













A neo cassette 
flanked by loxP 
sites is followed by 







4.13 Software and digital resources 
Utilized software were licensed and, if possible, used in the latest version. 
Table 16: Software 
Software Developer 
4D 4D Deutschland GmbH, Eching, Germany 
Adobe Photoshop CS5  
Adobe Systems Incorporated, San Jose, 
USA  
AlphaView Q SA 3.2.2  Cell Bioscience, Santa Clara, CA, USA  
CellSens Dimension  Olympus Optical Co., Ltd., Tokyo, Japan 
Endnote X5  
Thomson ISI ResearchSoft, Carlsbad, CA, 
USA  
Fiji  320 
Flowing Software 2 
Perttu Terho, Cell Imaging Core, Turku 
Centre for Biotechnology, Finland 
FlowJo V10 Tree Star Inc., Oregon, OR, USA  
Gen5 
BioTek Instruments GmbH, Bad 
Friedrichshall, Germany 
GraphPad Prism 6  GraphPad Software, Inc., La Jolla, CA, USA  
Microsoft Office  Microsoft Co., Redmond, WA, USA  
NanoDrop 800 V2.3 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Quantum FX μCT Software (Simple Viewer) 
PerkinElmer Health Sciences, Hopkinton, 
MA, USA 
SDS 2.2  Applied Biosystems, Waltham, MA, USA 
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All databases were used to get access to data and to perform further analyses. 
Table 17: Databases 
Database Online access 
Basic Local Alignment Search Tool 
(BLAST) 
https://blast.ncbi.nlm.nih.gov/Blast.cgi 
Broad-Novartis Cancer Cell Line 
Encyclopedia 
https://portals.broadinstitute.org/ccle 




Ensembl genome browser https://www.ensembl.org/index.html 
ExPASy Bioinformatics Resource Portal https://www.expasy.org/ 
MGI-Mouse Genome Informatics http://www.informatics.jax.org/ 
National Center for Biotechnology 
Information (NCBI) 
https://www.ncbi.nlm.nih.gov/ 
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5 Methods 
5.1 Cell culture methods 
All described cell culture methods were performed under sterile conditions using appropriate 
laboratory equipment. Frequent microscopic examinations were performed with special 
attention given to morphological changes, confluence and possible contaminations of the 
cells. 
5.1.1 Cultivation of eukaryotic cell lines 
All used eukaryotic cell lines (see Tab. 14) were cultured in their respective media in a CO2-
incubator at 37 °C, 5 % CO2 in a humidified atmosphere. For culture, the cells were seeded 
onto cell culture plates (ø 10 cm). The cell culture media with respective supplements (see 
Tab. 14) were renewed every fourth day at the latest. The cells were passaged and split 
when 90 % confluency was reached. For this purpose, media was removed, the cells were 
washed with PBS and the cell layer was covered with TrypLE Express. Cells were detached 
for 10 – 15 min within the cell culture incubator. The detachment process was stopped by 
adding FCS-containing cell culture media. The cell suspensions were collected from the 
plates and were pelleted at 300×g for 5 min. The supernatants were aspirated and cells were 
resuspended in fresh cell culture medium or PBS. Afterwards the cells were counted (see 
section 5.1.3) or split and then seeded onto new cell culture dishes containing fresh cell 
culture medium. 
5.1.2 Cryoconservation of cells 
Highly confluent cells at low passage numbers were detached as described above. After 
pelleting, the cells were resuspended in cell culture medium containing 5 % (v/v) DMSO. The 
cell suspensions were aliquoted in cryo-tubes and transferred into the freezing device 
Mr. Frosty for a slow freezing process. The cells were gradually frozen over night at -80 °C 
and afterwards moved into a liquid nitrogen tank for long term storage. 
To restore the cells, aliquots of frozen cells were quickly thawed at room temperature (RT). 
Thawed cells were diluted in cell culture medium and pelleted at 300×g for 5 min. The 
supernatants, which contained DMSO, were removed and the resulting pellets were 
resuspended in supplemented cell culture medium. The cells were seeded onto new cell 
culture plates for further usage. 
5.1.3 Counting of cells 
Cell numbers of replicates were defined to ensure comparability of the respective 
experiments. The seeding densities were adjusted to the different experimental setups 
(Tab. 18). 
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The cells were detached and diluted in medium or PBS as described in section 5.1.1. 
Appropriate dilutions of cell suspensions containing trypan blue (0.004 %), that stains dead 
cells, were used for counting. Then, 10 µl of every dilution was pipetted onto a 
hemocytometer (0.100 mm depth, 0.0025 mm2) and the cell numbers in all 4 big quadrants 
were counted manually. Dead/blue cells were not counted. The number of living cells was 




number of cells x 104
number of counted big squares 
x dilution factor 
 
Afterwards, dilutions with desired cell amounts were prepared and the cells were seeded for 
experiments as described in Tab. 18. 
Table 18: Conditions for in vitro assays 
5.1.4 Stable transduction of cell lines 
Stable transduction of RMS cell lines was part of a former doctoral thesis 299. Briefly, virus 
particles with the expression plasmids pMSCVpuro, pMSCVpuro-HRASG12V, pMSCVpuro-
KRASG12V, pMSCVpuro-NRASG12V were generated in collaboration with the Institute of 
Cellular and Molecular Immunology, University Medical Center Göttingen (RMS cell lines) or 
in collaboration with the Department of Biosciences, Paris-Lodron University of Salzburg 
(Daoy cell line). For this purpose, retroviral packaging cells were transfected with 3 μg of the 
plasmids. Cells were allowed to grow in fresh culture medium for 48 h. Afterwards, the virus 
particle containing supernatant was sterile filtered. For stable transduction 2 batches of each 
cell line were incubated with this supernatant. The virus containing media were refreshed 










Cell cycle analyses 
ø 10 cm cell 
culture dish 
Duplicates 1 × 106 cells/plate 8 ml/plate 
Cell viability assay 
(WST-1 assay) 
96 well plate 
Triplicates - 
Sextuplicates 
5 × 103 cells/well 100 µl/well 
Co-culture 
experiments 
96 well plate 
black 
Triplicates 
5 × 103 SHH light 
II cells + 7.5 × 
103 cells/well 
100 µl/well 
Electroporation 6 well plate Duplicates 5 × 105 cells/well 2 ml/well 
Gene expression 6 well plate Triplicates 2 × 105 cells/well 1 ml/well 
GLI reporter assay 
96 well plate 
black 
Triplicates 5 × 103 cells/well 100 µl/well 
Proliferation assay 
(BrdU assay) 




5 × 103 cells/well 100 µl/well 
Protein expression 
ø 10 cm cell 
culture dish 
- 
1 × 106 – 1.5 × 
106 cells/plate 
8 ml/plate 
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media 3 days after transduction. Different amounts of puromycin were applied to determine 
adequate concentrations for efficient selection. 
5.1.4.1 Plasmid identity verification 
The identities of the transduced plasmids were analyzed using a complementary DNA 
(cDNA) based PCR approach [95 °C (4 min), 35 cycles of: 95° C (30 sec) + 55 °C (1 min) + 
72 °C (1 min) and 72 °C for 5 min]. For this purpose, a forward primer located within the 
extended packaging sequence of the pMSCVpuro fragment and a mixture of 3 reverse 
primers located within the HRASG12V, KRASG12V or NRASG12V fragments were employed, 
which should result in plasmid specific amplificates (HRAS: 453 bp; KRAS: 596 bp; 
NRAS: 319 bp). 
5.1.5 Proliferation assay 
The cellular proliferation was measured using an ELISA-Kit according to the manufacturer’s 
instructions. The assay itself is based on DNA incorporation of the thymidine analog             
5-bromo-2’-deoxyuridine (BrdU) in DNA of proliferating cells and its detection via a 
chemiluminescent reaction. Briefly, 5 × 103 cells were seeded in black 96 well cell culture 
plates with clear bottom and were allowed to attach for 24 h. Afterwards the media were 
replaced by incubation medium for 24 h – 72 h. Simultaneously, the cells were labeled by 
addition of 10 µM BrdU to the respective incubation medium. Cells without BrdU labelling 
served as negative control. After the incubation, the cells were fixed and DNA was denatured 
by adding FixDenat solution for 30 min at RT. Fixed cells were incubated with a peroxidase 
conjugated anti-BrdU antibody (1:100) for 1 h at RT. The antibody solution was aspirated and 
wells were washed 3 times with the provided washing buffer. After removing the washing 
buffer, a peroxidase substrate solution was added sequentially by injectors of the SynergyMx 
microplate reader to all wells of the plate and luminescence was measured in the microplate 
reader with Gen5 software. Data were analyzed using Microsoft Excel and GraphPad 
Prism 6 software. 
5.1.6 Cell viability assay 
The sable tetrazolium salt WST-1 is cleaved into a soluble formazan by metabolically intact 
cells and was used to assess cell viability. The cells were seeded in a clear 96 well cell 
culture plate and were allowed to adhere for 24 h. Afterwards the media were replaced by 
medium containing respective drugs or reagents for 24 h – 72 h. At the end of treatment the 
incubation media were removed to prevent interactions between drugs and the tetrazolium 
salt. Then, the cells were incubated for 4 h at 37 °C with WST-1 reagent, which was diluted 
1:25 in fresh cell culture medium. Empty wells served as negative control. Afterwards, 
absorbance was measured at 450 nm and 655 nm in the microplate reader with Gen5 
software. The cell viability was calculated after subtraction of the reference wavelength 
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(655 nm) from the wavelength used for quantification of WST-1 cleavage (450 nm) using 
Microsoft Excel. 
5.1.7 Cell cycle analyses 
Cell cycle distribution was investigated by PI staining and subsequent fluorescence-activated 
cell scanning (FACS). The cells were seeded and allowed to grow for 48 h before harvest. 
Accutase was used to detach cells for 5 min at 37 °C. Then, cell culture medium was added 
to stop the reaction. The cell suspensions were pelleted at 300×g for 5 min and the 
supernatants were discarded. The pellets were resuspended in 1 ml of ice-cold PBS. The 
cells suspensions were transferred into pre-cooled (-80 °C) pure EtOH while shaking and 
then placed on dry ice. Afterwards, the cells were fixed in EtOH at –20 °C for at least 3 h. 
Fixed cells were pelleted at 600×g and 4 °C for 5 min. The cells were washed with ice-cold 
PBS and centrifuged again at 600×g and 4 °C for 5 min. The supernatants were discarded 
and the pellets were resuspended in 450 μl PI-staining solution (10 μg/mL PI and 100 μg/mL 
RNase A in PBS) and incubated for 30 min at 37 °C. Staining intensities were measured by 
flow cytometry (FACS Calibur) on the FL-3 channel. A minimum of 5 × 105 cells/sample were 
counted and data analysis was performed with Flowing Software 2. 
5.1.8 Transfection 
Cells were transfected with pDNA by electroporation using the Neon Transfection system 
according to the manufacturer’s instructions. A few days ahead of electroporation, the cells 
were cultured until 70 % - 90 % confluency in culture medium without antibiotics. The cells 
were detached as described in section 5.1 and the cell pellets were resuspended and 
washed with PBS. Cell counting was performed as described in section 5.1.3. The cell 
suspensions containing the desired cell number (0.5 × 106 cells/electroporation) were 
transferred into new reaction tubes and pelleted again at 300×g for 5 min. The supernatants 
were removed and cells were resuspended in resuspension buffer R at a final density of 
4.5 × 106 cells/ml. For transfection itself, 0.5 × 106 cells were mixed with 4.5 μg pDNA in a 
final volume of 110 µl. Electroporation was performed under conditions shown in Tab. 19. 
Table 19: Electroporation conditions for ERMS cell lines 
RD cells   RUCH-2 cell lines  
Pulse voltage (V) 1.000  Pulse voltage (V) 1.200 
Pulse width (ms) 30  Pulse width (ms) 40 
Pulse number 2  Pulse number 1 
After electroporation, cells were seeded in 6 well plates with pre-warmed cell culture medium 
without antibiotics. Transfection with an enhanced green fluorescent protein (EGFP) 
expression plasmid served as transfection control. Cells treated with an electric field pulse 
only served as additional control. All cells were allowed to attach for at least 18 h and were 
checked for viability and EGFP expression before performing further experiments. The 
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mentioned transfection conditions for each cell line had been established with different 
amounts of the the pEGFP-N1 plasmid using different electroporation conditions and cell 
amounts. They yielded over 70 % transfection efficiency as measured by flow cytometric 
analysis (BD LSR II flow cytometer and data evaluation by FlowJo). 
5.1.9 GLI reporter assay 
A luciferase-based GLI reporter system was used to measure transcriptional activity of GLI 
proteins. ERMS cell lines were transfected with a firefly luciferase reporter plasmid 
containing 9x GLI protein binding sites (pGL-9xGli BS) and a vector expressing constitutively 
active renilla (pRL-CMV) which served as an internal control. A plasmid overexpressing 
murine Gli1 served as positive control, whereas its pCR3.1 backbone was used in the 
negative control. Additionally, pEGFP-N1 transfected cells were included as transfection 
control. The transfections themselves were done by electroporation (see section 5.1.8). For 
transfection of cells that were grown ahead to > 75 % confluency, the plasmid concentrations 
in Tab. 20 were used. 
Table 20: Plasmid composition for GLI reporter assay in ERMS cell lines 
Positive control  
Treatment 
or treatment control 
 Negative control 
Plasmid amount  Plasmid amount  Plasmid amount 
pGL-9xGli BS 3.5 µg  pGL-9xGli BS 3.5 µg  pGL-9xGli BS - 
pRL-CMV 0.5 µg  pRL-CMV 0.5 µg  pRL-CMV 0.5 µg 
pCR3.1 mGli1 0.5 µg  pCR3.1 mGli1 -  pCR3.1 mGli1 - 
pCR3.1 -  pCR3.1 0.5 µg  pCR3.1 4 µg 
 
The transfected cells were detached after 24 h and seeded again in a black 96 well plate with 
clear bottom at a density of 5 × 103 cells/well (see section 5.1 for procedure). The cells were 
allowed to attach for at least 18 h before incubation with reagents/inhibitors for 24 h. Cells 
were checked for viability and EGFP expression microscopically before analyzing luciferase 
activity (see section 5.1.10). 
5.1.10 Dual luciferase reporter assay 
The dual luciferase reporter assay was performed according to the manufacturer’s 
instructions. Briefly, the transfected cells were washed and lysed with 21 µl of passive lysis 
buffer per well of a 96 well plate. The lyses were performed at RT for 15 min on a shaker 
(250 rounds per minute (rpm)). Afterwards culture plates containing the lysates were frozen 
at –80 °C for a minimum of 15 min, thawed at RT and shaken at 250 rpm for 1 min. LARII 
and Stop’n’Glo reagents were prepared freshly for each measurement. Firefly and renilla 
activities were measured after serial injection of the 2 substrates and subsequent 
luminescence measurement of each well using the SynergyMx microplate reader and the 
Gen5 software. For determination of the relative luciferase activity, the readouts from firefly 
luciferase activity were normalized to renilla luciferase activity.  
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5.1.11 Generation of conditioned medium (CM) 
Stably transfected HEK293 Shh-N cells and untransfected HEK293 cells were used to 
prepare Shh-CM and control-CM 310. For this purpose, the cells were cultured to a confluency 
of about 70 %. Then, the media were aspirated, cells were washed with PBS and cell culture 
media were replaced by low serum cell culture medium containing 2 % FCS instead of 10 % 
FCS. After 24 h to 48 h the CM was removed from the cell layer and sterile filtered through a 
0.2 μm pore filter. The CMs were selead with parafilm and stored at 4 °C for up to one 
month. Supernatants of ERMS cell lines were also used to generate CM under the same 
conditions. 
5.1.12 Analyses of HH ligand secretion and responsiveness 
In order to analyze whether cells were able to secrete HH ligands and thus to stimulate the 
HH pathway in surrounding cells, different cell culture approaches were applied. 
5.1.12.1 Incubation of cells with CM 
The Shh responsive B9 cells were seeded at a density of 2 × 105 cells in wells of a 6 well 
plate and allowed to attach for 24 h. Then, the culture media were replaced by CM derived 
from control and ERMS cell lines (see section 5.1.11) for 48 h. Afterwards RNA was isolated, 
reverse transcribed and analyzed for the expression of 18S, Hprt and Gli1 (see 
section 5.2.8). An increase in Gli1 expression was indicative for secretion of HH ligands into 
the cell culture medium. The results from Shh-CM treatment served as positive control. 
When responsiveness of ERMS cell lines to SHH was analyzed, the ERMS cells were 
seeded with a density of 2 × 105 cells/well in a 6 well plate and allowed to adhere for 24 h. 
Then the culture media were replaced by either Shh-CM or control-CM (see section 5.1.11) 
for 48 h. Afterwards RNA was isolated, reverse transcribed and the expression of 18S, Hprt 
and Gli1 was analyzed (see section 5.2.8). B9 cells were included in the experiments as a 
positive control. 
5.1.12.2 Co-culture experiments with the SHH light II reporter cell line 
Furthermore, the cells potentially secreting SHH were co-cultured with SHH light II cells, that 
harbor a Gli responsive luciferase reporter. For this purpose, SHH light II cells were seeded 
in a black 96 well plate with clear bottom at a density of 5 × 103 cells/well (see section 5.1.1 
for procedure) together with 7.5 × 103 cells of either HEK293 cells, HEK293 Shh-N cells or 
ERMS cells. After 24 h the media were replaced by starvation medium containing 0.5 % FCS 
for further 24 h to enhance responsiveness of SHH light II cells to a potential HH stimulus. 
Afterwards the dual luciferase reporter assay was performed as described in section 5.1.10 
to analyze HH signaling activity in the SHH light II cells. SHH light II cells stimulated with 
Smoothened agonist (SAG) and SHH light II cells co-cultured with HEK293 Shh-N cells 
served as positive controls, whereas co-culture of SHH light II cells with HEK293 cells served 
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as negative control. The culture of cells without a Gli responsive luciferase reporter was used 
as a further negative control. 
5.2 Molecular biology 
5.2.1 Plasmid cloning 
All required equipment for bacterial transformation and plasmid amplification were sterilized 
by an autoclave or a gas flame. 
5.2.1.1 Transformation of bacteria 
For cloning applications the Escherichia coli strain DH5α was used. Aliquots of 50 µl of 
competent bacteria were thawed on ice and mixed with 1 µl of pDNA. After 20 min of 
incubation a 30 sec heat shock was performed at 42 °C. Samples were cooled down on ice 
for approximately 1 min before adding 450 µl S.O.C. medium. The suspensions were shaken 
at 400 rpm and 37 °C for 50 min. Afterwards 150 µl were plated on LB agar plates containing 
adequate antibiotics for selection (100 µg/ml ampicillin or 50 µg/ml kanamycin). After a short 
drying period the plates were incubated upside down at 37 °C overnight. 
5.2.1.2 Plasmid amplification, isolation and purification 
Single colonies of transformed DH5α were picked the day after transformation (see 
section 5.2.1.1) and inoculated into 100 ml LB medium containing the adequate selection 
antibiotic (100 µg/ml ampicillin or 50 µg/ml kanamycin). For plasmid amplification bacteria 
were grown overnight on a shaker at 155 rpm and 37 °C. 
The PureLink HiPure Plasmid DNA Purification Kit was used for isolation and purification of 
pDNA according to the manufacturer’s instruction. For this purpose, the bacterial 
suspensions were distributed into 50 ml reaction tubes and centrifuged at 10,000×g for 
10 min at 4 °C. The supernatants were discarded and all pellets were resuspended in 4 ml of 
resuspension buffer (R3). Then, 4 ml of lysis buffer (L7) were added to each tube and the 
tubes were inverted once to mix the suspension. Lyses were performed for 5 min at RT and 
afterwards 4 ml precipitation buffer (N3) were added to the lysates. The suspensions were 
again mixed by inverting the tube. Then the tubes were centrifuged at 10,000×g for 10 min at 
4 °C. Meanwhile the DNA extraction columns were equilibrated with 10 ml equilibration buffer 
(EQ1). The supernatants from the centrifuged suspensions were then loaded onto the 
columns and were allowed to drain by gravity flow. Afterwards the columns were washed 
twice with 10 ml of washing buffer (W8). The bound pDNA was eluted by adding 5 ml of 
elution buffer (E4). The eluates were collected in falcon tubes and aliquoted in 1 ml aliquots. 
To each reaction tube 1 ml of pure isopropanol was added to precipitate the pDNA. The 
precipitation was performed at -20 °C overnight or at -80 °C for 30 min. The reaction tubes 
were centrifuged for 30 min at 13,000 rpm and 4 °C. Supernatants were discarded and the 
pellets were dried at 55 °C for 5 min. The isolated pDNAs were dissolved in 20 μl of ultrapure 
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H2O each by shaking at 42 °C with 1400 rpm for 10 min. pDNA concentration was quantified 
using the Nanodrop system (see section 5.2.6). 
5.2.1.3 Restriction enzyme hydrolysis 
The plasmid identity was analyzed by test-restriction hydrolysis. Based on the plasmid 
sequence, 2 adequate restriction endonucleases were chosen for hydrolysis. The digestions 
were performed using 500 ng of purified pDNA mixed with 3 units of the respective enzymes 
and hydrolysis buffer in a total volume of 10 µl. The incubation temperatures and times were 
chosen according to the manufacturer’s recommendations. The reactions were stopped by a 
heat shock at 70 °C for 10 min followed by incubation on ice. The products were analyzed 
after addition of 6× loading dye solution by separation on an agarose gel (see section 5.2.4). 
5.2.2 Isolation of genomic DNA (gDNA) 
5.2.2.1 Biopsies 
Biopsies from mouse tail tip, ear or tissue were used to isolate gDNA and to perform PCR-
based genotyping of animals. The biopsies were digested in 500 µl of STE buffer with 
0.25 mg proteinase K per sample at 55 °C overnight. The next day the samples were shaken 
thoroughly and afterwards they were centrifuged at 13,000 rpm at RT for 10 min. Then, 
300 µl of the supernatant were transferred into 1 ml of pure denatured EtOH to precipitate 
the gDNA. The samples were centrifuged for 30 min at 13,000 rpm and 4 °C. The 
supernatants were discarded and the pellets were washed with 200 µl of 70 % EtOH and 
centrifuged again at 13,000 rpm and 4 °C for 10 min. The supernatants were discarded again 
and the pellets were dried upside down at 55 °C for approximately 10 min. The isolated 
gDNA was dissolved in 125 μl ultrapure H2O and shaken at 1400 rpm 10 min at 42 °C. 
5.2.2.2 Paraffin-embedded tissue 
The isolation of gDNA from embedded tissue was performed using the QIAamp DNA FFPE 
Tissue kit according to the manufacturer’s instructions. Briefly, 8 freshly cut sections with a 
maximal thickness of 10 µm of formalin-fixed and paraffin-embedded tissue were prepared. 
Excess paraffin was removed from the sections using a scalpel. The sections were 
transferred into a reaction tube and 1 ml of xylene was added. After vigorous mixing the 
samples were centrifuged at 13,000 rpm and RT for 2 min. The supernatants were discarded 
and the pellets were resuspended in 1 ml of 96 % pure EtOH. After a further mixing step 
samples were centrifuged again at 13,000 rpm and RT for 2 min. The supernatants were 
discarded and the remaining EtOH was allowed to evaporate at 37 °C. The completely dried 
pellets were resuspended in 180 µl of ATL buffer. After adding 20 μl of proteinase K and 
mixing, the samples were incubated at 56 °C until they were completely lysed. Subsequently, 
the formaldehyde modifications were reversed by incubating the samples in ATL buffer at 
90 °C for 1 h. Afterwards, 200 μl of AL buffer were added to the samples. After a thorough 
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mixing step, 200 μl of 96 % pure EtOH were added and samples were mixed again and spun 
down. Then the lysates were transferred to elution columns (located in 2 ml collection tubes) 
and centrifuged at 8000 rpm for 1 min. The elution columns with bound gDNA were 
transferred into new 2 ml collection tube. After 2 washing steps with 500 µl of AW1 and 
500 µl of AW2 buffer by centrifugation at 8000 rpm for 1 min, the elution columns were dried 
by centrifugation at 13,000 rpm and RT for 3 min. For elution of the bound gDNA the 
columns were transferred into new 1.5 ml reaction tubes and incubated with 50 µl of ATE 
buffer for 5 min at RT. Afterwards the columns were centrifuged at 13,000 rpm and RT for 
1 min. The isolated gDNA was either used directly or stored at -20 °C. 
5.2.3 Polymerase chain reaction 
5.2.3.1 PCR-based genotyping analyses 
Genotyping of mice was performed by different PCR approaches within a total volume of 
10 µl. Each reaction contained 10-100 ng of gDNA template (0.75 µl - 1.25 µl), 0.5 µM 
forward primer (in 0.5 µl H2O), 0.5 µM reverse primer (in 0.5 µl H2O), 0.2 µM dNTPs (in 0.2 µl 
H2O), 0.3 mM MgCl2 (in 0.6 µl H2O), 10 % (v/v) Cresol (1 µl), polymerase buffer (in 1 µl), 
0.1 U MolTaq polymerase (in 0.1 µl buffer) and was filled with ultrapure H2O to 10 µl. In case 
2 reverse primers were needed the concentration of the forward primer was doubled (1 µM) 
and the amount of added H2O was reduced. The cycling conditions used for genotyping are 
listed in Tab. 21. All used Primers and size of PCR products are described in Tab. 11. 
Table 21: PCR approaches for genotyping 
 Mutant Ptch  Wildtype Ptch  Wildtype Myf5  Mutant Myf5 
Step Temp. Time Cycles Temp. Time Cycles Temp. Time Cycles Temp. Time Cycles 
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Denaturation 
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5.2.3.2 PCR-based recombination assays 
Recombination assays were performed to prove efficient recombination at the floxed Ras loci 
in tissue of genetically modified mice. For this purpose 1 µl of a gDNA (KRas and NRas) or 
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cDNA-template (HRas) was mixed with 0.5 µM forward primer (in 1 µl H2O), 0.5 µM reverse 
primer (in 1 µl H2O), 0.2 µM dNTPs (in 0.4 µl H2O), 0.2 mM MgCl2 (in 0.8 µl H2O), 10 % (v/v) 
Cresol (2 µl), polymerase buffer (2 µl), 0.1 U MolTaq polymerase (in 0.2 µl buffer). The 
reaction was filled with ultrapure H2O to 20 µl. The used primers for the different 
recombination assays and their sequences are listed in Tab. 11. The utilized PCR programs 
are listed in Tab. 22. 
 
Table 22: PCR approaches for recombination assays 
 HRas  KRas  NRas   
Step Temp. Time Cycles Temp. Time Cycles Temp. Time Cycles    
First 
Denaturation 







































     
 
5.2.3.2.1 KRas and NRas recombination assays 
The PCR products from KRas and NRas recombination assays were analyzed directly by 
agarose gel electrophoresis (see section 5.2.4). For both assays a double band 
(Kras: 270 bp for wt and 304 bp for recombined KRas; NRas: 487 bp for wt and 521 bp for 
recombined NRas) indicated efficient recombination whereas a single band (KRas: 270 bp 
for wt KRas; NRas: 487 bp for wt NRas) indicated no recombination. 
5.2.3.2.2 HRas recombination assays 
The recombination assay for HRas comprised an enzymatic digestion of PCR-amplified 
HRas fragments with BpmI. The enzyme recognizes the wt sequence, whereas the mutant 
HRas sequence is not recognized by the enzyme due to the HRasG12V mutation 303. 
For the recombination assay 12.5 µl of PCR-amplified HRas cDNA were mixed with 0.5 U 
BpmI (in 0.25 µl buffer) and 3.1 NEBuffer™ (2 µl), and the reactions were filled up with 
ultrapure H2O to 20 µl. The enzyme hydrolyses were performed at 37 °C for 30 min and 
reactions were stopped by a heat shock at 65 °C for 2 min. The products were analyzed by 
agarose gel electrophoresis (see section 5.2.4). Not digested samples, lacking the restriction 
enzyme, were used as negative control. Potential results from the recombination assay are 
shown and explained in Fig. 5. 
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Figure 5: Potential readouts from HRas recombination assays 
Heterozygous mice without recombination will show 2 strong digestion fragments (209 bp and 93 bp) and a weak 
undigested fragment (302 bp) (left cartoon). Heterozygous mice with successful recombination will show weak 
digestion bands (209 bp and 93 bp) and a strong undigested fragment (302 bp) (right cartoon). Since complete 
digestion was not feasible in this experimental setting an undigested fragment (302 bp) was always expected. 
5.2.4 Agarose gel electrophoresis 
DNA fragments were separated by agarose gel electrophoresis. Depending on the expected 
product sizes 1 % to 3 % (w/v) agarose gels were prepared in TBE buffer. The solutions 
were boiled for 3 min in a microwave oven at 1000 W to dissolve the agarose powder. The 
liquid gel was cooled down and a few droplets of ethidium bromide (0.07 %) were added. 
The agarose was poured into trays and combs were placed. After solidification, the combs 
were removed and the gels were covered with TBE buffer in an electrophoresis chamber. 
The samples were loaded and an electric field was applied (80-120 V, 500 mA, separation: 
30 min-2.5 h). Appropriate markers were used to indicate the DNA size. Fragments were 
visualized in an UV transilluminator and documented using the INTAS GDS 3.39 software. 
5.2.5 Ribonucleic acid (RNA) isolation 
To protect RNA from degradation, the isolation was performed on ice if not indicated 
otherwise. Filter tips and equipment was RNAse-free. For isolation, the Trizol reagent was 
used according to the manufacturer’s recommendations. 
5.2.5.1 Isolation of total RNA from eukaryotic cell lines 
The cultured cells were washed twice with ice-cold PBS and 1 ml of cold Trizol was added to 
one well of a 6 well plate. The suspensions were transferred into 2 ml tubes and were mixed 
thoroughly for 2 min on a shaker. After a 5 min incubation step at RT 200 µl chloroform were 
added to each sample. Again, the samples were mixed thoroughly for 20 sec on a shaker 
and incubated for 3 min at RT. A centrifugation step at 12,000 rpm and 4 °C for 10 min 
resulted in a phase separation. Approximately 600 µl/sample of the clear upper and aqueous 
phase were transferred into a tube with 700 µl of pre-cooled isopropanol. After precipitating 
overnight at -20 °C, the samples were centrifuged at 12,000 rpm and 4 °C for 30 min. The 
supernatants were discarded and the pellets were washed with 700 µl of pre-cooled 70 % 
pure EtOH. After 2 further washing steps (consisting of a centrifugation at 12,000 rpm and 
4 °C for 15 min, the removal of the supernatants and the addition of 700 µl of pre-cooled 
70 % pure EtOH) the RNA pellet was air-dried for about 1 h and solubilized in 15 µl – 45 µl 
ultrapure H2O while shaking at 900 rpm and 56 °C for 10 min. The RNA concentrations were 
quantified (see section 5.2.6) and samples were stored at -80 °C. 
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5.2.5.2 Isolation of total RNA from tissue samples 
Approximately 20 mg of frozen tissue sample were chopped in a petri dish on dry-ice using a 
scalpel blade. The chopped tissue was transferred into a 2 ml tube and covered with 1 ml of 
cold Trizol. Then the tissue samples were homogenized on ice using a disperser tool until a 
homogenous solution was achieved. The tool itself was cleaned after each sample. Further 
lyses were performed by incubation of the homogenates in Trizol for 5 min. The following 
steps were performed as described in section 5.2.5.1. 
5.2.6 Photometric quantification of nucleic acids 
The NanoDrop 8000 spectrophotometer was used to photometrically determine DNA and 
RNA concentrations. Optical densities (OD) of each sample were measured at 230 nm, 
260 nm, 280 nm and 340 nm. OD260 provides the concentration of nucleic acids, whereby an 
OD260 of 1.0 reflects 50 µg/ml pure dsDNA or 40 µg/ml pure RNA. Thus, DNA or RNA 
concentrations were calculated by multiplying the measured OD260 values with 50 or with 40, 
respectively. OD230 of the sample provides a measurement of the concentration of sugars, 
salts and phenols, OD280 of the sample provides the concentration of proteins and OD340 
measures turbidity and background signals. DNA and RNA samples with an OD260/OD280 
ratio between 1.8 and 2 and an OD260/OD230 ratio ≥ 2, respectively, were considered as pure 
nucleic acids. OD340 values were optimally close to zero. 
5.2.7 Reverse transcription 
For cDNA synthesis, the SuperScript II Reverse Transcriptase kit was used based on the 
manufacturer’s recommendations. In detail, 2 µg of total RNA (for isolation see section 5.2.5) 
were diluted in 7 µl of ultrapure H2O and mixed with 250 ng of random hexamer 
oligonucleotides (in 5 µl H2O) and incubated for 10 min at 70 °C. A mixture of 0.5 mM dNTPs 
(in 1 µl H2O), 10 mM DTT (in 2 µl H2O) and first strand buffer (4 µl) were added to the 
samples and the mixtures were incubated for 10 min at RT. After pre-warming at 42 °C for 
2 min, 100 U (in 1 µl) of reverse transcriptase were added (final volume of 20 µl). The 
enzyme-driven cDNA synthesis was performed at 42 °C for 1 h. A heat inactivation step at 
70 °C for 10 min stopped the synthesis. Assuming a reaction efficiency of 50 % the final 
cDNA concentration theoretically was 50 ng/µl. The samples were stored at -20 °C. 
5.2.8 Quantitative real time PCR 
Gene expression analyses were performed by SYBR-green based quantitative real time PCR 
(qRT-PCR). Dependent on the gene of interest (GOI) either the Platinum SYBR Green qPCR 
Super Mix (Invitrogen) or QuantiTect SYBR Green PCR (Qiagen) were applied using 
different qRT-PCR programs (see Tab. 23). For qRT-PCR reactions, 2 µl of diluted cDNA 
(see Tab. 24) were added to 8 µl of a prepared mastermix (see Tab. 23) resulting in a total 
reaction volume of 10 μl. Details of the used primer pairs are listed in Tab. 12. All 
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measurements were performed in triplicates in a sealed black 384 well plate on an ABI Prism 
7900HT device using the SDS software.  
The gene expression values were calculated using the standard curve method. To generate 
the standard curve a sample with high and constant expression of the GOI was chosen. Of 
this sample 20 ng/2 µl cDNA or 250 pg/2 μl cDNA were subjected to a 5-fold serial dilution 
row and amplified with primers specific for the GOI or 18S ribosomal RNA (rRNA), 
respectively. Logarithmic values of the calculated cDNA concentration from the dilution 
series were plotted against the corresponding measured cycle threshold (CT) from the same 
sample. A trend line was plotted and its formula was used to calculate the amount of GOI 
cDNA in the target samples. The resulting transcript levels of the GOI were normalized to 
those of 18S rRNA of the same sample. Furthermore, the GOI transcript levels were also 
normalized to the reference genes HPRT/Hprt or TBP/Tbp. The standard curves for these 
genes were generated by 5-fold serial dilutions starting with 20 ng/2 µl cDNA. Further 
analyses were done using the SDS 2.2, Microsoft Excel and GraphPad Prism 6 software. 
Additionally, the results were relativized to experimental control samples, such as solvent 
controls. 
Table 23: Mastermix and conditions for qRT-PCR 
Mastermix  Qiagen  Invitrogen 
Component Volume  Temp. Time Cycles Temp. Time Cycles 
SYBR Green 
Forward primer  




0.4 µl (0.4 µM) 
0.4 µl (0.4 µM) 
2.2 µl 






















 40 x 
cDNA template 2 µl  Dissociation stage 
(95 °C: 15 sec, 60 °C: 15 sec, 
95 °C: 15 sec) 
 Dissociation stage 
(95 °C: 15 sec, 60 °C: 15 sec, 
95 °C: 15 sec) 
 
Table 24: Assay informations for qRT-PCR 











18S rRNA E12.5 1:13,500 Qiagen, 
Invitrogen 
 18S rRNA E12.5 1:13,500 Qiagen, 
Invitrogen 
HPRT RMS-13 1:10 Invitrogen  Hprt E12.5 1:20 Qiagen, 
Invitrogen 
GLI1 RMS-13 1:10 Invitrogen  Tbp E12.5 1:20 Invitrogen 
GLI2 RMS-13 1:10 Qiagen  Gli1 E12.5 1:20 Invitrogen 
GLI3 RUCH-2 1:10 Qiagen  Gli2 E12.5 1:20 Qiagen 
HHIP RMS-13 1:10 Invitrogen  Gli3 RMS 1:20 Invitrogen 
PTCH RMS-13 1:10 Qiagen  Hhip E12.5 1:20 Qiagen 
SHH MET-4 undiluted Qiagen  Ptch E12.5 1:20 Qiagen 
     MyoD RMS 1:20 Qiagen 
     Myogenin RMS 1:20 Invitrogen 
     Myosin heavy 
chain (MyHC) 
RMS 1:20 Qiagen 
     Tropomyosin 3 RMS 1:20 Qiagen 
     p21 RMS 1:20 Qiagen 
     p27 RMS 1:20 Qiagen 
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5.3 Protein biochemistry 
The protein isolations were performed on ice if not indicated otherwise. Protein samples were 
stored at -80 °C. 
5.3.1 Protein isolation from cell culture 
Subconfluent cells grown on a 10 cm culture plate were used to detect the proteins 
pERK/ERK, pAKT/AKT, pS6/S6, pan-RAS, Caspase 3 and HSC70. For examination of 
nuclear and cytoplasmic GLI proteins 5 cell culture plates were pooled (see section 5.3.2). 
The cell layers were washed twice with ice-cold PBS. Afterwards 500 µl of ice-cold PBS were 
added and the cells were scraped off the plate. The cell suspensions were transferred into 
cooled 2 ml tubes. The samples were centrifuged at 2,000 rpm and 4 °C for 5 min, 
afterwards the supernatants were discarded. The cell pellets were snap frozen in liquid 
nitrogen and thawed on ice. The pellets were resuspended in 50 µl – 100 µl of lysis buffer 
(depending on the pellet size) and passed several times through a 30G needle using a 1 ml 
syringe. Lysis was performed 45 min on ice and samples were gently mixed every 15 min. 
Then the lysates were centrifuged at 13,000 rpm and 4 °C for 30 min. The supernatants 
containing the cellular proteins were transferred into new tubes. 
5.3.2 Subcellular fractionation of cellular lysates 
The protocol for subcellular fractionation is based on other protocols described in the 
literature 321,322. The cells were scraped off and washed as described in section 5.3.1. The 
pellets were resuspended in 500 µl PBS and the cell suspensions were split into 2 tubes to 
isolate cytosolic/nuclear proteins or the total protein fraction. Both tubes were centrifuged at 
2,000 rpm and 4 °C for 5 min and the supernatants were discarded. Isolation of the total 
fraction was performed as described above (see section 5.3.1). The samples for isolation of 
the cytosolic and nuclear proteins were thoroughly resuspended in 250 µl of subcellular 
fractionation (SF) buffer and passed several times through a 30G needle using a 1 ml 
syringe. Lysis was performed 45 min on ice and the samples were gently mixed every 
15 min. Afterwards the samples were centrifuged at 3,000 rpm and 4 °C for 15 min. The 
supernatants from this step were used to isolate cytosolic proteins, whereas the pellet was 
used to isolate nuclear proteins. 
For isolation of cytosolic proteins, the supernatants were transferred into a new 1.5 ml tube 
and centrifuged at 8,000 rpm and 4 °C for 12 min. The resulting supernatant contained the 
cytosolic and membrane fractions. 
To isolate nuclear proteins, the pellets were resuspended in 500 µl of SF buffer and washed 
by centrifugation at 3000 rpm and 4 °C for 10 min. The supernatants were discarded and the 
pellets were snap frozen in liquid nitrogen and thawed on ice. After thawing the pellets were 
resuspended in 50 µl of nuclear lysis buffer (NL buffer) and incubated for 45 min on ice and 
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gently mixed every 15 min. After lysis, the samples were centrifuged at 3000 rpm and 4 °C 
for 30 min and the supernatants containing the nuclear proteins were collected. 
5.3.3 Protein isolation from murine tissue samples 
Approximately 30 mg of a frozen tissue sample was chopped in a petri dish on dry ice using 
a scalpel blade. The chopped tissue was transferred into a 2 ml tube and covered with 200 µl 
of cold modified RIPA buffer. Tissue samples were homogenized on ice using a 
homogenizer. The homogenates were snap frozen in liquid nitrogen and thawed on ice. 
Afterwards the lysates were clarified by centrifugation at 10,000 rpm and 4 °C for 20 min. 
The supernatants, which contained cellular proteins, were collected and transferred into new 
tubes. The homogenizer was thoroughly cleaned before homogenizing another sample. 
5.3.4 Quantification of isolated protein samples 
The protein concentration was measured using the Pierce BCA (bicinchoninic acid) protein 
assay kit according to the manufacturer’s recommendations. Briefly, the proteins were 
quantified in technical triplicates by adding 1 µl protein lysate to a well of a clear 96 well 
plate. Then, 200 µl of freshly prepared substrate solution was added to each well and the 
plate was incubated at 37 °C for 30 min to allow for the colorimetric reaction. A BSA dilution 
series in the respective lysis buffer was used to generate a standard curve. Absorbance was 
measured at 540 nm in a SynergyMx microplate photometer. The total protein concentration 
was calculated using the standard curve values. 
5.3.5 Western Blot 
For Western Blot analyses 20-45 µg of protein lysate were dissolved in 20 µl of ultrapure 
H2O. SDS loading buffer was added and thereby diluted to a one fold concentration. The 
samples were denatured by boiling for 5 min at 96 °C and 500 rpm. After cooling on ice the 
samples were loaded onto appropriate SDS gels. The SDS gel electrophoresis was 
performed on ice. 
5.3.5.1 Semi-dry blotting 
Semi-dry blotting was used to detect smaller proteins with a maximal size of 100 kDa. For 
this purpose, proteins were separated on 4-12 % Bis-Tris gels using the MES SDS running 
buffer. The denaturated protein samples and an appropriate protein marker were loaded onto 
the gels and separated at 110-160 V and 160 mA for approximately 1.5 h. The separated 
proteins were blotted onto a nitrocellulose (NC) membrane with 0.2 µm pore size using semi-
dry blotting buffer. The blotting itself was performed in a Trans-Blot® SD Semi-Dry Transfer 
Cell at 120 mA and 20 V for 1 h 25 min. 
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5.3.5.2 Tank blotting 
The tank blotting was used to detect larger proteins. For this purpose, denaturated samples 
were loaded onto 3-8 % Tris-acetate gels. A high range protein marker was loaded to 
determine protein size. Separation by SDS gel electrophoresis was performed in Tris-acetate 
SDS running buffer at 100-110 V and 100 mA for approximately 2.5 h. The separated 
proteins were blotted onto a NC membrane with 0.45 µm pore size at 55 V and 300 mA for 
2 h 35 min at 4 °C in a tank containing constantly stirred tank blotting buffer. 
5.3.5.3 Antigen detection and visualization 
After blotting, the membranes were blocked with 5 % (w/v) milk powder dissolved in TBST for 
1 h at RT on a shaker. Afterwards the membranes were washed 3 x 10 min with TBST. The 
blocked membranes were incubated with primary antibodies dissolved in BSA-azide (for 
dilutions compare Tab. 9) at 4°C on a roller overnight. The membranes were washed again 
3 × 10 min with TBST. Then HRP-conjugated secondary antibodies were added in 5 % (w/v) 
milk in TBST for 1 h at RT (see Tab. 10). After 3 washing steps with TBST, signals were 
detected using an enhanced chemiluminiescence reagent (ECL) in combination with the 
FluorChem Q system. For this purpose, luminol and peroxidase substrate were mixed 1:1 
directly before use. The membranes were covered with the solution and after a short 
incubation time excess ECL was removed. Picture acquisition and processing was done with 
AlphaView Q SA and Adobe Photoshop CS5 softwares. 
5.3.5.4 Stripping of membranes 
For detection of multiple proteins of a similar size on the same membrane, the antibodies 
were stripped off. For this purpose, the membranes were washed with TBST for 2 × 10 min 
to remove the ECL reagent. The bound antibodies were stripped off by incubation of the 
membrane with stripping buffer at 55 °C for 30 min under constant rotation. Afterwards the 
membranes were washed thoroughly at least 4 times for 10 min in TBST. Then the 
membranes were blocked again and incubated with new primary antibodies solutions 
(section 5.3.5.3). 
5.3.6 Ras pull-down activation assay 
The Ras activation assay was strictly performed according to the manufacturer’s instructions. 
5.3.6.1 Cell culture samples 
Subconfluent cells grown on a 10 cm cell culture plate were washed twice with ice-cold PBS 
and scraped off the plate using 500 µl of ice-cold PBS. The suspensions of 4 plates were 
pooled and centrifuged at 2,000 rpm and 4 °C for 5 min. The supernatants were discarded 
and cells were resuspended in 500 µl of the provided ice-cold lysis buffer. The lyses were 
performed for 10 min on ice and samples were centrifuged at 10,000 rpm and 4 °C for 2 min. 
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For protein quantification and detection of total Ras protein 60 µl of lysates were separated. 
The remaining cell lysates were immediately snap frozen in liquid nitrogen. Afterwards the 
protein concentrations were determined utilizing the BCA assay (see section 5.3.4). 
As control, one sample was either loaded with GTPγS or GDP. For this purpose, 200 µg of 
protein were mixed with one-tenth volume of loading buffer. Immediately one-hundredth 
volume of supplied GTPγS or GDP was added. The samples were incubated at 37 °C for 
30 min at 300 rpm on a shaker. Afterwards, the samples were mixed with one-tenth volume 
of stop buffer and stored on ice until the pulldown assay was performed. These GTPγS- or 
GDP-loaded samples were used to prove an efficient pulldown of active Ras protein. 
Furthermore, the kit supplied a pure His-Ras control protein, which was diluted in 2×Laemmli 
buffer and water before use. This protein served as a size marker. Moreover, 30 µg of total 
lysate of each analyzed sample was used to detect total Ras protein on a separate gel. 
These lysates were diluted in 20 µl of ultrapure H2O and SDS loading buffer and seubjected 
to Western Blot analyses. 
For the pulldown assay, 200 µg of protein were loaded onto 100 µg (30 µl) of Raf-RBD beads 
on platform shaker at 4 °C for 1 h. Afterwards, the beads were pelleted by centrifugation at 
10,000 rpm at 4 °C for 2 min. The supernatant was carefully discarded and the beads were 
washed with 500 µl of supplied washing buffer and centrifuged again at 10,000 rpm and 4 °C 
for 3 min. The supernatant was discarded and the bead pellet was resuspended in 15 µl of 
2×Laemmli buffer. All prepared samples were boiled at 96 °C and 400 rpm for 3 min and then 
rapidly cooled down on ice. Afterwards, samples were loaded onto 4-12 % Bis-Tris gels and 
semi-dry blotting was performed as described in section 5.3.5.1. 
5.3.6.2 Tissue samples 
Approximately 30 mg of a frozen tissue sample was chopped in a petri dish on dry ice using 
a scalpel blade. The chopped tissue was transferred into a 2 ml tube containing 200 µl of 
cold lysis buffer. Tissue samples were homogenized on ice. The homogenates were clarified 
by centrifugation at 10,000 rpm and 4 °C for 2 min. The supernatants containing the protein 
lysates were transferred into new tubes and immediately snap frozen. The following steps 
were identical to the procedure described above (see section 5.3.6.1) with the exception that 
600 µg of protein were loaded onto 100 µg (30 µl) of Raf-RBD beads. 
5.4 Immunohistochemical stainings 
Tissue samples were fixed in 4 % (w/v) PFA in PBS for 24 h – 48 h at RT and then 
transferred into cold PBS and stored at 4 °C until embedding. The paraffin embedding was 
performed by Anke Frommhold and in cooperation with the Institute of Neuropathology, 
University Medical Center Göttingen. 
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The paraffin-embedded tissues were cut into 4-5 µm sections on a microtome. The sections 
were mounted onto microscope glass slides or superfrost glass slides and dried at 37 °C 
overnight prior immunohistochemical stainings. 
5.4.1 Haematoxylin and eosin staining 
For haematoxylin and eosin (HE) staining, sections were deparaffinized 2 times in xylene for 
10 min and then rehydrated by a descending ethanol series (2 x 99 %, 96 %, 80 % and 
70 %). After a thorough washing step under running ddH2O, the slides were stained in 
hematoxylin solution for 20 min. Afterwards, the slides were washed under running warm tap 
water until hematoxylin was completely washed out from the cuvette. Then the slides were 
incubated with 1 % eosin solution for a maximum of 20 sec and shortly washed under 
running ddH2O. Immediately after washing, the sections were dehydrated using ascending 
ethanol solutions (70 %, 80 %, 96 %, 99 %) and placed in fresh xylene twice in succession. 
Finally, the sections were mounted with Pertex and dried at least for 20 min at 55 °C. 
5.4.2 Ki67 staining 
For Ki67 staining the sections were deparaffinized 2 times in xylene for 10 min and were 
rehydrated by a descending ethanol series (2 x 99 %, 96 %, 80 % and 70 %). After washing 
under running ddH2O, antigen-retrieval was performed by cooking the slides in citric acid 
buffer (pH 6) once for 4 min and 3 times for 3 min at 600 W in a microwave oven. Afterwards, 
the slides were cooled down to RT while shaking. Then the slides were washed 2 times in 
TBS buffer. Blocking of endogenous peroxidase activity was performed for 20 min on a 
shaker by incubating the sections in 3 % H2O2 in TBS buffer. The slides were washed for 
5 min with ddH2O and then placed in a moist chamber. A blocking against unspecific 
antibody binding was performed by adding 0.2 % casein in TBS buffer onto the slides. The 
primary antibody against Ki67 was diluted 1:50 in TBS and 50 µl of this solution were applied 
to each tissue section and incubated overnight at 4 °C. Then the slides were washed 3 times 
with TBST and afterwards they were incubated with the HRP-conjugated secondary antibody 
from the Dako EnVision kit for 30 min within a moist chamber at RT. After washing with 
TBST the staining was visualized by incubation with AEC staining solution. Haematoxylin 
was used for counter staining. Then, the slides were mounted with glycergel. 
The results were evaluated by counting the number of Ki67+ nuclei compared to the total 
number of nuclei. For this purpose, the staining was documented by 6 or 10 consecutive 
pictures of randomly chosen areas within the tumor tissue. The pictures were taken at 
200 x magnification with the CellSens Dimension software and total number of nuclei, as well 
as Ki67+ nuclei were counted manually using AlphaView Q SA software. 
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5.4.3 X-Gal staining 
For X-Gal staining, the tissue samples were embedded in cryoblock media. For this purpose, 
freshly isolated tissue was fixed in 4 % PFA on ice for 2 h. Afterwards the tissue samples 
were washed 3 times with PBS for 20 min while shaking. The fixed tissues were equilibrated 
overnight in 25 % (w/v) sucrose in PBS at 4 °C. The next day, the tissue samples were 
embedded in cryoblock media on dry ice and cut into thin sections at -20 °C to -22 °C using a 
cryotome. The sections were mounted onto superfrost glass slides and were dried at RT for 
at least 2 h. The dried sections were incubated for 10 min with 0.2 % (v/v) glutaraldehyd in 
PBS on ice. Afterwards, the sections were washed 3 times with LacZ buffer (see Tab. 4) for 
5 min on a shaker. Subsequently the sections were incubated with LacZ staining solution 
(see Tab. 4) at 30 °C overnight. If necessary, the staining solution was renewed after 24 h to 
enhance the signal intensity. The reactions were stopped by washing with PBS. Finally, the 
sections were mounted with mounting medium containing DAPI. Then pictures were taken at 
600 x magnification using a Color View camera operated by CellSens software. 
5.5 Animal experiments 
All animal experiments were performed after approval of the Lower Saxony State Office for 
Consumer Protection and Food Safety and in accordance with all relevant ethical and legal 
requirements. Housing and breeding of animals was performed within the animal facility at 
the Institute of Human Genetics, University Medical Center Göttingen. In general, mice were 
housed at a 12 h light-dark cycle at 20 ± 2 °C and a relative humidity of 55 ± 10 % in 
individually ventilated Makrolon type 2 cages located in air-flow racks. Health checks were 
performed daily by animal caretakers. Mice received tap water and food pellets ad libitum. All 
used mouse lines are listed in Tab. 15. 
5.5.1 Tumor xenografts 
Immunodeficient Nu/Nu mice were used for transplantation studies and were purchased from 
Charles River Laboratories (Wilmington, USA). These mice were housed in autoclaved and 
individually ventilated type 2 cages and received sterilized food pellets as well as autoclaved 
water ad libitum. Genotypes of Nu/Nu mice were determined by the presence (Nu/+) or 
absence (Nu/Nu) of hairs. 
For analyses of the in vivo growth behavior of oncRAS-expressing ERMS cell lines, cells 
harboring the control vector or cells expressing oncRAS were transplanted subcutaneously 
into the left and right flank of one Nu/Nu mouse, respectively. For the transplantation 
experiments animals of both genders at an age between 8 and 11 weeks were used. 
Ahead of transplantation ERMS cell lines were grown in cell culture to 90 % confluence. One 
day before transplantation the cells were split 1:3 to ensure exponential growth. On the day 
of transplantation cells were collected and counted (compare sections 5.1.1 and 5.1.3). 
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Then, 2 × 106 TE617.T cells in PBS or 9 × 106 RUCH-2 cells in 1:1 Matrigel:PBS in a total 
volume of 200 µl were transferred into pre-cooled Sub-Q syringes and kept on ice. Mice were 
anesthetized with 1-3 % isoflurane in a 1:1 air/oxygen mix. Then the cells were injected 
subcutaneously. After transplantation mice were carefully monitored and tumor size was 
measured every second or every day by a caliper. The tumor volume was calculated by 
assuming an ellipsoid shape using de formula: 
Tumor volume =
tumor width x height x length
2
 
Mice were sacrificed when a tumor reached a diameter of 1.5 cm or latest 55 days after 
transplantation. The tumors were isolated, their exact size and weight was documented and 
then they were fixed in 4 % PFA in PBS. If possible, parts of the tumor tissue were frozen on 
dry ice and stored at -80 °C for further experiments. 
Transplantation and tumor monitoring of TE617.T KRAS xenografts was part of the doctoral 
thesis of N. Cuvelier 299. 
5.5.2 Breeding of mice 
For ERMS monitoring studies Ptchdel/+ Balb mice were used. These mice harbor a 
heterozygous deletion of exon 8 and 9 within the Ptch gene and spontaneously develop 
RMS, which resembles human ERMS 137,143. These mice were bred to conditional 
HRasflox_B6 303, KRasflox_B6 317 or NRasflox_B6 220 mice. The latter mice are heterozygous 
for a floxed oncogenic Ras allele that is expressed upon Cre-mediated recombination. The 
resulting Ptchdel/+oncRasfl/+ offspring were crossed to Myf5CreER/+ mice 305. Since, as in 
humans, RMS of Ptchdel/+ Balb mice express high levels of Myf5 143,323, activation of the Cre 
recombinase in this model should result in expression of oncogenic Ras isoforms in the 
tumors. An overview of the breeding is displayed below (Fig. 6). 
 
Figure 6: Breeding scheme for tumor monitoring studies 






 mice. For 
details, see text. 
When analyzing potential oncRas-dependent effects on ERMS precursor lesions the parental 
Myf5CreER/+ mice were on a mixed C57BL/6 x BALB/c background, whereas those used for 
the analyses of oncRas-dependent effects in established ERMS were incipient-congenic and 
had been backcrossed 8 generations to BALB/c. Backcrossing had been done because the 
BALB/c background confers high susceptibility to ERMS 324,325. 
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5.5.3 Identification of mice 
Mice were weaned at the age of 3 weeks and were numbered by ear clipping. Younger mice, 
which still were not weaned, were labeled by a tattoo code on their paws. At the same time 
tail tip biopsies were taken and were used for genotyping of the respective mice (see 
section 5.2.3.1).  
5.5.4 Tamoxifen application 
To induce recombination of the floxed Ras loci in Ptchdel/+oncRasfl/+Myf5CreER/+ mice 1 mg of 
tamoxifen in 100 µl solvent was injected intraperitoneally (i.p.) for 5 consecutive days 
resulting in a total dose of 5 mg tamoxifen per mouse. Tamoxifen was prepared by mixing 
200 mg tamoxifen with 20 ml Sunflower seed oil and 800 µl pure EtOH. The solution without 
tamoxifen served as solvent control. The solutions were aliquoted into syringes and frozen at 
-20 °C until use. 
5.5.5 Tissue isolation 
Mice were euthanized by CO2 or isoflurane narcosis and subsequent cervical dislocation. All 
tumors, skeletal muscles from the leg and back, cysts or suspicious tissues were taken and 
washed with PBS. If possible, tumors were weighed and measured using a caliper. Tumor 
tissue, cysts and suspicious tissues were fixed in 4 % PFA in PBS and were embedded in 
paraffin for immunohistochemical stainings (see section 5.4). The skeletal muscles and parts 
of the tumor samples were frozen on dry ice or snap frozen in liquid nitrogen and stored 
at -80 °C for protein and gene expression analyses. 
5.5.6 Testing of the Myf5CreER/+ deleter 
To check the activity of the Myf5CreER/+ deleter in ERMS, Ptchdel/+Myf5CreER/+R26R+/- reporter 
mice were generated 299. Tumor bearing mice were injected with 1 mg tamoxifen on 
5 consecutive days and sacrificed 1 or 5 weeks thereafter. X-Gal stainings were performed 
on frozen sections of brain, heart, intestine, skeletal muscle and ERMS as described in 
section 2.4.3. 
5.5.7 Tumor monitoring: induction of oncRas in ERMS precursor lesions 
At the age of 4 weeks mice were injected with 1 mg. of tamoxifen i.p for 5 consecutive days 
to induce cre-mediated recombination at the respective Ras loci. Mice were monitored once 
a week for palpable tumors and were visually controlled for other abnormalities until the age 
of 200 days. The appearance of palpable tumors was recorded. Animals with poor general 
condition or those carrying tumors exceeding a size of 1.5 cm were sacrificed. Tissue was 
isolated as described in section 5.5.5. An overview of the study design is shown in Fig. 7. 
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 mice at the age of 4 weeks were injected with tamoxifen for 5 consecutive 
days or left untreated. Afterwards mice were monitored weekly until the age of 200 days. For details, see text. 
The studies were performed using tamoxifen-treated Ptchdel/+HRasfl/+Myf5CreER/+, 
Ptchdel/+KRasfl/+Myf5CreER/+ and Ptchdel/+NRasfl/+Myf5CreER/+ mice. Untreated siblings of the same 
genotype served as control. In order to analyze the effect of tamoxifen itself on tumor growth, 
ERMS-growth of tamoxifen- and untreated Ptchdel/+ mice from the same breeding were used. 
Part of these experiments have been done by N. Cuvelier and are described in her doctoral 
thesis 299. Here, the already generated data were re-analyzed and the collected material was 
used for further analyses. Thus, the genotypes of each mouse were verified by a second 
round of genotyping PCR (see section 5.2.3.1). For this purpose, frozen and embedded 
tissue samples were used. In addition, recombination assays were performed using frozen or 
embedded samples from skeletal muscle and ERMS (see section 5.2.2). Finally, the study 
using Ptchdel/+NRasfl/+Myf5CreER/+ mice was completely repeated. 
5.5.8 Tumor monitoring: induction of oncRas in already established ERMS 
After weaning, mice were monitored once a week for palpable ERMS and were visually 
controlled for other abnormalities. Tumors occurred mainly at the extremities and the lower 
back and were observed until they reached a diameter of approximately 0.5 cm. Then the 
mice were subjected to micro computed tomography (µCT) measurement to determine the 
exact tumor volume (see section 5.5.9). Afterwards the mice were injected with 1 mg of 
tamoxifen for 5 consecutive days to induce the cre-mediated recombination at the Ras loci. 
After tamoxifen induction the mice were further monitored for changes in ERMS growth and 
general health conditions. Seven weeks after onset of the tamoxifen treatment, the mice 
underwent a second µCT measurement, which was defined as the end point of the study. 
Animals were euthanized, and tissue samples were taken as described in section 5.5.5. An 
overview of the study design is shown in Fig. 8. 
 
 









 mice were monitored for palpable tumors. After tumor 
detection, mice were subjected to micro computed tomography (µCT) measurement and were injected with 
tamoxifen or solvent for 5 consecutive days. The mice were monitored for further 7 weeks and then subjected to a 
second µCT measurement. For more details, see text. 
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The study was performed with Ptchdel/+HRasfl/+Myf5CreER/+, Ptchdel/+KRasfl/+Myf5CreER/+ and 
Ptchdel/+NRasfl/ Myf5CreER/+ mice. Mice were injected with 1 mg of tamoxifen i.p. for 5 
consecutive days to induce cre-mediated recombination or with solvent as a control. In 
addition, tamoxifen-treated or solvent-treated Ptchdel/+ siblings from each breeding cohort 
served as controls. 
5.5.9 Tumor volume measurement by µCT 
A low dose in vivo μCT (QuantumFX) was used to measure the tumor volume in living 
animals. The data acquisition was performed at 90 kVp tube voltage, 200 μA tube current 
and with 2 min total acquisition time. Mice were anesthetized with 1-3 % isoflurane in a 1:1 
air/oxygen mix. Then the contrast agent Imeron 300 (5 ml/kg) was injected intravenously 
(i.v.) into the tail vain or into the retro-bulbar venous plexus. Approximately 30 sec later, the 
imaging was performed. Data sets were reconstructed with a voxel size of 80 μm and 
analyzed. Size of each tumor (precisely tumor width, height and length) at onset and end of 
the study was determined using simple viewer software.  
The tumor volume was calculated by assuming an ellipsoid shape using the formula: 
Tumor volume =
tumor width x height x length
2
 
For data evaluation logarithmic values of the calculated tumor volume were plotted. 
5.6 Statistical analyses 
Statistical analyses were performed with MS Office Excel or GraphPad Prism 6 software. 
Data were considered significant when probability values (p-values) were < 0.05. 
Comparison of 2 samples or 2 groups was done by unpaired, non-parametric t-test (Mann 
Whitney) or Student’s t-test. In order to compare more than 2 groups a one-way analysis of 
variance (ANOVA) and Dunn’s multiple comparisons test were performed. Differences in 
ERMS-free survival were tested by Log-rank (Mantel-Cox) test and tumor latency time was 
tested by Gehan-Breslow-Wilcoxon test. Differences in tumor incidence and multiplicity were 
tested by Chi-square test. If not indicated otherwise graphs represent mean + standard error 
of the mean (SEM) values. Statistical significant results were visualized in graphs by * or $ 
(p-values < 0.05); ** or $$ (p-values < 0.01); *** or $$ (p-values < 0.001) and **** or $$$$    
(p-values < 0.0001).
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6 Results 
6.1 Effects of oncogenic RAS mutations on human ERMS cell lines 
Previous studies indicated a crosstalk of RAS and HH signaling in human RMS cell lines, 
whereby the interaction of the signaling pathways seemed to be differently regulated in cell 
lines of the embryonal and alveolar subtype. The studies showed that oncRAS isoforms can 
suppress the expression of the main HH target GLI1 in a MEK-dependent manner at least in 
the ERMS cell line RUCH-2 299. 
In this work some of the already performed experiments were repeated and the role of 
oncRAS isoforms in regulation of HH targets and associated cellular responses of ERMS 
cells were analyzed in more depth. For this purpose, ERMS cell lines, originally wt for RAS, 
were stably transduced with different plasmids expressing oncogenic HRAS, KRAS or NRAS 
(collectively named oncRAS) isoforms (see section 5.1.4). Stably transduced cell lines with 
the empty plasmid (pMSCV) served as controls. In addition, experiments were performed 
with the human ERMS cell line RD, which harbors a NRASQ61H mutation 312,326. 
All described experiments within section 6.1 were also performed with untransduced (wt) 
cells. These experiments served as control for potential vector-dependent effects. Since no 
significant differences between wt cells and cells transduced with pMSCV were detected, the 
respective data were not included into the graphs of this thesis. 
6.1.1 Characterization of stably transduced RMS cell lines with oncRAS 
isoforms 
Ahead of all experiments, the stably transduced TE617.T, RUCH-2 and RMS-13 cell lines 
were analyzed to confirm successful transduction. In order to further characterize the cell 
lines, the impact of oncRAS isoforms on phosphorylation of downstream kinases, relative 
RAS activity and cell cycle distribution were analyzed. 
6.1.1.1 Successful transduction of human RMS cell lines 
The successful transduction of human RMS cell lines with the plasmids pMSCVpuro 
(pMSCV), pMSCVpuro-HRASG12V (oncHRAS), pMSCVpuro-KRASG12V (oncKRAS) or 
pMSCVpuro-NRASG12V (oncNRAS) was examined by PCR (see section 5.1.4.1). For this 
purpose, cDNAs from the stably transduced cell lines were analyzed with a common forward 
primer within the pMSCVpuro sequence and with 3 reverse primers specific for the 
transcribed oncRAS isoform (Fig. 9). All cell lines were screened using all primers to rule out 
potential contamination. 
Successful transduction with vectors for pMSCV, oncHRAS, oncKRAS or oncNRAS was 
confirmed for the RMS-13 and RUCH-2 cell lines (Fig. 9B and Fig. 9C). The TE617.T cell line 
RESULTS | 67 
(Fig. 9A) had been successfully transduced with oncKRAS. Unfortunately, oncHRAS and 
oncNRAS were expressed in one and the same TE617.T line probably due to a mix-up of the 
plasmids or a cross contamination of the cells during production. The PCR was also done on 
the pure single plasmids or on a mixture of all plasmids, which served as positive control 
(Fig. 9D). 
 
Figure 9: Successful transduction of RMS cell lines 
RNA was isolated from TE617.T (A), RUCH-2 (B) and RMS-13 (C) cell lines, that have been stably transduced 
with the empty plasmid (pMSCV) or plasmids expressing oncHRAS (HRAS), oncKRAS (KRAS), oncNRAS 
(NRAS), or remained untransduced (wt). RNA were subjected to cDNA synthesis and analyzed by PCR with a 
common forward primer and isoform-specific reverse primers. Amplificates were separated by agarose gel 
electrophoreses and analyzed. Single plasmids or a mixture of the plasmids (100 ng/reaction) served as positive 
control (D). H-/NRAS indicate expression of oncHRAS and oncNRAS in one and the same cell line. 
6.1.1.2 Transduction of RMS cell lines with oncRAS isoforms results in elevated 
protein level of RAS and pERK  
Next, the stably transduced cell lines were analyzed by Western Blot for the general 
expression level of RAS proteins (pan-RAS), for the expression and activation of 
downstream kinases of RAS, which are pERK/ERK, pAKT/AKT, pS6/S6, and for caspase 3 
cleavage to investigate apoptosis induction. Representative results for TE617.T cells 
(Fig. 10A), RUCH-2 cells (Fig. 10B) and RMS-13 cells (Fig. 10C) are shown. 
In general, the level of RAS proteins were higher in all cell lines after transduction with any 
oncRAS isoform. Transduction with oncKRAS resulted in a protein double band, because 
KRASG12V expressed by the pMSCVpuro-KRASG12V plasmid contains a Hemagglutinin (HA)-
tag sequence 299. The transduction with oncRAS isoforms did not influence the protein level 
of pAKT/AKT and pS6/S6. It also did not influence caspase 3 cleavage, which was 
investigated as a readout for apoptosis. In contrast, pERK protein level were elevated in 
oncRAS-expressing RUCH-2 and RMS-13 cell lines. The exceptions were the oncRAS-
transduced TE617.T cell lines and RUCH-2 KRAS cells, which did not show elevated level of 
ERK phosphorylation in comparison to pMSCV control cells. 
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Figure 10: Characterization of protein expression of transduced RMS cell lines 
Protein was isolated from TE617.T (A), RUCH-2 (B) and RMS-13 (C) cell lines, that have been stably transduced 
with the empty plasmid (pMSCV) or plasmids expressing oncHRAS (HRAS), oncKRAS (KRAS), oncNRAS 
(NRAS) or a mixture of oncHRas and oncNRAS (H-/NRAS). Western Blot analyses were done to detect the 
protein level of pAKT/AKT, pS6/S6, pERK/ERK, pan-RAS and caspase 3 cleavage (Caspase 3 and cleaved 
Casp. 3) with specific antibodies. HSC70 served as loading control. Protein names and sizes in kDa are displayed 
on the right side of the blots. The blots are representative for 2 independent experiments. 
 
6.1.1.3 OncRAS isoforms are active in transduced RMS cell lines 
Since not all cell lines showed phosphorylation of the RAS-downstream target ERK (see 
above), RAS activity in the cells was also investigated in an RAS activity assay (for 
experimental procedure compare section 5.3.6). 
The analysis revealed that RAS activity was higher in all oncRAS-transduced cell lines in 
comparison to cell lines that have been transduced with the control vector. A densitometrical 
quantification (histograms in Fig. 11) indicated a 16-fold or 12-fold upregulation of RAS 
activity in TE617.T cells expressing oncKRAS or oncH-/NRAS, respectively, in comparison to 
cells harboring the pMSCV vector (Fig. 11A). For RUCH-2 cells a 2.5-fold (oncHRAS), 2.3-
fold (oncKRAS) or 1.8-fold (oncNRAS) increase of RAS activity was measured after stable 
transduction with oncRAS isoforms (Fig. 11B). In the ARMS cell line RMS-13, stable 
transduction with oncRAS isoforms increased RAS activity approximately 4.7-fold 
(oncHRAS) 8.8-fold (oncKRAS) or 8.4-fold (oncNRAS) in comparison to RMS-13 pMSCV 
cells (Fig. 11C). 
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Figure 11: RAS activity assay of transduced RMS cell lines 
Protein was isolated from TE617.T (A), RUCH-2 (B) and RMS-13 (C) cell lines, that have been stably transduced 
with the empty plasmid (pMSCV) or plasmids expressing oncHRAS (HRAS), oncKRAS (KRAS), oncNRAS 
(NRAS) or a mixture of oncHRas and oncNRAS (H-/NRAS). Afterwards cell lysates were subjected to a bead-
based pull-down assay to precipitate active RAS. Whole lysates of the same cells were used to detect total RAS. 
Afterwards precipitated and not-precipitated lysates were analyzed by Western Blot to detect the protein level of 
active RAS and total RAS with specific antibodies. HSC70 served as loading control for total RAS. Protein names 
and sizes in kDa are displayed on the right side of the blots. The relative RAS activity was calculated by 
normalization of active RAS to total RAS/HSC70 and is displayed in histograms below the representative Western 
Blots. The results are representative for 1 or 2 independent experiments. 
6.1.1.4 OncRAS isoforms do not influence cell cycle distributions of RMS cell lines 
OncRAS isoforms are well-established modulators of cell cycle progression 183. In order to 
investigate whether oncRAS modulate the cell cycle distribution of the stably transduced 
RMS cell lines, the cells were stained with PI and analyzed by flow cytometry 48 h after 
seeding (see section 5.1.7). An analysis of stably transduced RUCH-2 cell lines was not 
performed, because it was not possible to detach these cells with accutase. 
OncRAS isoforms did not change cell cycle distribution in TE617.T cells (Fig. 12A). Thus, 
approximately 28.3 % (pMSCV), 25.3% (oncKRAS) or 33.9 % (oncH-/NRAS) of TE617.T 
cells were in G1/G0 phase, whereas 4.8 % (pMSCV), 6.5 % (oncKRAS) or 4.0 % (oncH-
/NRAS) were in S phase and 17.6 % (pMSCV), 17.9 % (oncKRAS) or 22.4 % (oncH-/NRAS) 
were in G2/M phase. In the same experimental setup oncRAS isoforms did not change the 
cell cycle distribution of RMS-13 cells (Fig. 12B). Thus, approximately 37.9% (pMSCV), 
33.9 % (oncHRAS), 34 % (oncKRAS) or 35.8 % (oncNRAS) of RMS-13 cells were in G1/G0 
phase, whereas 6.9 % (pMSCV), 7.8 % (oncHRAS), 7.8 % (oncKRAS) or 5.5 % (oncNRAS) 
were in S phase and 27.9 % (pMSCV), 32.1 % (oncHRAS), 35.2 % (oncKRAS) or 24.5 % 
(oncNRAS) were in G2/M phase. 
Taken together, there might be a difference in cell cycle distribution between TE617.T and 
RMS-13 cell lines. However, oncRAS isoforms do not influence cell cycle progression. 
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Figure 12: OncRAS isoforms do not influence cell cycle distribution of TE617.T and RMS-13 cells 
TE617.T (A) and RMS-13 (B) cell lines that have been stably transduced with the empty plasmid (pMSCV) or 
plasmids expressing oncHRAS (HRAS), oncKRAS (KRAS), oncNRAS (NRAS) or a mixture of oncHRas and 
oncNRAS (H-/NRAS) were subjected to cell cycle analyses 48 h after seeding. Cells were detached, fixed and 
stained with PI. Cell cycle distribution was analyzed by flow cytometry and the relative amounts of cells resident in 
G1/G0 phase, S phase and G2/M phase were calculated. Bars represent the mean + SEM of 3 independent 
experiments performed in technical duplicates. For statistical analyses non-parametric t-tests (Mann Whitney) 
were performed. 
In summary, the data presented in chapter 6.1 demonstrate that the human ERMS cell lines 
TE617.T and RUCH-2 and the human ARMS cell line RMS-13 express oncRAS isoforms 
after transduction with respective constructs. The activity of oncRAS isoforms in the cells 
was demonstrated by phosphorylation of the RAS-downstream kinase ERK and/or by a RAS 
activity assay. However, oncRAS isoforms apparently do not induce apoptosis as measured 
by caspase 3 cleavage in Western Blots. They also do not alter the cell cycle distribution of 
the cells. Moreover, no obvious morphological changes of the cells were detected 
microscopically (data not shown). 
6.1.2 OncRAS isoforms modulate mRNA expression of HH signaling pathway 
members 
6.1.2.1 OncRAS isoforms downregulate GLI1 expression in RMS cell lines 
Previous studies revealed an oncRAS-dependent downregulation of GLI1 transcription in 
RUCH-2 and RMS-13 cell lines 299. Here, the expression of the HH target GLI1 was 
measured in stably transduced TE617.T. The measurement was also repeated in RUCH-2 
and RMS-13 cell lines. Additionally, the HH-responsive medulloblastoma cell line Daoy 327, 
stably transduced with oncRAS-expressing plasmids, was analyzed for GLI1 expression. 
GLI1 was chosen as readout, because it is considered to be the most reliable marker for HH 
signaling activity 69. For qRT-PCR analyses, 18S rRNA and HPRT were chosen as suitable 
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reference genes 328. The data confirmed that oncRAS decrease GLI1 mRNA expression 
irrespective of the RMS subtype and the RAS isoform (see Fig. 13A for ERMS and Fig. 13B 
for ARMS cell lines) 299. In contrast, oncRAS had no significant effect on GLI1 mRNA level in 
Daoy cells (Fig. 13C). This indicates that oncRAS-mediated GLI1 downregulation may be 
specific for RMS cell lines. 
 
Figure 13: OncRAS isoforms downregulate relative GLI1 expression in RMS cell lines 
The ERMS cell lines TE617.T and RUCH-2 (A), the ARMS cell line RMS-13 (B) and the Medulloblastoma (MB) 
cell line Daoy (C) stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS, H-
/NRAS) were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH target 
gene GLI1. The expression data were normalized to 18S rRNA (18S, upper row) and HPRT (lower row) and are 
shown as fold expression to respective pMSCV control cells that were set to 1. Bars represent the mean + SEM of 
1 (Daoy), 3 (RUCH-2) or 4 (TE617.T, RMS-13) independent experiments performed in technical triplicates. For 
statistical analyses a non-parametric t-test (Mann Whitney) was performed. *p<0.05, **p<0.01, ***p<0.001, 
****p< 0.0001 compared to expression level of pMSCV control cells. 
6.1.2.2 Different oncRAS isoforms modify gene expression of GLI3 and SHH in ERMS 
cells 
In the following the focus is on the ERMS cell lines TE617.T and RUCH-2 stably transduced 
with oncRAS isoforms. After oncRAS-dependent downregulation of GLI1 has been confirmed 
in these cell lines (see Fig. 13), the expression of other genes of the HH signaling pathway, 
namely GLI2, GLI3, PTCH1 (in the following named PTCH), HHIP and SHH, was analyzed. 
TE617.T cells expressing oncKRAS showed a moderate downregulation of the HH signaling 
activator GLI2 and the HH ligand SHH in comparison to pMSCV control cells. In contrast, 
oncNRAS downregulated the HH signaling inhibitor GLI3 and the HH ligand receptor PTCH 
72 | RESULTS 
in comparison to pMSCV cells. The effects on GLI2 and PTCH level were dependent on the 
reference gene used and were consequently considered as a trend in regulation. Relative 
gene expression of the HH signaling inhibitor protein HHIP was not significantly (n.s.) 
influenced by the oncRAS mutations (Fig. 14). 
 
Figure 14: OncKRAS decreases SHH, whereas oncH-/NRAS decrease GLI3 in TE617.T cells 
TE617.T cells stably transduced with the pMSCV control vector or oncRAS isoforms (KRAS, H-/NRAS) were 
subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH signaling pathway 
genes GLI2, GLI3, PTCH, HHIP and SHH. The expression data were normalized to 18S rRNA (18S, upper row) 
and HPRT (lower row) and are shown as fold expression to TE617.T pMSCV control cells that were set to 1. Bars 
represent the mean + SEM of 4 independent experiments performed in technical triplicates. For statistical 
analyses a non-parametric t-test (Mann Whitney) was performed. *p<0.05, **p<0.01, ****p< 0.0001 compared to 
expression level of pMSCV control cells. 
 
In RUCH-2 cells all oncRAS isoforms significantly downregulated GLI2 expression in 
comparison to pMSCV control cells (Fig. 15). Interestingly, and in contrast to TE617.T cells, 
all oncRAS isoforms increased the expression of the HH ligand SHH. Furthermore, GLI3 
expression was decreased by oncNRAS. The oncogenic isoforms of HRAS and KRAS 
increased the expression of PTCH, while the expression of HHIP was not affected in any of 
the settings (Fig. 15). 
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Figure 15: OncRAS isoforms modify GLI2 and SHH expression in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS) were 
subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH signaling pathway 
genes GLI2, GLI3, PTCH, HHIP and SHH. The expression data were normalized to 18S rRNA (18S, upper row) 
and HPRT (lower row) and are shown as fold expression to RUCH-2 pMSCV control cells that were set to 1. Bars 
represent the mean + SEM of 3 independent experiments performed in technical triplicates. For statistical 
analyses a non-parametric t-test (Mann Whitney) was performed. *p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001 
compared to expression level of pMSCV control cells. 
Taken together, the results from chapter 6.1.2 highlight that oncRAS isoforms apparently 
inhibit HH signaling in RMS cell lines, because the expression of the main HH target gene 
GLI1 decreases. This phenomenon is apparently specific for RMS cell lines, because it was 
not observed in medulloblastoma cells. Furthermore, oncRAS isoforms also modify the gene 
expression level of other central players of the HH signaling pathway such as GLI2 (RUCH-2 
cells only), GLI3, PTCH (RUCH-2 cells only) and SHH. However, the modulation is different 
between the ERMS cell lines TE617.T and RUCH-2. 
6.1.3 Canonical HH signaling plays a subordinate role in ERMS cell lines 
In oncRAS-transduced RUCH-2 and TE617.T cell lines the expression of SHH was up- or 
downregulated, respectively (see section 6.1.2.2). This suggested that oncRAS isoforms may 
affect canonical HH signaling in ERMS due to secretion of SHH. In order to test this 
hypothesis, the ability of the cells to secrete HH ligands was analyzed. In addition, it was 
analyzed whether the cells itself respond to the HH stimulus. 
6.1.3.1 ERMS cell lines do not secrete HH ligands 
In order to investigate whether ERMS cell lines are able to secrete HH ligands, CM of the 
transduced cell lines was prepared as described in section 5.1.11. Then, the murine HH-
responsive cell line B9 was incubated for 48 h with the CM and expression of Gli1 was 
measured by qRT-PCR. The supernatants from HEK293 or HEK293-Shh cells were used as 
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controls. Preliminary results already showed that oncRAS-transduced RUCH-2 cells are not 
able to secrete HH ligands 299. As indicated here (Fig. 16), this was similar for oncRAS-
transduced TE617.T cells. Thus, whereas HEK293-Shh CM strongly increased Gli1 
expression in B9 cells, incubation with CM from TE617.T pMSCV, TE617.T KRAS or 
TE617.T H-/NRAS cells did not influence the Gli1 level of B9. 
Figure 16: OncRAS-transduced TE617.T cells are not able to 
secrete HH ligands 
B9 cells were incubated with conditioned media from TE617.T cells 
stably transduced with the pMSCV control vector or oncRAS isoforms 
(KRAS, H-/NRAS), or with media of HEK293 (wt) or HEK293-Shh 
(SHH) cells for 48 h. Afterwards B9 cells were subjected to RNA 
isolation, cDNA synthesis and subsequent qRT-PCR analyses of the 
HH target gene Gli1. The data were normalized to 18S rRNA (18S) and 
are shown as fold expression in comparison to B9 cells incubated with 
TE617.T pMSCV (pMSCV) conditioned medium which was set to 1. 
Bars represent the mean + SEM of 3 independent experiments 
performed in technical triplicates. For statistical analyses a non-
parametric t-test (Mann Whitney) was performed. *p<0.05, **p<0.01, 
***p<0.001, ****p< 0.0001 compared to expression level of B9 cells 
were incubated with conditioned media from HEK293 cells. 
The ability of stably transduced RUCH-2 cells or RD cells to secrete HH ligands was also 
tested by co-culture with the HH-responsive SHH light II reporter cell line. The activity of the 
HH signaling cascade in SHH light II reporter cells can be measured by a dual luciferase 
reporter assay, because these cells harbor a Gli responsive luciferase reporter system 310 
(compare section 5.1.12.2). 
 
Figure 17: OncRAS-transduced RUCH-2 cells and RD cells do not stimulate Gli reporter activity in co-
cultured SHH light II cells 
SHH light II cells were either co-cultured with RUCH-2 cells (A) stably transduced with the pMSCV control vector 
or oncRAS isoforms (HRAS, KRAS, NRAS) or RD cells (B) for 24 h. SHH light II cells co-cultured with HEK293 
Shh cells (SHH) or treated with 150 nM SAG served as positive controls, whereas SHH light II cells alone 
(untreated) or co-cultured with HEK293 cells (wt) served as negative controls. Afterwards the relative activity of 
the HH signaling cascade in SHH light II cells was determined by a dual luciferase assay. The luminescence 
readout from firefly luciferase activity was normalized to that of renilla luciferase activity and is displayed in 
relative light units (RLU). Bars represent the mean + SEM of 3 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. 
Neither RUCH-2 cells with or without oncRAS (Fig. 17A) nor RD cells (Fig. 17B) were able to 
stimulate HH signaling in co-cultured SHH light II cells. Positive controls, i.e. stimulation with 
SAG or co-culturing with HEK293-Shh cells, increased the Gli reporter activity in SHH light II 
cells in comparison to the negative controls, which were untreated SHH light II cells or SHH 
light II cells co-cultured with HEK293 cells. However, the stimulation was not significant 
(Fig. 17A and Fig. 17B). 
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Taken together, the results demonstrate that the ERMS cell lines TE617.T, RUCH-2 and RD 
are in all likelihood not able to secrete HH ligands, regardless if they harbor a oncRAS 
mutation or not. 
6.1.3.2 Moderate activation of HH signaling in ERMS cells by SHH-CM 
Next, it was tested whether the HH signaling pathway could be activated in ERMS cells. For 
this purpose, stably transduced RUCH-2 cells were incubated for 48 h with CM from HEK293 
or HEK293-Shh cells. Additionally, B9 cells were incubated with the same media and served 
as controls. Then the expression of GLI1/Gli1 was measured. The results were dependent on 
the reference gene used for normalization (compare Fig. 18A and Fig. 18B). When the data 
were normalized to 18S rRNA the results obtained from 3 independent experiments showed 
that the CM from HEK293-Shh cells moderately regulated the expression of GLI1 in RUCH-2 
HRAS and RUCH-2 KRAS cells, whereas it did not affect GLI1 expression in RUCH-2 
pMSCV and RUCH-2 NRAS cells. The functionality of Shh containing medium was proven by 
a strong Gli1 induction in B9 cells. 
 
Figure 18: SHH moderately induces GLI1 transcription in oncRAS-expressing RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS) were 
incubated with conditioned media from HEK293 (wt) or HEK293-Shh (SHH) cells for 48 h. B9 cells incubated with 
conditioned media from HEK293 or HEK293-Shh were used as negative and positive controls, respectively. 
Afterwards cells were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH 
target gene GLI1/Gli1. The data were normalized to 18S rRNA (18S, A) or HPRT (B) and are shown as fold 
expression in comparison to RUCH-2 pMSCV cells incubated with HEK293 conditioned medium, which was set to 
1. Bars represent the mean + SEM of 3 independent experiments performed in technical triplicates. For statistical 
analyses a non-parametric t-test (Mann Whitney) was performed. *p<0.05, **p<0.01, ****p< 0.0001 compared to 
expression level of control medium treated cell lines. 
To sum up, the data from section 6.1.3 indicate that the ERMS cell lines TE617.T and 
RUCH-2 stably transduced with the pMSCV control vector or oncRAS isoforms, and RD cells 
probably are not able to secrete HH ligands. Additionally, stimulation with SHH may 
marginally regulate HH signaling activity, as measured by GLI1 expression in RUCH-2 cell 
lines that express oncHRAS and oncKRAS isoforms. 
6.1.4 OncRAS isoforms regulate GLI1 expression in ERMS cells via the 
MEK/ERK axis 
Next, it was investigated whether oncRAS isoforms regulate GLI1 expression in a non-
canonical manner via the PI3K/AKT/mTOR or the MEK/ERK axes. In order to inhibit 
PI3K/AKT/mTOR signaling the dual PI3K/mTOR inhibitor PI-103 329 was used, whereas the 
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RAF/MEK/ERK axis was targeted with the specific MEK inhibitor UO126 330 or the specific 
ERK1/2 inhibitor SCH772984 331. Additionally, the SMO inhibitor HhAntag (HhA) 332 was 
employed. The experiments were performed in accordance with previous work, which 
indicated an oncRAS-dependent regulation of the HH signaling pathway via the MEK axis in 
RUCH-2 cells 299. 
The inhibitors HhA (30 µM), PI-103 (3 µM) and UO126 (10 µM) were applied in 
concentrations as described 299. The concentration of the ERK inhibitor SCH772984 was first 
assessed in RUCH-2 cells in a range between 0.1 µM to 10 µM applied for 24 h. A Western 
Blot of RUCH-2 HRAS cells shows that all applied concentrations of SCH772984 inhibited 
phosphorylation of ERK protein level in comparison to solvent (DMSO) treated cells without 
showing an apoptotic effect (Fig. 19). The exception was 1 µM SCH772984, which only 
moderately inhibited ERK phosphorylation. This result was not only seen in RUCH-2 HRAS 
cells but also in other stably transduced RUCH-2 cell lines and in the MET-1 cell line, which 
is also used in our group. This effect is hard to explain. However, it is possible that specific 
concentrations of SCH772984 influence other signaling molecules that in turn phosphorylate 
ERK. Indeed, a similar scenario has been described for other small molecules such as the 
SMO Agonist SAG. Thus, SAG usually activates GLI1 expression, but inhibits GLI1 when 
used at concentration above 1 µM 310. 
Based on these results and observations, a concentration of 0.5 µM SCH772984 was 
employed in subsequent experiments. 
Figure 19: SCH772984 inhibits phosphorylation of ERK in 
different concentrations 
Protein was isolated from RUCH-2 cells stably transduced with 
oncHRAS (RUCH-2 HRAS) after incubation with 0.1 µM to 10 µM 
SCH772984 for 24 h. The total cell lysates were analyzed by 
Western Blot for protein expression of pERK/ERK and caspase 3 
cleavage (Caspase 3 and cleaved casp. 3) with specific 
antibodies. HSC70 served as loading control. Protein names and 
sizes in kDa are displayed on the right side of the blot. The 
depicted results were also obtained in experiments with RUCH-2 
pMSCV and RUCH-2 KRAS and NRAS cells (data not shown). 
 
The functionality of HhA, PI103, UO126 and SCH772984 was tested by analyses of protein 
level of pAKT/AKT, pS6/S6, pERK/ERK after treatment of the cells for 24 h (Fig. 20). 
Additionally, caspase 3 cleavage was analyzed. Representative Western Blots of TE617.T 
cells (Fig. 20A), RUCH-2 cells (Fig. 20B) and RD cells (Fig. 20C) show that in general 
SCH772984 effectively downregulated the pERK level in all cell lines. SCH772984 also 
slightly downregulated AKT level in TE617.T pMSCV cells, whereas it strongly reduced it in 
RUCH-2 cells stably transduced with oncRAS isoforms (Fig. 20B). However, this result is 
based on 1 biological replicate and needs further validation. Nevertheless, a downregulation 
of AKT protein level after SCH772984 treatment was also described for BxPC-3 and HPAC 
cells in the literature 333. 
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Figure 20: PI-103, UO126 and SCH772984 inhibit phosphorylation of their downstream kinases in TE617.T, 
RUCH-2 and RD cells 
Protein was isolated from TE617.T (A) and RUCH-2 (B) cells stably transduced with the pMSCV control vector or 
oncRAS isoforms (HRAS, KRAS, NRAS, H-/NRAS) and RD cells (C) that have been incubated with HhA (30 µM), 
PI-103 (3 µM), UO126 (10 µM) or SCH772984 (0.5 µM) for 24 h. The total cell lysates were used for Western Blot 
analyses to detect the protein level of pAKT/AKT, pS6/S6, pERK/ERK, pan-RAS and caspase 3 cleavage 
(Caspase 3 and cleaved casp. 3) with specific antibodies. HSC70 served as loading control. Protein names and 
sizes in kDa are displayed on the right side of the blots. The results are representative for 1 (TE617.T + 
SCH772984, RUCH-2), 3 (TE617.T + HhA, PI-103 or UO126) or 4 (RD) independent experiments. 
As expected, the MEK inhibitor UO126 decreased phosphorylation of ERK in all used cell 
lines and additionally increased phosphorylation of AKT in all TE617.T cell lines. This 
increase has already been described for other RMS cell lines 271. These observations are 
already described in the literature, e.g. in breast cancer and RMS cells 271,333,334 . It has been 
suggested that the MEK inhibitor-induced activation of PI3K/AKT results from an inhibitory 
phosphorylation in conserved domains of the EGFR, which leads to hyperactivation of Erb-
B2 Receptor Tyrosine Kinase 3 (ERBB3) that in turn upregulates the PI3K/AKT signaling 
pathway 335. In RUCH-2 and TE617.T cells the dual PI3K/mTOR inhibitor PI-103 
downregulated phosphorylation of AKT and S6 (Fig. 20A, Fig. 20B). Unfortunately, 
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phosphorylation of S6 was not measured in TE617.T cells. Additionally, PI-103 slightly 
induced phosphorylation of ERK and modified basal level of AKT in oncRAS-expressing 
RUCH-2 cells (Fig. 20B). Increased pERK level upon inhibition of mTOR has been described 
by others 336. The SMO inhibitor HhA increased phosphorylation of ERK in all RUCH-2 and 
TE617.T cell lines (Fig. 20A, Fig. 20B). Furthermore, it decreased pAKT in all RUCH-2 cell 
lines (Fig. 20B). This phenomenon has already been described by our group 299,337. These 
secondary actions of HhA were considered as an additional hint for an interaction of HH and 
RAS signaling, either via the PI3K/AKT/mTOR axis, or via the RAF/MEK/ERK pathway.  
6.1.4.1 ERK inhibits GLI1 expression in TE617.T cells, in oncRAS-expressing RUCH-2 
cells and in RD cells 
The above-mentioned inhibitors were then used to investigate if oncRAS-mediated 
downregulation of GLI1 expression is regulated via the PI3K/AKT/mTOR axis or via the 
RAF/MEK/ERK pathway. 
6.1.4.1.1 GLI1 expression in TE617.T is inhibited by ERK without general involvement 
of oncRAS isoforms 
The stably transduced TE617.T cells were treated for 24 h with HhA (30 µM), PI-103 (3 µM), 
UO126 (10 µM) or SCH772984 (0.5 µM) and GLI1 expression was analyzed via qRT-PCR. 
The inhibition of SMO did not influence GLI1 expression in any of the TE617.T cell lines 
(Fig. 21). 
 
Figure 21: MEK and ERK suppress GLI1 in TE617.T irrespective of oncRAS mutations 
TE617.T stably transduced with the pMSCV control vector or oncRAS isoforms (KRAS, H-/NRAS) were incubated 
with DMSO, HhA (30 µM), PI-103 (3 µM) and UO126 (10 µM) or SCH772984 (0.5 µM) for 24 h. Afterwards cells 
were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH target gene 
GLI1. The data were normalized to 18S rRNA (18S) and are shown as fold expression in comparison to TE617.T 
pMSCV cells incubated with DMSO, which was set to 1. The respective bar is shown in each histogram as a 
reference. Bars represent the mean + SEM of 4 independent experiments performed in technical triplicates. For 
statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance compared to 
DMSO treated TE617.T pMSCV cells, whereas $ indicate significance compared to solvent control of the 
respective cell line. $ p<0.05, **/$$ p<0.01, ****/$$$$ p< 0.0001 
This indicates again that it is not possible to modulate HH signaling via the canonical axis in 
these cells. PI-103 increased GLI1 expression in oncH-/NRAS-expressing TE617.T cells, 
however not in oncKRAS-expressing or TE617.T control cells. The treatment with the MEK 
inhibitor UO126 increased GLI1 level in oncKRAS-expressing and control cells, whereas 
inhibition of ERK increased GLI1 in all TE617.T cell lines. Taken together, these data 
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indicate that inhibition of ERK (and also of MEK) results in a significant increase of GLI1 
expression in all TE617.T cells investigated. In fact, the observed effect was independent of 
oncRAS mutations, since it was also observed in control cells. 
6.1.4.1.2 ERK mediates oncRAS-induced downregulation of GLI1 expression in 
RUCH-2 cells  
In RUCH-2 pMSCV control cells inhibition of PI3K/mTOR significantly decreased GLI1 
expression, whereas treatment with the other inhibitors had no significant effect (Fig. 22A). 
 
Figure 22: ERK mediates oncRAS-induced downregulation of GLI1 in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector (A) or oncRAS isoforms (HRAS, KRAS, NRAS) 
(B) were incubated with DMSO, HhA (30 µM), PI-103 (3 µM), UO126 (10 µM) or SCH772984 (0.5 µM) for 24 h. 
Afterwards cells were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH 
target gene GLI1. The data were normalized to 18S rRNA (18S) and are shown as fold expression in comparison 
to RUCH-2 pMSCV cells incubated with DMSO, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 3 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated RUCH-2 pMSCV cells, whereas $ indicate significance compared to solvent control of 
the respective cell line. $ p<0.05, **/$$ p<0.01, $$$ p<0.001, **** p< 0.0001 
In contrast, in RUCH-2 cells stably transduced with oncRAS isoforms the incubation with 
HhA or PI-103 decreased the relative GLI1 expression in comparison to solvent-treated cells, 
whereas treatment with UO126 or SCH772984 significantly increased GLI1 in comparison to 
DMSO treated RUCH-2 oncRAS cell lines. Moreover, inhibition of MEK in RUCH-2 HRAS 
and RUCH-2 KRAS cells or inhibition of ERK in all oncRAS-expressing cells restored GLI1 
expression back to the basal level of control RUCH-2 pMSCV cells (Fig. 22B). These results 
show that oncRAS-dependent downregulation of GLI1 in RUCH-2 cells is mediated by ERK. 
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6.1.4.1.3 ERK inhibits GLI1 expression in RD cells 
In addition to ERMS cell lines stably transduced with oncRAS isoforms, RD cells harboring 
an endogenous oncNRAS mutation were incubated with 0.5 µM SCH772984 for 24 h. In this 
cell line and as already demonstrated by our group, PI-103 treatment results in a decrease of 
GLI1 expression whereas UO126 treatment increases GLI1 160. Here, the ERK inhibitor 
SCH772984 increased the GLI1 level (Fig. 23). This result indicates that the oncRAS 
mutation in RD cells might suppress GLI1 expression via the ERK axis, which is similar to 
RUCH-2 cells (compare section 6.1.4.1.2). 
Figure 23: ERK inhibition increases GLI1 expression in RD cells 
RD cells were incubated with DMSO or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA 
isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH target gene GLI1. The data were 
normalized to 18S rRNA (18S, left) or HPRT (right) and are shown as fold expression in comparison to RD cells 
incubated with DMSO, which was set to 1. Bars represent the mean + SEM of 3 independent experiments 
performed in technical triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. 
** p<0.01 compared to expression level of DMSO treated RD cells 
6.1.4.2 ERK regulates PTCH and SHH expression in TE617.T cells, SHH expression in 
oncRAS-expressing RUCH-2 cells and GLI3 in RD cells  
Next it was analyzed whether the ERK inhibitor SCH772984 also influences the gene 
expression level of GLI2, GLI3, PTCH, HHIP and SHH in stably transduced TE617.T and 
RUCH-2 cells and in RD cells. 
6.1.4.2.1 PTCH and SHH expression in TE617.T cells is inhibited by ERK without 
general involvement of oncRAS 
In TE617.T pMSCV control cells, ERK inhibition did not influence the expression of GLI2 or 
GLI3, but generally increased transcription of PTCH, HHIP and SHH (Fig. 24). 
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Figure 24: ERK inhibits PTCH and SHH expression in TE617.T pMSCV cells 
TE617.T cells stably transduced with the pMSCV control vector were incubated with DMSO or SCH772984 
(0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR 
analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data were normalized to 
18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in comparison to cells 
incubated with DMSO, which was set to 1. Bars represent the mean + SEM of 4 independent experiments 
performed in technical triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. 
***p<0.001, ****p< 0.0001 compared to expression level of DMSO treated cells 
 
In TE617.T KRAS cells, which showed an oncKRAS-dependent downregulation of SHH, 
application of SCH772984 restored SHH back to basal level of pMSCV control cells. 
Furthermore, SCH772984 downregulated GLI2 and upregulated PTCH transcription, 
whereas gene expression of GLI3 and HHIP were not affected (Fig. 25). 
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Figure 25: ERK activates GLI2 and inhibits PTCH expression in TE617.T KRAS cells and restores 
oncKRAS–dependent decrease of SHH back to basal level 
TE617.T cells stably transduced with the pMSCV control vector or oncKRAS (KRAS) were incubated with DMSO 
or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and 
subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data 
were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in 
comparison to DMSO treated TE617.T pMSCV cells, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 4 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated TE617.T pMSCV cells, whereas $ indicate significance compared to TE617.T KRAS 
cells treated with DMSO.*/$ p<0.05, **/$$ p<0.01, *** p<0.001, ****/$$$$ p< 0.0001 
 
In TE617.T H-/NRAS cells SCH772984 had no obvious impact on GLI2 or HHIP level. It also 
had no clear-cut effect on GLI3, which is downregulated in these cells by oncH-/NRAS 
compared to the pMSCV control cells. Like in TE617.T pMSCV cells, SCH772984 increased 
the relative mRNA level of SHH. However, SCH772984 increased the expression of PTCH. 
The latter result was considered as a tendency, since the result was only significant upon 
normalization to HPRT but not to 18S rRNA (Fig. 26). 
Taken together, SCH772984 generally increases PTCH and SHH in TE617.T cells 
irrespective of an oncRAS mutation. 
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Figure 26: ERK inhibits PTCH and SHH expression in TE617.T H-/NRAS cells  
TE617.T cells stably transduced with the pMSCV control vector or oncH-/NRAS (H-/NRAS) were incubated with 
DMSO or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and 
subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data 
were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in 
comparison to DMSO treated TE617.T pMSCV cells, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 4 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated TE617.T pMSCV cells, whereas $ indicate significance compared to TE617.T H-
/NRAS cells treated with DMSO.*/$ p<0.05, *** p<0.001, ****/$$$$ p< 0.0001 
 
6.1.4.2.2 OncRAS-mediated upregulation of SHH expression in RUCH-2 cells depends 
on ERK  
The expression of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH were 
also measured in RUCH-2 cell lines, which were treated with 0.5 µM of the ERK inhibitor 
SCH772984 for 24 h and 48 h. Since the results after 24 h and 48 h were identical, only the 
24 h values are shown. 
In RUCH-2 pMSCV control cells SCH772984 did not significantly influence expression of any 
of the analyzed genes (Fig. 27). 
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Figure 27: ERK inhibition does not influence expression of HH signaling genes in RUCH-2 pMSCV cells 
RUCH-2 cells stably transduced with the pMSCV control vector were incubated with DMSO or SCH772984 
(0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR 
analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data were normalized to 
18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in comparison to cells 
incubated with DMSO, which was set to 1. Bars represent the mean + SEM of 3 independent experiments 
performed in technical triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. 
 
 
Figure 28: ERK mediates oncHRAS-dependent increase of SHH in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncHRAS (HRAS) were incubated with DMSO 
or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and 
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subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data 
were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in 
comparison to DMSO treated RUCH-2 pMSCV cells, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 3 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated RUCH-2 pMSCV cells, whereas $ indicate significance compared to RUCH-2 HRAS 
cells treated with DMSO.*/$ p<0.05, **/$$ p<0.01, $$$ p<0.001, **** p< 0.0001 
 
Treatment of oncHRAS-expressing RUCH-2 cells, with SCH772984 restored oncRAS-
mediated downregulation of GLI2 back to the basal expression level of the control RUCH-2 
pMSCV cells. However, this was only seen after normalization to 18S rRNA, but not upon 
normalization to HPRT. In contrast, the oncHRAS-dependent increase in SHH transcription 
was significantly downregulated and did not differ from the expression level of the control 
RUCH-2 pMSCV cells. Finally, the oncHRAS-mediated upregulation of PTCH was not 
affected by application of SCH772984 (Fig. 28). 
 
Figure 29: ERK mediates oncKRAS-dependent increase of SHH in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncKRAS (KRAS) were incubated with DMSO 
or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and 
subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data 
were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in 
comparison to DMSO treated RUCH-2 pMSCV cells, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 3 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated RUCH-2 pMSCV cells, whereas $ indicate significance compared to RUCH-2 KRAS 
cells treated with DMSO.*/$ p<0.05, ** p<0.01, *** p<0.001, **** p< 0.0001 
 
OncKRAS-expressing RUCH-2 cells showed a downregulation of GLI2 and an upregulation 
of SHH and PTCH, whereas HHIP and GLI3 were not changed in comparison to the control 
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vector harboring cells. The treatment with SCH772984 did not alter HHIP level. It however 
restored GLI2 and SHH level back to basal expression of the control RUCH-2 pMSCV cells, 
whereas PTCH expression was not affected by ERK inhibition (Fig. 29). 
OncNRAS-expressing RUCH-2 cells showed a downregulation of GLI2 and an upregulation 
of SHH and PTCH, whereas HHIP was not affected. Treatment with SCH772984 increased 
the GLI2 expression level, however without reaching the basal expression level of control 
RUCH-2 pMSCV cells. The oncNRAS-mediated decrease in GLI3 expression was not 
affected, whereas the oncNRAS-dependent upregulation of SHH was restored to basal level 
of the control. Additionally, SCH772984 increased the expression of PTCH, at least after 
normalization to HPRT. The relative expression of HHIP was not affected (Fig. 30). 
 
Figure 30: ERK mediates oncNRAS-dependent decrease in GLI2 and increase in SHH in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncNRAS (NRAS) were incubated with DMSO 
or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA isolation, cDNA synthesis and 
subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, PTCH, HHIP and SHH. The data 
were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are shown as fold expression in 
comparison to DMSO treated RUCH-2 pMSCV cells, which was set to 1. The respective bar is shown in each 
histogram as a reference. Bars represent the mean + SEM of 3 independent experiments performed in technical 
triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was performed. * indicate significance 
compared to DMSO treated RUCH-2 pMSCV cells, whereas $ indicate significance compared to RUCH-2 NRAS 
cells treated with DMSO.*/$ p<0.05, **/$$ p<0.01, $$$ p<0.001, **** p<0.0001 
Taken together, ERK is responsible for the oncRAS-mediated upregulation of SHH in RUCH-
2 cells, whereas (in contrast to GLI1) it’s involvement in oncRAS-mediated downregulation of 
GLI2 is not unambiguously clear. Furthermore, ERK is generally not involved in oncHRAS 
and oncKRAS-mediated induction of PTCH expression or in oncNRAS-dependent 
downregulation of GLI3. 
RESULTS | 87 
6.1.4.2.3 ERK inhibits GLI3 expression in RD cells 
The data from section 6.1.4 show that ERK upregulates GLI1 mRNA expression in RD cells. 
When analyzing the expression level of GLI2, GLI3, PTCH, HHIP and SHH after SCH772984 
treatment, GLI2 and SHH expression slightly increased, whereas the GLI3 mRNA level was 
significantly upregulated. PTCH and HHIP expression level were not affected (Fig. 31). 
 
Figure 31: ERK inhibits GLI3 expression in RD cells 
RD cells were incubated with DMSO or SCH772984 (0.5 µM) for 24 h. Afterwards cells were subjected to RNA 
isolation, cDNA synthesis and subsequent qRT-PCR analyses of the HH signaling pathway genes GLI2, GLI3, 
PTCH1, HHIP and SHH. The data were normalized to 18S rRNA (18S, upper row) or HPRT (lower row) and are 
shown as fold expression in comparison to cells incubated with DMSO, which was set to 1. Bars represent the 
mean + SEM of 3 independent experiments performed in technical triplicates. For statistical analyses a non-
parametric t-test (Mann Whitney) was performed. **p<0.01, ***p<0.001 compared to expression level of DMSO 
treated RD cells. 
To sum up, the results from sections 6.1.4.1 show that ERK (and MEK) inhibit GLI1 in 
TE617.T cells and in RUCH-2 cells with oncRAS isoforms. Additionally, ERK inhibits GLI1 in 
RD cells, harboring an oncNRAS mutation. In TE617.T cells ERK inhibits PTCH and SHH 
irrespective of an oncRAS mutation. Furthermore, the oncRAS-mediated upregulation of 
SHH in RUCH-2 cells is dependent on ERK. In RD cells, ERK inhibits GLI3. The implication 
of ERK in regulation of GLI2 in these ERMS cell lines is not clear since statistical significance 
is not given in all cases. In contrast, ERK is not involved in oncHRAS and oncKRAS-
mediated induction of PTCH expression in RUCH-2 cells. It is also not involved in oncNRAS- 
and oncH-/NRAS-dependent downregulation of GLI3 in RUCH-2 and TE617.T cells, 
respectively. 
6.1.4.3 ERK inhibits GLI transcriptional activity in RD cells 
To investigate whether oncRAS itself or the inhibition of ERK indeed modifies the activation 
status of GLI transcription factors and thus of the HH signaling cascade, a GLI reporter assay 
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was performed as described in section 5.1.9. The cells were transfected with a firefly 
luciferase reporter plasmid and a constitutively active renilla expression plasmid. The 
transfected cells were incubated for 24 h with DMSO or SCH772984 and measurement of 
GLI reporter activity was performed. 
ERK inhibition did not influence activity of the GLI reporter neither in wt RAS nor in RUCH-2 
cells expressing oncRAS (Fig. 32A). This is in contrast to GLI1 mRNA level that was 
suppressed by oncRAS in an ERK-dependent manner (compare section 6.1.4.1). On the one 
hand that may indicate that the suppression of GLI1 level apparently is regulated 
independently of GLI transcription factors. On the other hand, and more likely, the assay did 
simply not work in this very cell line, because the luciferase activity in the positive control was 
also not significantly elevated over the negative control. However, electroporation with the 
pEGFP-N1 control plasmid yielded over 70 % transfection efficiency in RUCH-2 cell lines 
(data not shown). This is sufficient and consequently other parameters of the assay need to 
be optimized. 
 
Figure 32: ERK suppresses GLI activity in RD cells but not in stably transduced RUCH-2 cell lines 
RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS) (A) 
and RD cells (B) were transfected with plasmids for a GLI reporter assay. The cells were incubated with DMSO or 
0.5 µM SCH772984 for 24 h. Afterwards, the relative GLI reporter activity was determined by a dual luciferase 
assay. The luminescence readout from firefly luciferase activity was normalized to renilla luciferase activity. The 
transfection with an mGli1 overexpressing plasmid (positive control), its pCR3.1 backbone (negative control) or 
untreated RMS cell lines transfected with the firefly luciferase reporter plasmid and the renilla vector served as 
controls. Bars represent the mean + SEM of 3 (RUCH-2) or 4 (RD) independent experiments performed in 
technical sextuplicates or triplicates. For statistical analyses a non-parametric t-test (Mann Whitney) was 
performed. *p<0.05 
This was different in RD cells. In these cells SCH772984 significantly increased GLI reporter 
activity in comparison to DMSO treated or untreated cells. In addition, also the positive 
control revealed significant different results (Fig. 32B). In conclusion, ERK inhibits GLI 
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activity and thus HH signaling activity in RD cells. This is in line with gene expression 
analyses, which showed that ERK inhibits the transcription of GLI1 and GLI3 (compare 
section 6.1.4.1.3 and section 6.1.4.2.3). 
6.1.4.4 OncRAS decrease GLI1 protein level in RUCH-2 cells 
Since oncRAS isoforms decreased GLI1 mRNA expression in all ERMS cell lines, further 
experiments focused on examination of GLI protein level and on the translocation of GLI 
repressor and activator forms into the nucleus. For this purpose, protein lysates were 
fractionated into total, cytosolic and nuclear fractions and a Western Blot for GLI proteins 
was established and performed (see section 5.3.2 and 5.3.5.2). 
 
Figure 33: OncRAS isoforms modulate GLI protein expression in different cellular compartments in 
RUCH-2 cells 
Protein was isolated from RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms 
(HRAS, KRAS, NRAS). Afterwards the lysates were fractionated into total, cytosolic and nuclear lysates and 
subjected to Western Blot analyses. Protein level of GLI1, GLI2 and GLI3 activator (GLI3
A
) and repressor forms 
(GLI3
R
) were detected using specific primary antibodies. HSC70 served as reference protein for total fraction, α-
Tubulin as reference for cytosolic fraction and LaminB1 as reference for nuclear fraction. Protein names and sizes 
in kDa are displayed on the right side of the blots. The results are representative for 3 independent experiments. 
As seen in RUCH-2 cells, oncRAS isoforms downregulated GLI1 regardless of the cellular 
compartment (Fig. 33). This result was consistent in 3 independent experiments. 
Furthermore, a downregulation of the full length GLI2 activator form and probably also the 
GLI3 full length activator and truncated repressor proteins were detected regardless of the 
cellular compartment. However, these results were uniformly seen only in 2 out of 3 
experiments and thus need to be considered with care. 
6.1.4.5 OncRAS-dependent decrease of GLI1 is mediated by ERK in RUCH-2 cells 
Next it was investigated whether ERK inhibition in RUCH-2 oncRAS cells restores GLI1 
protein level and also that of GLI2, GLI3A and GLI3R back to basal level of RUCH-2 pMSCV 
control cells. For this purpose, the cells were incubated with SCH772984 for 24 h. The 
protein lysates of cytosolic and nuclear fraction were used for a Western Blot analyses. As 
controls, lysates from HH-responsive Daoy cells treated with DMSO or SAG, or lysates from 
RMS-13 cells, which show GLI1 amplification 326, were used. In most Western Blots the 
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efficient fractionation in the cytosolic and nuclear fraction was revealed by level of the 
reference proteins α-Tubulin and Lamin B1, respectively (Fig. 34). Unfortunately, the GLI2 
and GLI3 data were not evaluable due to highly variable results between the 5 experiments. 
However, the experiments unambiguously showed that SCH772984 elevated GLI1 protein 
level in all oncRAS expressing cell lines (Fig. 34A: RUCH-2 HRAS, Fig. 34B: RUCH-2 KRAS, 
Fig. 34C: RUCH-2 NRAS) in both the cytosolic and nuclear fraction up to basal level 
detected in the control. This again confirms that oncRAS-mediated decrease of GLI1 is 
regulated by ERK. 
RD cells were also treated with SCH772984 (data not shown). In this cell line ERK inhibition 
by SCH772984 did not change the protein level of any of the analyzed GLI proteins. 
However, similar to RUCH-2 cells the results were ambiguous and varied between the 
experiments and thus were not reliable. 
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Figure 34: ERK inhibition reverses oncRAS-dependent decrease of GLI1 protein in RUCH-2 cells 
RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS) were 
treated for 24 h with 0.5 µM SCH772984. Afterwards protein was isolated from RUCH-2 pMSCV, RUCH-2 HRAS 
(A), RUCH-2 KRAS (B) and RUCH-2 NRAS (C) and the lysates were fractionated into cytosolic and nuclear 





) were detected using specific primary antibodies. Protein lysates from starved Daoy cells 
treated with DMSO served as size control for GLI3
R, 
whereas lysates from starved Daoy cells treated with 150 nM 
SAG and lysates of RMS-13 cells served as control for GLI1, GLI2 and GLI3
A
. α-Tubulin served as reference for 
cytosolic fraction and LaminB1 as reference for nuclear fraction. Protein names and sizes in kDa are displayed on 
the right side of the blot. The results are representative for 5 independent experiments. 
6.1.5 OncRAS isoforms induce proliferation of TE617.T and RUCH-2 cells 
Next, the impact of oncRAS on the proliferative and metabolic activity of ERMS cell lines was 
investigated. For this purpose, BrdU incorporation assays and WST-1 based colorimetric 
assays (see section 5.1.5 and 5.1.6) were performed on TE617.T and RUCH-2 cells with and 
without oncRAS mutations. The assays were conducted 24 h after seeding for TE617.T cell 
lines. Analyses for RUCH-2 cell lines were performed in a serial experiment from 24 h to 
72 h, because RUCH-2 cells are slow-growing. 
The results show that oncRAS strongly induced proliferation (Fig. 35A) and increased 
metabolic activity (Fig. 35B) in TE617.T cells. In RUCH-2 cells expressing oncHRAS a 
significant increase in proliferation was detected 72 h after seeding, whereas proliferation of 
RUCH-2 cells expressing oncKRAS increased 48 h and 72 h after seeding in comparison to 
pMSCV control cells. The oncNRAS mutation apparently had no impact on proliferation 
within this time frame (Fig. 35C). Furthermore, none of the oncRAS mutations altered 
metabolic activity of RUCH-2 cells (Fig. 35D). 
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Figure 35: Impact of oncRAS on proliferation and metabolic activity of ERMS cell lines 
In TE617.T stably transduced with the pMSCV control vector or oncRAS isoforms (KRAS, H-/NRAS) (A, B) and 
RUCH-2 cells stably transduced with the pMSCV control vector or oncRAS isoforms (HRAS, KRAS, NRAS) (C, D) 
the proliferative (A, C) and metabolic activity (B, D) were measured 24 h (TE617.T, RUCH-2), or 48 h and 72 h 
(RUCH-2) after seeding. BrdU incorporation and cell viability of pMSCV control cells were set to 100 %. Bars 
represent the mean + SEM of 3 (RUCH-2) or 7 (TE617.T) independent experiments performed in technical 
sextuplicates or triplicates, respectively. For statistical analyses a non-parametric t-test (Mann Whitney) was 
performed. *p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001 compared to level of respective pMSCV control cells. 
6.1.6 Chapter summary 
In summary, the results of chapter 6.1 show that RMS cell lines, which are wt for RAS, have 
been successfully transduced with oncH-, oncK- or oncNRAS isoforms. A PCR using vector 
specific primers confirms successful transduction of all cell lines. Western Blot analyses 
confirm an increase in pERK and pan-RAS protein expression level. Additionally RAS activity 
is increased in these cell lines. Further analyses reveal that oncRAS mutations decrease 
GLI1 mRNA expression irrespective of the RMS subtype and the RAS isoform. Additionally, 
oncRAS does not only influences GLI1 expression, which is the major readout for HH 
signaling activity, but also the expression of other central stakeholders of the signaling 
pathway like GLI2, PTCH and SHH. 
Since oncRAS isoforms increase or decrease SHH expression in RUCH-2 oncRAS or 
TE617.T oncKRAS cells, respectively, it was also investigated whether the cells secrete SHH 
or not. Medium transfer experiments demonstrate that none of the investigated ERMS cell 
line was able to secrete HH ligands, regardless of the oncRAS mutation status. In addition, 
the data show that it is not possible to significantly activate HH signaling at least in RUCH-2 
cells. Together these data suggest a non-canonical regulation of HH signaling or at least of 
GLI1 expression in ERMS by oncRAS. 
Subsequent application of several kinase inhibitors shows that the oncRAS-mediated 
downregulation of GLI1 in RD and RUCH-2 cell lines is ERK-dependent. In TE617.T cells, 
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GLI1 expression is inhibited already intrinsically by ERK and can be strengthened by 
oncRAS. A subsequent GLI reporter assay shows that ERK indeed regulates GLI activity in 
RD cells. However, this is not seen in RUCH-2 cells, in which the assay probably does not 
work efficiently. 
Furthermore, Western Blot analyses reveal that oncRAS mutations indeed downregulate the 
protein level of GLI1 both in the cellular and nuclear compartment of RUCH-2 cells and that 
ERK inhibition restores the protein expression back to basal level. Unfortunately, the data for 
GLI2, GLI3A and GLI3R are too heterogeneous to make a final statement. 
Finally, oncRAS induces proliferation of TE617.T and RUCH-2 cell lines despite 
downregulation of GLI1/GLI1. This indicates that the level of HH signaling, or at least of 
GLI1/GLI1, is not associated with the proliferative capacity of ERMS cells. 
6.2 Effects of oncRAS isoforms on xenografts derived from ERMS 
cell lines 
In vitro results described in section 6.1.5 and section 6.1.2.1 showed that oncRAS induces 
proliferation of ERMS cell lines despite GLI1 downregulation. In order to see, if the tumor 
cells behave similarly in the in vivo situation, all stably transduced ERMS cell lines were 
transplanted subcutaneously into flanks of 8-10 weeks old Nu/Nu mice. In this experimental 
setting, pMSCV control cells were implanted into the left flank and oncRAS-expressing cells 
into the right flank of one and the same animal. The cohorts consisted of 8-12 animals. The 
approximate tumor volume was measured every or every second day with a caliper. When a 
tumor reached a diameter of 1.5 cm the mice were sacrificed. The exact tumor volume and 
the tumor weight were assessed after isolation. In order to see whether the tumor cells 
influence expression of HH target genes in the tumor microenvironment, species specific 
primers were used in qRT-PCR analyses of tumor samples. 
6.2.1 OncRAS increase tumorigenicity of TE617.T cells 
For the generation of tumors 2 × 106 TE617.T pMSCV, TE617.T KRAS or TE617.T H-/NRAS 
cells were injected into the animals. As already mentioned, all mice were sacrificed when a 
tumor reached a diameter of 1.5 cm or latest after 55 days. The transplantation studies were 
performed with either 8 (TE617.T pMSCV and TE617.T KRAS) or 12 (TE617.T pMSCV and 
TE617.T H-/NRAS) Nu/Nu mice. 
6.2.1.1 OncRAS enhance tumor growth and weight of TE617.T xenografts 
Transplanted TE617.T KRAS and TE617.T H-/NRAS cells resulted in a more aggressive 
tumor growth in comparison to simultaneously transplanted TE617.T pMSCV cells. Thus, the 
approximate tumor volume in living mice (measured by caliper), tumor weight and exact 
tumor volume after tumor isolation were significantly increased in comparison to the control 
(see Fig. 36A for TE617.T KRAS and Fig. 36B for TE617.T H-/NRAS). 
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These results are in line with cell culture experiments, which showed an increased 
proliferation rate of TE617.T cells with an oncRAS mutation in comparison to control cells 
(section 6.1.5). 
 
Figure 36: OncRAS isoforms increase tumor growth and weight of TE617.T xenografts 
2 × 10
6 
TE617.T pMSCV and 2 × 10
6 
TE617.T KRAS (A) or 2 × 10
6 
TE617.T H-/NRAS (B) cells in 200 µl PBS 
were transplanted into the left or right flanks, respectively, of Nu/Nu mice (n=8 for TE617.T pMSCV and TE617.T 
KRAS, n= 12 for TE617.T pMSCV and TE617.T H-/NRAS). Tumor size was measured with a caliper every or 
every second day after transplantation and the approximate tumor volume was calculated. The results are shown 
in the tumor growth curves in the left panels. At the end of the study tumors were isolated, weighed and measured 
to determine exact tumor volume. The results are shown in the respective middle and right panels. For statistical 
analyses multiple t-tests (growth curve) and non-parametric t-tests (Mann Whitney; for tumor weight and exact 
tumor volume) were performed. * indicate significance compared to characteristics of TE617.T pMSCV 
xenografts.* p<0.05 
6.2.1.2 OncH-/NRAS may influence tumorintrinsic SHH expression in TE617.T 
xenografts 
In cultured TE617.T cells the oncRAS mutations resulted in a slight decrease in GLI1 and 
SHH mRNA level (compare section 6.1.2). In order to analyze, whether this is still true for 
transplanted cells, the expression of these genes was also measured in the xenografts using 
primers specific for the human transcripts (Fig. 37A). Although the cultured cells apparently 
did not secrete SHH (compare section 6.1.3.1), the potential effects of Hh signaling was also 
analyzed, i.e. on expression of murine mGli1, mGli2 in the surrounding murine stroma cells 
using primers specific for murine transcripts (Fig. 37B). 
The RNA was isolated from all available frozen tumor samples of TE617.T pMSCV (n=7), 
TE617.T KRAS (n=5) and TE617.T H/NRAS (n=6). Data were normalized to gene 
expression of TE617.T pMSCV tumors that have been transplanted simultaneously in the 
same animal. The results indicate that tumor-intrinsic hGLI1 expression was slightly, but not 
significantly, decreased in tumors of oncKRAS and oncH/NRAS-expressing TE617.T cells in 
comparison to pMSCV control tumors. Additionally, a significant decrease of hSHH was 
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detected in oncH/NRAS tumors, whereas no influence on hGLI2 was measured (Fig. 37A). 
Analyses of mGli1 and mGli2 expression in the tumor microenvironment indicated no 
significant changes induced by oncRAS-expressing tumors (Fig. 37B). These results partly 
reflect the situation in cell culture (at least for SHH; compare section 6.1.2.2). They also 
suggest that oncRAS-expressing TE617.T xenografts do not influence Hh signaling in the 
tumor microenvironment. 
 
Figure 37: OncRAS do not significantly change the expression of hGLI1/mGli1, hGLI2/mGli2 in TE617.T 
xenografts 
Xenograft tumors were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the 
HH signaling pathway genes hGLI1/mGli1, hGLI2/mGli2, hSHH using species specific primers for human (A) and 
murine genes (B). The data were normalized to hHPRT for human gene expression (A) and to mHprt for murine 
gene expression (B) and are shown as fold expression to TE617.T pMSCV xenografts that were set to 1. Bars 
represent the mean ± SEM of 7(pMSCV), 5 (KRAS) or 6 (H/NRAS) isolated tumors. For statistical analyses non-
parametric t-tests (Mann Whitney) were performed. **p<0.01 compared to expression level of TE617.T pMSCV 
xenografts. 
6.2.2 OncKRAS and oncNRAS increase tumorigenicity of RUCH-2 cells 
The transplantation of RUCH-2 cell lines were performed with 8 Nu/Nu mice for each cohort. 
In contrast to TE617.T cells, 9 × 106 RUCH-2 cells in matrigel were implanted. All mice were 
sacrificed when a tumor reached a diameter of 1.5 cm or latest after 21 days. 
6.2.2.1 OncKRAS and oncNRAS increase tumor growth and weight of RUCH-2 
xenografts 
The transplantation of RUCH-2 KRAS (Fig. 38B) and RUCH-2 NRAS (Fig. 38C) cells 
resulted in a strongly enhanced tumor growth in comparison to simultaneously transplanted 
RUCH-2 pMSCV cells. In contrast, RUCH-2 HRAS cells did not grow and the tumor volume 
started to regress early after transplantation (Fig. 38A). However, since BrdU incorporation in 
cultured RUCH-2 HRAS cells was significant (see section 6.1.5) and since RUCH-2 KRAS 
and RUCH-2 NRAS xenotransplants grew very fast, it is likely that the RUCH-2 HRAS cells 
have died prior or during the transplantation procedure. Nevertheless, this study should be 
repeated to see whether this assumption is true or not. 
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Figure 38: OncKRAS and oncNRAS increase tumor growth and weight of RUCH-2 xenografts 
9 × 10
6 
RUCH-2 pMSCV, RUCH-2 HRAS (A), RUCH-2 KRAS (B) or RUCH-2 NRAS (C) cells in 200 µl PBS were 
transplanted into the left or right flanks, respectively, of Nu/Nu mice (n=8 for each cohort). Tumor size was 
measured with a caliper every or every second day after transplantation and the approximate tumor volume was 
calculated. The results are shown in the tumor growth curves in the left panels. At the end of the study tumors 
were isolated, weighed and measured to determine the exact tumor volume. The results are shown in the 
respective middle and right panels. For statistical analyses multiple t-tests (growth curve) and non-parametric t-
tests (Mann Whitney; for tumor weight and exact tumor volume) were performed. * indicate significance compared 
to characteristics of RUCH-2 pMSCV xenografts. *p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001 
The approximate tumor volume of RUCH-2 xenografts with oncKRAS or oncNRAS mutations 
in living mice, and their weight and exact tumor volume after tumor isolation were 
significantly increased, when compared to RUCH-2 pMSCV xenografts (Fig. 38). For 
oncKRAS this result fits to cell culture experiments, in which oncKRAS also increased the 
proliferation rate. However, the in vivo results for the oncNRAS-expressing RUCH-2 cell line 
are different from the in vitro situation, in which oncNRAS did not increase the proliferation 
rate, even not after 72 h of incubation with BrdU (compare section 6.1.5). 
6.2.2.2 OncRAS may downregulate GLI1 expression in tumor cells and upregulate 
Gli2 expression in stromal cells of RUCH-2 xenografts 
In vitro experiments using oncRAS-expressing RUCH-2 cell lines showed a decrease in GLI1 
and GLI2 mRNA level and a simultaneous increase in SHH mRNA level in comparison to the 
control (compare section 6.1.2). The expression of these genes was also analyzed in the 
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xenografts. In addition and in order to see, whether RUCH-2 cell with oncRAS secrete SHH 
in vivo, the expression of Gli1 and Gli2 was measured in the tumor stroma. 
In xenografts derived from oncKRAS-expressing RUCH-2 cells the expression of hGLI1 and 
hSHH was somewhat lower in comparison to RUCH-2 pMSCV xenografts. However, these 
results were not significant. In addition, the level of hGLI2 remained unchanged (Fig. 39A). 
When the expression level of mGli1 and mGli2 were measured, an increase in xenografts 
derived from oncKRAS-expressing RUCH-2 was detected, which was not significant for Gli1 
but significant for Gli2. This indicates a potential impact of oncKRAS-expressing tumor cells 
on HH signaling in surrounding stromal cells (Fig. 39B). However, since SHH was rather 
downregulated in these xenografts, the increase in mGli1 or mGli2 is rather not mediated by 
secretion of the SHH ligand by tumor cells. 
 
Figure 39: OncKRAS significantly induces mGli2 expression in the stroma of RUCH-2 xenografts 
Xenograft tumors were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the 
HH signaling pathway genes hGLI1/mGli1, hGLI2/mGli2, hSHH using species specific primers for human (A) and 
murine genes (B). The data were normalized to hHPRT for human gene expression (A) and to mHprt for murine 
gene expression (B) and are shown as fold expression to RUCH-2 pMSCV xenografts that were set to 1. Bars 
represent the mean ± SEM of 8 isolated tumors of each cohort. For statistical analyses non-parametric t-tests 
(Mann Whitney) were performed. **p<0.01 compared to expression level of RUCH-2 pMSCV xenografts. 
Gene expression analyses of xenografts derived from oncNRAS-expressing RUCH-2 cells 
revealed that, as seen in cell culture, oncNRAS decreased hGLI1 and hGLI2 in the tumor 
cells. Whereas the decrease in GLI1 was significant, the decrease in hGLI2 was not. In 
contrast to cell culture, oncNRAS also decreased hSHH in comparison to RUCH-2 pMSCV 
xenografts (Fig. 40A). In the murine stroma, no significant changes in mRNA level of mGli1 
and mGli2 were measured (Fig. 40B). 
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Figure 40: OncNRAS significantly decreases hGLI1 expression in tumor cells of RUCH-2 xenografts 
Xenograft tumors were subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the 
HH signaling pathway genes hGLI1/mGli1, hGLI2/mGli2, hSHH using species specific primers for human (A) and 
murine genes (B). The data were normalized to hHPRT for human gene expression (A) and to mHprt for murine 
gene expression (B) and are shown as fold expression to RUCH-2 pMSCV xenografts that were set to 1. Bars 
represent the mean ± SEM of 8 isolated tumors of each cohort. For statistical analyses non-parametric t-tests 
(Mann Whitney) were performed. ***p<0.001 compared to expression level of RUCH-2 pMSCV xenografts. 
Taken together, the results show that transplanted RUCH-2 cells with oncKRAS or oncNRAS 
behave somewhat different when compared to cell culture (compare section 6.1.2). Thus, 
hGLI1 is only moderately decreased in RUCH-2 oncKRAS xenografts (it however is 
significantly decreased in RUCH-2 oncNRAS xenografts) and an upregulation of hSHH is 
observed in none of the analyzed xenografts. Nevertheless, the expression of mGli2 in the 
tumor stroma is significantly increased, at least in oncKRAS xenografts. 
6.2.3 Chapter summary 
In chapter 6.2, the impact of oncRAS on growth and HH signaling activity in ERMS 
xenotransplants is described. As in cell culture, the tumor growth is significantly stimulated by 
oncRAS mutations in ERMS cell lines. In addition, oncRAS tend to decrease tumorintrinsic 
GLI1 expression, although the respective results are only significant for oncNRAS-
expressing RUCH-2 xenografts. In contrast, the transplantation of oncRAS cells rather 
results in a decrease in SHH expression (which was significant for oncH-/NRAS expressing 
TE617.T cells), whereas SHH expression of cultured oncRAS RUCH-2 or oncRAS TE617.T 
cells is elevated or decreased, respectively. Finally, tumor-extrinsic Gli2 expression in 
oncKRAS-expressing RUCH-2 xenografts is increased, which may indicate that the 
transplanted tumor cells indeed secrete HH ligands and thus may affect HH signaling activity 
in the tumor microenvironment. 
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6.3 Effects of oncRas mutations on ERMS of Ptchdel/+ mice 
In addition, a genetic approach was pursued to study possible interactions of Hh and Ras 
signaling in ERMS. For this purpose the Ptchdel/+ mouse model was used. These mice 
spontaneously develop RMS, which resemble ERMS in humans and show active Hh 
signaling 137,143,323,324. Ptchdel/+ mice were crossed to mice which conditionally express one of 
the oncRas genes. In order to activate the expression of oncRas, the Myf5CreER deleter 305 
mouse was used.  
6.3.1 Pilot testing and validation of the utilized mouse models 
6.3.1.1 Testing the activity of the Myf5CreER driver in ERMS using the R26R+/- reporter 
strain 
In a pilot test, the activity of the Myf5CreER driver was analyzed in ERMS of Ptchdel/+ mutant 
mice. This Cre driver was chosen, because human and murine ERMS from Ptch mutant mice 
highly express Myf5 323. In order to ensure that the oncRas mutations indeed will be induced 
in ERMS of Ptchdel/+ mice, Ptchdel/+Myf5CreER mice were bred to the cre-reporter strain R26R. 
When the mice developed a palpable tumor, they were injected i.p. with tamoxifen or solvent 
for 5 consecutive days and were sacrificed 1 or 5 weeks thereafter. ERMS and skeletal 
muscle (SM) as well as brain, heart (negative controls, not shown) and intestine (positive 
control due to endogenous β-galactosidase activity, not shown) were isolated and subjected 
to X-Gal stainings (see section 5.4.3). Another positive control was SM from Rosa26-lacZ 
mice. These mice express lacZ and thus show high β-galactosidase activity in every organ of 
the body 306. 
Tissue sections of SM and ERMS from solvent-treated Ptchdel/+Myf5CreERR26R+/- mice showed 
no X-Gal staining, whereas ERMS from tamoxifen-treated Ptchdel/+Myf5CreERR26R+/- mice 
stained positive (Fig. 41). The galactosidase activity visualized by X-Gal staining was 
detected in ERMS 1 or 5 weeks after treatment. Since no staining was detected in SM, it was 
concluded that the Myf5CreER driver is primarily active in ERMS and also does not show any 
leakiness i.e. it is not active without tamoxifen. Nevertheless, the staining itself was not as 
strong as expected from literature 305. 
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 mice were subjected to X-Gal staining. Cryo-embedded sections of SM from ROSA26-
lacZ mice served as positive control. The arrows point to areas of staining. Pictures were taken at 600x fold 
magnification. 
6.3.1.2 HRas, KRas and NRas are expressed in SM and ERMS of Ptchdel/+ mice 
Next, the expression of HRas, KRas and NRas were analyzed by PCR and qRT-PCR in SM 
and ERMS from Ptchdel/+ mice. These analyses were done to confirm that the Ras isoforms 
are expressed mainly in ERMS: if Ras should not be expressed in ERMS from Ptchdel/+ mice, 
an activation of oncRas from the endogenous Ras locus is not possible. As shown in Fig. 42, 
HRas, KRas and NRas are expressed in SM and ERMS tissue, respectively (Fig. 42A, 
Fig. 42C and Fig. 42E, respectively). Moreover, qRT-PCR data showed that the level of 
HRas expression is equal in SM and ERMS, whereas KRas and NRas level are higher in 
ERMS compared to SM (Fig. 42B, Fig. 42D and Fig. 42F, respectively). 
In addition, the Ras loci were sequenced to rule out endogenous mutations in the 3 genes. 
However, all 3 Ras loci were wt in more than 5 analyzed RMS from Ptchdel/+ mice (data not 
shown). 
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Figure 42: Ras isoforms are expressed in SM and ERMS tissue samples of Ptch
del/+ 
mice 
The basal expression of HRas (A, B), KRas (C, D) and NRas (E, F) were analyzed in skeletal muscle (SM) and 
ERMS (RMS) tissue samples of Ptch
del/+ 
mice by PCR (A, C, E) and quantified by qRT-PCR (B, D, E). The 
numbers in A, C and E indicate the mouse identification number. The expression in embryos at E12.5 served as 
positive control. The histograms shown in B, D and F represent qRT-PCR analyses and show the mean gene 
expression ± SEM of 7 tissue samples for SM and ERMS. Data were normalized to 18S rRNA (18S, left) or Tbp 
(right). For statistical analyses non-parametric t-tests (Mann Whitney) were performed. *p<0.05, **p<0.01, 
***p<0.001 compared to expression level within SM. 
6.3.1.3 Testing Myf5CreER activity at the Ras loci in ERMS of 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice 
After having checked the activity of the Myf5CreER driver in ERMS (see section 6.3.1.1), it was 
tested whether this Cre driver also efficiently targets the 3 oncogenic Ras loci. This was done 
because it is well known that the recombination efficiency of one and the same Cre driver 
can vary at different loci 338-340. The recombination assays were performed on frozen or 
paraffin-embedded tissue samples from SM and ERMS of Ptchdel/+HRasfl/+Myf5CreER/+, 
Ptchdel/+KRasfl/+Myf5CreER/+ and Ptchdel/+NRasfl/+Myf5CreRE/+ mice (compare section 5.2.3.2). 
Additionally, frozen tissue samples from these mice were used for a second round of 
genotyping to confirm the genetic setting (compare section 5.2.3.1). 
The recombination assay for HRas was done on PCR-amplified cDNA by enzymatic 
digestion with BpmI. The enzyme recognizes the wt sequence (derived from the wt and the 
floxed locus), whereas the mutant HRas exon is not recognized due to the HRasG12V 
mutation 303 (compare section 5.2.3.2.2). As already described, successful recombination 
was indicated by weak 209 bp and 93 bp digestion bands and a strong undigested fragment 
of 302 bp. 
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SM tissue samples from untreated, solvent-treated (not shown) and tamoxifen-treated 
Ptchdel/+HRasfl/+Myf5CreER/+ mice showed a weak band for undigested transcript and a strong 
band for the digested, wt transcripts. The same bands were also observed in ERMS samples 
from untreated and solvent-treated (not shown) Ptchdel/+HRasfl/+Myf5CreER/+ mice (Fig. 43). 
This might indicate that the Myf5CreER driver is leaky at the HRas loci. However, it could also 
mean that the BpmI-mediated digestion of the cDNA was incomplete. Nevertheless, the 
recombination efficiency at the HRas locus increased in ERMS samples of tamoxifen-treated 
mice (Fig. 43). Thus, a strong band for the undigested, recombined transcript and a weak 
band for the digested, wt transcripts were observed, which indicated efficient recombination 
at the HRas locus in ERMS. 
 
Figure 43: Recombination assays for the floxed HRas loci 
Skeletal muscle (SM) and ERMS (RMS) tissue samples were subjected to RNA isolation and subsequent cDNA 
synthesis. Fragments of the HRas gene were PCR-amplified and then digested using BpmI. Products were 
separated by agarose gel electrophoresis. A successful recombination is indicated by weak digestion bands (209 
bp and 93 bp) and a strong band for the undigested fragment (302 bp). No recombination should be indicated by 
strong digestion bands (209 bp and 93 bp) and lack of the undigested band (302 bp). However, due to either 
incomplete digestion or leakiness of the Cre driver at the floxed HRas locus the undigested band was always 
present. For more details, see text. 
The recombination assay for KRas was done on PCR-amplified gDNA samples. A band of 
304 bp represents the recombined KRas allele, whereas a band of 270 bp represents the wt 
KRas allele. Due to the fact that all mice were heterozygous for the floxed Ras alleles, 
efficient recombination at the KRas locus was demonstrated by the occurrence of the 304 bp 
fragment in addition to the 270 bp band. A double band was clearly observed in ERMS 
samples from tamoxifen-treated mice, whereas it was only detected in very rare cases of 
untreated or solvent-treated (data not shown) mice (Fig. 44). This suggests that the Myf5CreER 
driver might be leaky at the floxed KRas locus in very few cases. Due to these data the 
ERMS incidence of tamoxifen- and untreated Ptchdel/+KRasfl/+Myf5CreER/+ mice were 
compared, whereas all untreated Ptchdel/+KRasfl/+Myf5CreER/+ mice showing spontaneous 
recombination have been excluded from analyses (see section 6.3.2.3). 
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Figure 44: Recombination assays for the floxed KRas loci 
Skeletal muscle (SM) and ERMS (RMS) tissue samples were subjected to gDNA isolation and subsequent PCR 
which was used to prove efficient recombination at the floxed KRas locus. Amplificates were separated by 
agarose gel electrophoresis and analyzed afterwards. A double band (270 bp for wt and 304 bp for the floxed 
KRas locus after recombination) indicated efficient recombination, whereas a single band (270 bp for wt KRas) 
indicated no recombination. 
The recombination assay for NRas was also done with PCR-amplified gDNA samples. As 
already stated above, all mice were heterozygous for the floxed Ras alleles. Therefore, 
efficient recombination at the floxed NRas locus was demonstrated by the occurrence of the 
521 bp fragment in addition to the 487 bp band that represents the wt NRas allele. The 
analysis revealed that the double band only occurred in ERMS samples isolated from 
tamoxifen-treated mice, whereas it was never seen in ERMS from untreated 
Ptchdel/+NRasfl/+Myf5CreER/+ mice (Fig. 45). However, in rare cases recombination also 
occurred in SM of tamoxifen-treated Ptchdel/+NRasfl/+Myf5CreER/+ mice (data not shown). Since 
the latter fact probably is of no importance for ERMS growth, all tamoxifen-treated 
Ptchdel/+NRasfl/+Myf5CreER/+ mice (and all untreated mice) with the correct genotype were 
included in the analysis described in section 6.3.2.4. 
 
Figure 45: Recombination assays for the floxed NRas loci 
Skeletal muscle (SM) and ERMS (RMS) tissue samples were subjected to gDNA isolation and subsequent PCR, 
which was used to prove efficient recombination at the floxed NRas locus. Amplificates were separated by 
agarose gel electrophoresis and analyzed afterwards. A double band (487 bp for wt and 521 bp for the 
recombined floxed NRas alleles) indicated efficient recombination, whereas a single band (487 bp for the wt NRas 
allele) indicated no recombination. 
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6.3.1.4 Testing Ras activity in ERMS of tamoxifen-treated Ptchdel/+oncRasfl/+Myf5CreER/+ 
mice 
Next, the functionality of the expressed oncRas alleles was investigated. For this purpose, 
ERMS samples from tamoxifen-treated Ptchdel/+oncRasfl/+Myf5CreER/+ mice were analyzed in a 
Ras activity assay (experimental details are explained in section 5.3.6). The densitometrical 
analysis (Fig. 46A) of two independent experiments and a representative Western Blot 
(Fig. 46B) highlight an approximate twofold increase in Ras activity in tumor tissue of 
tamoxifen-treated Ptchdel/+ mice with oncRas mutation. 
 
















(oncHRas, oncKRas, oncNRas) mice. Afterwards cell lysates were subjected to a bead-based pull-down assay to 
precipitate active Ras. Whole lysates of the same samples were used to detect total Ras. Afterwards, precipitated 
and whole lysates were analyzed by Western Blot to detect the protein level of active Ras and total Ras with 
specific antibodies. Hsc70 served as loading control for total Ras. The relative Ras activity was calculated by 
normalization of active Ras to total Ras/Hsc70 and is displayed in histograms showing the mean Ras activity of 6 
tumors each cohort ± SEM. Ras activity in ERMS from Ptch
del/+
mice served as control and was set to 1 (A). A 
representative Western Blot is shown in (B). Protein names and sizes in kDa are displayed on the right side of the 
blot. The depicted results are representative for 6 tumors of each cohort analyzed in two independent 
experiments. For statistical analyses unpaired non-parametric t-tests (Mann Whitney) were performed. *p<0.05, 
**p<0.01 compared to relative Ras activity within tumor tissue from Ptch
del/+ 
mice. 
Taken together, the results described in section 6.3.1 show that ERMS of Ptchdel/+ mice 
express wt HRas, KRas and NRas. In order to activate oncRas expression in 
Ptchdel/+oncRasfl/+ mice the Myf5CreER driver was used. Indeed, tamoxifen-mediated activation 
of this driver induces recombination of the conditional floxed oncRas alleles primarily in the 
tumor tissue. Moreover, Ras activity assays verify the successful Ras activation in ERMS of 
tamoxifen-treated Ptchdel/+oncRasfl/+Myf5CreER/+ mice. 
6.3.2 Activation of oncRas in ERMS precursor lesions 
ERMS in Ptchdel/+ mice are initiated before birth and become conspicuous and palpable 
earliest at the age of approximately 7 weeks 323. In order to analyze the impact of oncRas on 
ERMS precursor lesions, the expression of oncRas in Ptchdel/+HRasfl/+Myf5CreER/+, 
Ptchdel/+KRasfl/+Myf5CreER/+ or Ptchdel/+NRasfl/+Myf5CreER/+ mice was induced with tamoxifen at 
the age of 4 weeks. Untreated siblings of the same genotype or untreated or tamoxifen-
treated Ptchdel/+ mice served as controls. 
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Breeding and tumor monitoring of the mice was part of another doctoral thesis 299. Here, the 
data were evaluated again and the monitoring study of Ptchdel/+NRasfl/+Myf5CreER/+ mice was 
repeated entirely. Overall survival was defined as the percentage of mice, which remained 
alive within the time frame of monitoring. RMS-free survival indicated the time point of first 
detection of a palpable ERMS of a mouse. On this basis the mean ERMS-free survival and 
the median latency time until tumor detection of the cohort was calculated. The tumor 
incidence specifies the percentage of mice with a detected ERMS in the complete cohort. 
The tumor multiplicity was calculated as proportion of mice with 1 or more ERMS compared 
to all ERMS-bearing mice. 
6.3.2.1 Tamoxifen does not influence growth or incidence of ERMS of Ptchdel/+ mice 
First, it was tested whether tamoxifen itself modulates ERMS in Ptchdel/+ mice. For this 
purpose, Ptchdel/+ mice were treated with tamoxifen at an age of 4 weeks and monitored for 
ERMS development. All Ptchdel/+ mice were the siblings of all Ptchdel/+oncRasfl/+Myf5CreER/+ 
mice. The time point of first tumor detection was recorded for approximately 200 days. The 
details and characteristics of all animals are listed in Tab. 25. The respective Kaplan-Meier 
curves for overall survival and ERMS-free survival and graphs for tumor incidence and 
multiplicity are shown in Fig. 47A, Fig. 47B, Fig. 47C and Fig. 47D, respectively. The 
analyses did not reveal any significant differences between untreated and tamoxifen-treated 
Ptchdel/+ mice. 
Table 25: Influence of tamoxifen treatment on ERMS development of 4 week old Ptch
del/+ 
mice 
Absolute numbers, median survival, premature death, ERMS incidence, latency time and further observed 
abnormalities of Ptch
del/+
 mice with and without tamoxifen injection. The respective Kaplan-Meier curves and 
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mice were injected with tamoxifen at the age of 4 weeks or remained untreated. Mice were monitored 
until the age of approximately 200 days and the time point of first tumor detection and death were recorded. 
Kaplan-Meier curves of overall (A) and ERMS-free (B) survival of untreated (black) and tamoxifen-treated (grey) 
Ptch
del/+
 mice are shown. The data were analyzed by Gehan-Breslow-Wilcoxon test for statistical differences in 
overall and ERMS-free survival. Differences in latency time were analyzed by Log-rank (Mantel-Cox) test. 
Differences in total number of animals with ERMS (C) and in tumor multiplicity (D) were analyzed by Chi square 
tests. For more details see Tab. 25. 
 
6.3.2.2 OncHRas increases the ERMS incidence in Ptchdel/+ mice 
Ptchdel/+HRasfl/+Myf5CreER/+ mice were treated with tamoxifen at an age of 4 weeks. Untreated 
animals served as controls. The details and characteristics of all animals of this cohort are 
listed in Tab. 26. The respective Kaplan-Meier curves for overall and ERMS-free survival are 
shown in Fig. 48A and Fig. 48B, respectively. The results show that the ERMS incidence was 
significantly higher in tamoxifen-treated Ptchdel/+HRasfl/+Myf5CreER/+ mice compared to 
untreated mice (Fig. 48C). In addition, the time until detection of palpable ERMS was shorter 
and just missed significance (Fig. 48B). However, no significant differences in the median 
overall survival, tumor multiplicity (Fig. 48D) or other abnormalities were observed (Tab. 26). 














mice with and without tamoxifen injection. The respective Kaplan-
























(65 – 211) 










Tamoxifen 32  
200 days 
(76 – 204) 










RESULTS | 107 
 









mice were injected with tamoxifen at the age of 4 weeks or left untreated. Mice were 
monitored until the age of approximately 200 days and the time point of first tumor detection and death were 







mice are shown. The data were analyzed by Gehan-Breslow-
Wilcoxon test for statistical differences in overall and ERMS-free survival. Differences in latency time were 
analyzed by Log-rank (Mantel-Cox) test. Differences in total number of animals with ERMS (C) and in tumor 







For more details see Tab. 26. 
 
6.3.2.3 OncKRas increases tumor incidence and reduces ERMS-free survival in 
Ptchdel/+ mice  
The Ptchdel/+KRasfl/+Myf5CreER/+ cohorts were treated as described above. Untreated mice 
served as controls. The details and characteristics of the animals are listed in Tab. 27 and 
are shown in Fig. 49. The data reveal that oncKRas significantly decreased the overall 
survival and ERMS-free survival (Tab. 27 and Fig. 49A, Fig. 49B). It also significantly 
increased the tumor incidence (Fig. 49C). On the other hand, oncKRas did not influence the 
occurrence of other abnormalities or tumor multiplicity (Tab. 27 and Fig. 49D). 
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mice were injected with tamoxifen at the age of 4 weeks or left untreated. Mice were 
monitored until the age of approximately 200 days and the time point of first tumor detection and death were 







mice are shown. The data were analyzed by Gehan-Breslow-
Wilcoxon test for statistical differences in overall and ERMS-free survival. The data were analyzed for differences 
in latency time using the Log-rank (Mantel-Cox) test. Differences in total tumor incidence (C) or tumor multiplicity 







mice. For more details see Tab. 27. 
 
6.3.2.4 OncNRas does not influence ERMS growth of Ptchdel/+ mice 
Mice from the Ptchdel/+NRasfl/+Myf5CreER/+ cohorts were treated as described above. Untreated 
mice served as controls. The details and characteristics of the animals are shown below 
(Tab. 28 and Fig. 50A, Fig. 50B, Fig. 50C and Fig. 50D). The data show that oncNRas does 
neither significantly influence overall survival, ERMS free survival, ERMS latency time, tumor 
incidence nor multiplicity (Fig. 50A, Fig. 50B, Fig. 50C and Fig. 50D). It also does not 
influence the occurrence of other abnormalities (Tab. 28). 
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mice were injected with tamoxifen at the age of 4 weeks or left untreated. Mice were 
monitored until the age of approximately 200 days and the time point of first tumor detection and death were 







mice are shown. The data were analyzed by Gehan-Breslow-
Wilcoxon test for statistical differences in overall and tumor free survival. The data were analyzed for differences 
in latency time using the Log-rank (Mantel-Cox) test. Differences in total tumor incidence (C) or tumor multiplicity 
(D) were analyzed with Chi square tests. For more details see Tab. 28. 
6.3.2.5 OncHRas and oncKRas increase proliferation rate of ERMS in Ptchdel/+ mice, 
whereas oncNRas does not 
Next, the impact of oncRas isoforms on proliferation of ERMS was analyzed by staining of 
paraffin sections for Ki67+ nuclei (compare section 5.4.2). 
Tamoxifen treatment did not influence proliferation of ERMS in Ptchdel/+ mice (Fig. 51A). In 
contrast, an increase in Ki67+ nuclei in ERMS of tamoxifen-treated Ptchdel/+HRasfl/+Myf5CreER/+ 
(Fig. 51B) and Ptchdel/+KRasfl/+Myf5CreER/+ (Fig. 51C) mice was observed in comparison to 
untreated mice of the same cohort. OncNRas induction did not influence proliferation of 
ERMS in Ptchdel/+ mice (Fig. 51D). Thus, the mean of Ki67+ nuclei in tumors of untreated mice 
from all cohorts ranged between 5.5 % and 6.5 % regardless of the genotype and did not 
differ significantly between the analyzed groups. In tumors of tamoxifen-treated mice the 
mean of Ki67+ nuclei ranged between 6.0 % and 13 %. In contrast, tumors with oncHRas or 
oncKRas mutations showed a significantly higher proliferation rate than ERMS from 
tamoxifen-treated Ptchdel/+ mice and tumors with oncNRas mutations. 
Additionally, the tumor weight and volume were assessed for ERMS from untreated and 
tamoxifen-treated Ptchdel/+NRasfl/+Myf5CreER/+ mice. However, oncNRas did not influence the 
respective parameters (data not shown). 
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Figure 51: OncHRas and oncKRas increase the percentage of Ki67
+
 nuclei in ERMS from Ptch
del/+
 mice 
ERMS tissue sections from untreated (n= 19 ERMS from 10 mice) and tamoxifen-treated (n= 15 ERMS from 12 
mice) Ptch
del/+ 







mice (B), untreated (n= 14 ERMS from 10 mice) and tamoxifen-treated (n= 39 ERMS 






mice (C) and untreated (n= 27 ERMS from 14 mice) and tamoxifen-






mice (D) were stained with a specific antibody 
against the proliferation marker Ki67. Number of all nuclei and Ki67
+
 nuclei were counted manually in 10 pictures 
of each tumor and percentage of Ki67
+
 nuclei was calculated. For statistical analyses non-parametric t-tests 






mice from the respective cohort. 
6.3.2.6 OncRas isoforms do not change expression of Hh target genes in ERMS of 
Ptchdel/+ mice 
Next, SM and ERMS tissue samples were analyzed for the expression level of the major Hh 
target Gli1 and of other downstream targets, namely Gli2, Gli3, Ptch and Hhip (Fig. 52). The 
expression of 18S rRNA or Tbp was used for normalization. Furthermore, the expression of 
the respective gene is shown as fold induction over the expression level in SM of the same 
animal, which was set to 1. Unfortunately, only 2 freshly frozen tumor samples of untreated 
Ptchdel/+KRasfl/+Myf5CreER/+ mice were available for the analyses. Hence, a statistical analysis 
was not possible for this cohort. 
None of the comparisons showed significant differences (Fig. 52). Thus, tamoxifen itself did 
not have significant effects on Hh target gene expression in tumors of Ptchdel/+ mice 
(Fig. 52A) and no significant differences between mRNA expression of tumors with and 
without oncRas were detected (Fig. 52B, Fig. 52C, Fig. 52D). Nevertheless, a tendency for 
downregulation of Gli1 in oncRas-expressing tumors was observed. This is notable because 
a similar, but significant downregulation of GLI1 was revealed in human ERMS cell lines (see 
section 6.1.2.1). 
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Figure 52: OncRas does not influence the expression of Hh signaling genes in ERMS 
ERMS and skeletal muscle (SM) tissue samples were isolated from untreated (n= 9) and tamoxifen-treated (n= 4) 
Ptch
del/+






mice (B), untreated 






mice (C) and untreated (n= 12) and tamoxifen-






mice (D). Afterwards tissue samples were subjected to RNA isolation, 
cDNA synthesis and subsequent qRT-PCR analyses of the Hh signaling pathway genes Gli1, Gli2, Gli3, Ptch1 
and Hhip. The data were normalized to 18S rRNA (18S, upper row) or Tbp (lower row) and are shown as fold 
expression to the expression of the same gene within SM of the respective mouse, which was set to 1. Bars show 
the mean ± SEM of one cohort and represent measurements in technical triplicates. For statistical analyses non-
parametric t-tests (Mann Whitney) were performed in comparison to ERMS from untreated mice of the same 
cohort. 
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6.3.2.7 OncNRas, but not oncHRas or oncKRas, increases the expression of muscle 
differentiation markers in ERMS of Ptchdel/+ mice 
Next, the expression of the muscle differentiation marker MyoD, Myogenin, Tropomyosin 3 
and Myosin Heavy Chain (MyHC) was analyzed in SM and ERMS samples by qRT-PCR. 
The expression of 18S rRNA or Tbp was used for normalization. Again the data are shown in 
relation to the expression of the respective gene in SM tissue of the same animal that was 
set to 1. Data are shown for tamoxifen-treated Ptchdel/+ mice (Fig. 53A), 
Ptchdel/+HRasfl/+Myf5CreER/+ (Fig. 53B), Ptchdel/+KRasfl/+Myf5CreER/+ (Fig. 53C) and 
Ptchdel/+NRasfl/+Myf5CreER/+ (Fig. 53D) mice in comparison to the untreated controls. 
The expression level of MyoD and Myogenin are reflective for proliferation and differentiation 
of muscle precursors during myogenesis and are considered to be early differentiation 
markers. The expression level of Tropomyosin 3 and MyHC indicate differentiation of already 
established muscle cells and are considered to be late differentiation markers 341. As 
demonstrated in Fig. 53A no significant differences in the expression of MyoD, Myogenin, 
Tropomyosin 3 and MyHC mRNA level were detected in RMS from Ptchdel/+ mice after 
tamoxifen treatment (Fig. 53A) or upon expression of oncHRas or oncKRas (Fig. 53B, 
Fig. 53C). In contrast, oncNRas significantly increased mRNA expression of Myogenin (at 
least when the data was normalized to 18S rRNA) and Tropomyosin 3 (Fig. 53D). This 
implicates that oncNRas induces a higher differentiation status of ERMS and thus potentially 
a less aggressive phenotype. 
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Figure 53: OncNRas induces expression of myogenic differentiation markers in ERMS, whereas oncHRas 
and oncKRas do not 
ERMS and skeletal muscle (SM) tissue samples were isolated from untreated (n= 9) and tamoxifen-treated (n= 4) 
Ptch
del/+






mice (B), untreated 






mice (C) and untreated (n= 12) and tamoxifen-






mice (D). Afterwards tissue samples were subjected to RNA isolation, 
cDNA synthesis and subsequent qRT-PCR analyses of the myogenic differentiation markers MyoD, Myogenin, 
Tropomyosin 3 and Myosin Heavy Chain (MyHC). The data were normalized to 18S rRNA (18S, upper row) or 
Tbp (lower row) and are shown as fold expression to the expression of the same gene within SM of the respective 
mouse, which was set to 1. Bars show the mean ± SEM of one cohort and represent measurements in technical 
triplicates. For statistical analyses non-parametric t-tests (Mann Whitney) were performed in comparison to ERMS 
from untreated mice of the same cohort. *p<0.05 compared to untreated mice from the respective cohort 
When the tumors were reviewed histologically by the pathologist Prof. Dr. med. Hans-Ulrich 
Schildhaus, no general differences between untreated and tamoxifen-treated tumors were 
detected. However, single tumor samples expressing oncRas were less differentiated than 
control tumors. In addition, single ERMS expressing oncKRas showed a more pleomorphic 
phenotype and more signs of necrosis in comparison to ERMS with oncHRas or oncNRas. 
Due to these data, we also examined the expression of the cell cycle marker p21 that 
influences apoptosis, proliferation and cell cycle arrest 342. However, no differences between 
the tumor samples were observed (data not shown). 
6.3.2.8 No obvious changes in pAKT, pERK, pS6 or caspase 3 cleavage in oncRas-
expressing ERMS of Ptchdel/+ mice 
Finally, the protein expression level of phosphorylated Erk, Akt and S6 and cleavage of 
caspase 3 in SM and ERMS of untreated and tamoxifen-treated Ptchdel/+HRasfl/+Myf5CreER/+ 
and Ptchdel/+KRasfl/+Myf5CreER/+ mice was compared. In general, the results were very 
heterogeneous and no common differences between control ERMS and oncRas-expressing 
ERMS were detected (Fig. 54A and Fig. 54B). 
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Figure 54: Impact of oncHRas and oncKRas on phosphorylation of Erk, Akt and S6 and caspase cleavage 
in ERMS of Ptch
del/+ 
mice 














(B) mice. Afterwards cell lysates were subjected to Western Blot analyses. 
Phosphorylation of Erk, Akt and S6 and cleavage of caspase 3 were detected using specific primary antibodies. 
Hsc70 served as reference protein and loading control. The Western Blots are representative for at least two 
independent technical replicates. Protein names and sizes in kDa are displayed on the right side of the Blots. 
Unfortunately, only 2 control ERMS samples from untreated Ptchdel/+KRasfl/+Myf5CreER/+ mice 
were available for the analyses (Fig. 54B). Therefore, it is not possible to judge whether there 
are real differences between control ERMS and oncKRas-expressing ERMS in this cohort. 
Nevertheless, the results show that phosphorylation either of Erk, Akt or S6 as well as 
caspase 3 cleavage is generally higher in tumors compared to normal skeletal muscle. 
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These results are similar to those shown by our group in 2004 138. However, due to these 
heterogeneous results and the time-consuming procedure the analysis of tissue samples 
from Ptchdel/+ or Ptchdel/+NRasfl/+Myf5CreER/+ mice was set aside. 
To sum up, the data within section 6.3.2 highlight that the expression of oncKRas and 
oncHRas accelerate Hh-associated ERMS formation, whereas oncNRas does not. This was 
measured by overall and ERMS-free survival, tumor incidence and the proliferation status of 
the tumors. Interestingly, oncNRas elevated the expression of specific muscle differentiation 
markers in ERMS, which thus correlates with the lack of increased aggressiveness of the 
tumors. In addition, oncRas seem to generally decrease the expression of Gli1 in the tumors. 
Although the decrease was not significant, these results are similar to human ERMS cell 
lines. 
6.3.3 Activation of oncRas in established ERMS  
In a next study, oncRas mutations were induced in already established ERMS of Ptchdel/+ 
mice. For this purpose, mice with palpable tumors (diameter of approximately 0.5 cm) were 
subjected to µCT measurement to document the exact tumor size. Then the 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice were injected i.p. 5 times with tamoxifen to induce Cre-
mediated recombination and thereby oncRas expression in the tumor. Solvent-treated 
ERMS-bearing Ptchdel/+oncRasfl/+Myf5CreER/+ siblings served as controls. In addition, the 
ERMS growth of solvent or tamoxifen-treated Ptchdel/+ mice was analyzed. Seven weeks after 
tamoxifen injection the tumor volume was again analyzed by µCT. 
6.3.3.1 OncRas isoforms do not influence growth of established ERMS of Ptchdel/+ 
mice 
As stated above, the tumor volume of Ptchdel/+oncRasfl/+Myf5CreER/+ mice were analyzed by 
µCT before and 7 weeks after induction of oncRas expression. The relative tumor volumes at 
the first and last µCT measurement are shown in Fig. 55A. The data were plotted on a 
logarithmic scale with linear trend lines for assumed tumor growth curves. The relative tumor 
growth, calculated as percentage increase of the tumor volume when comparing the absolute 
tumor volume at the first and last µCT measurement, is displayed on logarithmic scale as 
well (Fig. 55B). Solvent-treated mice served as controls. 
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Mice with palpable tumors were subjected to µCT measurements before and 7 weeks after solvent or tamoxifen 
treatment and tumor volume was calculated (A). The relative percentage of increase was additionally calculated 
for each tumor (B). Solvent or tamoxifen treatment is represented by black or grey graphs, respectively. Multiple 
ERMS within the same mouse were analyzed as individual tumors. Data analyses was performed for solvent-
treated (n= 29 ERMS from 17 mice) or tamoxifen-treated (n= 27 ERMS from 18 mice) Ptch
del/+
 mice, solvent-













mice and solvent-treated (n= 16 ERMS from 11 mice) or tamoxifen-treated (n= 20 






mice. The tumor volume at the start and the end of tumor growth 
measurement and percental increase of each tumor are displayed on a logarithmic scale. For statistical analyses 
Student's t-tests were performed in comparison to tumor volume from solvent-treated mice of the same cohort. 
At the onset of the study the sizes of all RMS of the Ptchdel/+oncRasfl/+Myf5CreER/+ cohorts 
were almost identical. This was different in Ptchdel/+ control mice, in which the mean tumor 
volume of mice that underwent tamoxifen-injection was accidentally larger. Seven weeks 
after solvent or tamoxifen treatment, all tumors had grown. However, neither tamoxifen nor 
oncRas had significantly influenced ERMS growth (Fig. 55A). This is also demonstrated in 
Fig. 55B, which represents the relative tumor growth of individual tumors. Finally, a 
comparison between tumors expressing different oncRas isoforms also revealed no 
significant differences (data not shown). 
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6.3.3.2 OncRas isoforms do not influence proliferation of established ERMS of 
Ptchdel/+ mice 
Next, all available tumor samples were analyzed for the expression of the proliferation 
marker Ki67. In all analyzed tumors the mean amount of Ki67+ nuclei ranged between 2.5 % 
and 4.0 % and did not differ significantly between the cohorts (Fig. 56). Together with the 
data shown in section 6.3.2.1, the results demonstrate that oncRas isoforms have no impact 
on proliferation of established ERMS of Ptchdel/+ mice. 
 
Figure 56: Percentage of Ki67
+
 nuclei in established ERMS from Ptch
del/+
 mice with and without oncRas 
ERMS tissue sections from solvent-treated (n= 29 ERMS from 17 mice) and tamoxifen-treated (n= 27 ERMS from 
18 mice) Ptch
del/+ 







mice, solvent-treated (n= 15 ERMS from 12 mice) and tamoxifen-treated (n= 24 






mice and solvent-treated (n= 16 ERMS from 11 mice) and 






mice were stained with a specific 
antibody against the proliferation marker Ki67. Number of all nuclei and Ki67
+
 nuclei were counted manually in 6 
pictures of each tumor and the percentage of Ki67
+
 nuclei was calculated. For statistical analyses non-parametric 
t-tests (Mann Whitney) were performed. 
6.3.3.3 OncRas does not change expression of Hh target genes in established ERMS 
Afterwards, the expression level of the Hh genes Gli1 and Gli2 were analyzed in the SM and 
ERMS tissue samples (Fig. 57). The expression of 18S rRNA or Tbp was used for 
normalization. 
Again and as already mentioned, the expression of the respective gene in ERMS is shown 
relative to the expression in SM of the same animal and the expression level of the gene in 
SM was set to 1. However, the analyses revealed no significant differences in Gli1 and Gli2 
mRNA expression between ERMS of solvent- or tamoxifen-treated 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice. This was true for Ptchdel/+HRasfl/+Myf5CreER/+ (Fig. 57B), 
Ptchdel/+KRasfl/+Myf5CreER/+ (Fig. 57C) and Ptchdel/+NRasfl/+Myf5CreER/+ mice (Fig. 57C) and also 
for Ptchdel/+ mice (Fig. 57A). 
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Figure 57: Tamoxifen treatment and oncRas mutations do not influence expression of Gli1 and Gli2 in 
established ERMS in Ptch
del/+ 
mice 
ERMS and skeletal muscle (SM) tissue samples were isolated from solvent-treated (n= 19) and tamoxifen-treated 
(n= 20) Ptch
del/+ 













mice (C) and solvent-treated 






mice (D). Afterwards tissue samples were 
subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the Hh signaling genes Gli1 
and Gli2. The data were normalized to 18S rRNA (18S, left) or Tbp (right) and are shown as fold expression to 
expression of the same gene within SM of the respective mouse, which was set to 1. Bars show the mean ± SEM 
of one cohort and represent measurements in technical triplicates. For statistical analyses non-parametric t-tests 
(Mann Whitney) were performed in comparison to RMS from untreated mice of the same cohort. 
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6.3.3.4 OncRas do not influence expression of muscle differentiation markers in 
established ERMS 
Subsequently, the expression of the muscle differentiation markers MyoD, Myogenin, 
Tropomyosin 3 and MyHC were analyzed in SM and ERMS. The analyses were done as 
described in the previous chapters. 
The results show that there was no significant difference between mRNA expression of 
muscle differentiation markers in established tumors with and without tamoxifen treatment or 
with and without oncRas expression (Fig. 58A-Fig. 58D). 
 
122 | RESULTS 
 
Figure 58: Tamoxifen treatment and oncRas mutations do not influence myogenic differentiation in 
established ERMS in Ptch
del/+ 
mice 
ERMS and skeletal muscle (SM) tissue samples were isolated from solvent-treated (n= 19) and tamoxifen-treated 
(n= 20) Ptch
del/+ 













mice (C) and solvent-treated 






mice (D). Afterwards tissue samples were 
subjected to RNA isolation, cDNA synthesis and subsequent qRT-PCR analyses of the myogenic differentiation 
markers MyoD, Myogenin, Tropomyosin 3 and Myosin Heavy Chain (MyHC). The data were normalized to 18S 
rRNA (18S, upper row) or Tbp (lower row) and are shown as fold expression to the expression of the same gene 
within SM of the respective mouse which was set to 1. Bars show the mean ± SEM of one cohort and represent 
measurements in technical triplicates. For statistical analyses non-parametric t-tests (Mann Whitney) were 
performed. 
To sum up, the results from chapter 6.3.3 indicate that oncRas do not influence growth, 
proliferation and thus aggressiveness of established ERMS. Furthermore, oncRas isoforms 
do not influence the expression of different muscle differentiation markers. Moreover, oncRas 
isoforms do not downregulate targets of Hh signaling such as Gli1 and Gli2. 
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6.3.4 Chapter summary 
Within chapter 6.3 the effect of oncRas on Hh/Ptch-driven ERMS in Ptchdel/+ mice is 
described. The data show that all 3 Ras isoforms are expressed in SM and ERMS of Ptchdel/+ 
mice and are not mutated. In addition, activity of the Myf5CreER driver, which was used to 
conditionally activate oncRas isoforms, is indeed mainly active in ERMS. This is not only 
revealed by using Ptchdel/+Myf5CreER/+R26R+/- mice, but also by recombination assays using 
normal SM and ERMS tissue samples and Ras activity assays using ERMS tissue samples 
from tamoxifen-treated Ptchdel/+ and Ptchdel/+oncRasfl/+Myf5CreER/+ mice. 
The results reporting induction of oncRas in ERMS precursor lesions also show that 
oncKRas and most likely also oncHRas accelerate Hh-associated ERMS formation, whereas 
oncNRas or tamoxifen itself do not. Thus, tamoxifen-treated Ptchdel/+HRasfl/+Myf5CreER/+ and 
Ptchdel/+KRasfl/+Myf5CreER/+ mice show an increased ERMS incidence in comparison to 
untreated mice and oncKRas mutations even decrease overall survival of Ptchdel/+ mice. 
OncKRas and oncHRas also increase proliferation of tumor cells, whereas oncNRas does 
not. However, oncHRas, oncNRas, and most likely also oncKRas (please note that there 
were only 2 control samples available for analysis), do not significantly influence Hh 
signaling, although a tendency of downregulation of Gli1 was detected. OncHRas and 
oncKRas also do not influence myogenic differentiation of ERMS, whereas oncNRas induces 
the expression of late myogenic differentiation markers in ERMS. Finally, the analyses of the 
phosphorylation status of Erk, Akt and S6 in SM and ERMS show very heterogeneous 
results and no unambiguous influence of the oncRas mutations. However, as already shown 
by our group before, the phosphorylation of the mentioned proteins was in generally higher in 
ERMS as in SM (please note that tamoxifen treatment itself did not modulate any of the 
mentioned parameters). 
When expression of oncRas isoforms is induced in established ERMS, the relative tumor 
volume, relative tumor growth and proliferation of ERMS do not change. On molecular level, 
oncRas also do not modulate gene expression of Gli1, Gli2, MyoD, Myogenin, Tropomyosin 
3 and MyHC. Together, these results show that oncRas isoforms do not influence any of the 
analyzed parameters in established ERMS. 
In summary, the results highlight that oncHRas and oncKRas mutations affect Hh-associated 
ERMS precursor lesions but not full-blown ERMS. This was most obvious when analyzing 
the aggressiveness of the tumors by proliferation, tumor incidence and ERMS-free survival. 
In contrast, oncNRas never influences these parameters but apparently induces a more 
differentiated ERMS phenotype. Finally, it has to be mentioned that the results differ from 
that of cultured ERMS cell lines, in which all oncRAS mutations induces a more aggressive 
tumor phenotype.
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7 Discussion 
RMS, the most common malignant soft tissue sarcoma in children, is currently treated with 
multimodal therapies. However, the efficiency is limited 3,4,13,23,25. This indicates a need for a 
deeper understanding of the tumor’s pathology to design improved therapies for the patients. 
Interestingly, human RMS, especially ERMS, frequently show an activation of the HH 
signaling cascade and mutations within the RAS signaling pathway 6,14,15,141-143. Furthermore, 
interactions between these signaling pathways have been discovered 284,343. In dependency 
of the cellular context and the experimental setting oncRas signaling can either activate or 
suppress Hh signaling activity 75,84,295,296,298 (for more details, see section 2.4). This shows a 
cooperation of both pathways in tumor development, maintenance or progression and led to 
the conclusion that the RAS and/or the HH signaling pathways could also be interesting 
therapeutic targets in RMS. 
Indeed, recently our group has discovered a crosstalk between both pathways in RMS 299. As 
already stated above, ERMS, but not ARMS, strongly express HH target genes and show 
oncRAS mutations. Therefore, the focus of this thesis was on unravelling the role of oncRAS 
mutations in regulation of genes implicated in the HH signaling pathway and associated 
cellular responses of ERMS. Moreover, the impact of a crosstalk between both pathways in 
ERMS pathogenesis, growth and aggressiveness was analyzed. For this purpose, 
oncRAS/oncRas signaling was activated in human cell lines derived from sporadic ERMS 
and in precursor lesions and full-blown ERMS of Ptchdel/+oncRasfl/+Myf5CreER/+ mice, which is a 
Hh/Ptch-driven ERMS mouse model. Finally, some of the already performed experiments of 
our group were validated. 
7.1 OncRAS mutations stimulate growth of cell lines derived from 
sporadic ERMS despite inhibition of the major HH target GLI1 
7.1.1 Differences and limitations of the utilized RMS cell lines 
To unravel interactions between HH and RAS signaling, the human ERMS cell lines TE617.T 
and RUCH-2 and the human ARMS cell line RMS-13, all wt for RAS, were stably transduced 
with different oncRASG12V isoforms 299. In addition to experiments with stably transduced cell 
lines, experiments were performed with the ERMS cell line RD that harbors an endogenous 
NRASQ61H mutation 312,326. 
After generation of RMS cell lines that stably express oncRAS isoforms, a PCR-based assay 
detected that a TE617.T clone has been generated, which expresses both oncHRAS and 
oncNRAS (Fig. 9). This was probably due to a mistake during production. Nevertheless, 
these cells were analyzed in the same manner as the other cell clones. The analyses 
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showed that oncRAS-expressing TE617.T cells have an increased RAS activity (Fig. 11), 
measured by a pulldown assay with beads that are coated with the RBD of RAF-1 kinase 
that specifically binds to active RAS 344. However, the cells do not show a strong activation of 
the MEK/ERK or the PI3K/AKT/mTOR axes (Fig. 10). Whether other RAS target pathways or 
molecules, such as JNK, p38 and ERK5, are activated by RAS/RAF is currently unknown. In 
contrast to TE617.T cells, oncRAS-transduced RUCH-2 and RMS-13 cell lines showed 
elevated levels of pERK (Fig. 10). Since RAS activity in these cells was high, whereas no 
changes in pAKT or pS6 levels were detected, the MEK/ERK axis must be the main, or at 
least one of the main active downstream effector of oncRAS in these cell lines. 
As described in the results sections, culture experiments showed that the RMS cell lines also 
respond differently to e.g. ERK inhibition. To a certain extent, these findings can be 
explained by the origin of these cells and by their specific genetic make-up. 
Thus, the TE617.T cell line was originally isolated from the connective tissue of a 1.7-year-
old girl with ERMS 315,326. Although this cell line is wt for RAS, it shows protein-changing 
mutations in MAP3K14 (different splice variant) and MAP3K1 (threonine deletion at 
position 949) 345. The MAP3K14 gene encodes for the Nuclear factor “kappa-light-chain-
enhancer” of activated B-cells (NFκB)-inducing kinase (NIK) and is involved in the alternative 
NFκB induction through tumor necrosis factor (TNF), CD95 and interleukin (IL)-1 24 346. 
MAP3K1 encodes for the Mitogen-activated protein kinase kinase kinase 1 (MEKK1) and can 
activate the ERK and JNK kinase pathways by phosphorylation of MAPK8, MAP2K1 and 
MAP2K4 347,348. The indicated protein changes are not located within structural motifs, like 
the catalytic domain. Nevertheless, an effect on protein functionality and on the functionality 
function of the MAPK pathways cannot be excluded. Consequently, these mutations could be 
responsible for the effects discussed in sections 7.1.2 and 7.1.3. 
The RUCH-2 cell line, which is also wt for RAS, was established from a primary ERMS of the 
botryoid type detected in the vagina of a 1.3-year-old girl and shows multiple chromosomal 
rearrangements 314,315,326,349. Until now not many characteristics have been described for this 
cell line 326,349. However, it is known that RUCH-2 cells originally expressed MYF3 and MYF5 
but lost the expression of these markers during cell culture 314. MYF5, together with MYOD 
and the calcineurin pathway, is known to activate the transcription of different MyHC genes 
350. This could explain why RUCH-2 cells do not express further myogenic markers, like 
MyHC1 and myogenic regulatory factor (MRF). In addition, RUCH-2 cells show increased 
invasiveness at higher passages 314. 
RD is the most commonly used RMS cell line and was isolated from an recurrent pelvic 
ERMS of a 7-year-old girl 312. Besides a heterozygous NRASQ61H mutation, the cells have an 
amplification of the MYC oncogene and a homozygous mutation of TP53 16,275,312,326,351. Thus, 
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this cell line is a valid model system for ERMS since these characteristic mutations are also 
observed in human ERMS 14,15,141,231,232,267. Nevertheless, due to the endogenous NRAS 
mutation, a comparison to “baseline” expression without oncRAS mutation of e.g. GLI1 was 
not possible. 
The RMS-13 cell line was isolated from a bone marrow metastasis of a 17-year-old boy and 
shows alveolar histology. The cell line is PAX3:FOXO1a fusion-positive, shows a TP53 
mutation and amplifications of CDK4 and GLI1 313,352,353. A limitation of the RMS-13 cell line is 
the fact that until now RAS mutations have not been described in fusion-positive ARMS 
14,15,141. Consequently, experiments with the fusion-positive ARMS cell line RMS-13 do not 
necessarily represent the biology of human ARMS. However, the focus of this thesis was on 
ERMS and only few experiments were done with this cell line. 
Finally, cultured cells poorly mimic the conditions of primary tumors 354. Hence, all cell culture 
experiments are limited to the specific characteristics of the utilized cell lines and do not 
necessarily reflect the situation in vivo. 
7.1.2 Influence of oncRAS mutations on expression of GLI1 and the related 
mechanisms 
The data show that oncRAS mutations in general decrease the mRNA expression of the 
major HH target GLI1 (Fig. 13). This effect was not only detected in cell culture, but also in 
vivo in transplanted oncRAS-expressing cells (Fig. 37, Fig. 39, Fig. 40). In cultured TE617.T 
cells the oncH-/NRAS-induced decrease of GLI1 is dependent on the reference gene. The 
discrepancy in statistical significance is due to a higher SEM in gene expression of oncH-
/NRAS-expressing TE617.T cells after normalization to 18S rRNA (Fig. 13). Furthermore, an 
oncRAS-dependent decrease of GLI1 was observed in RUCH-2 and RMS-13 cells and 
thereby confirmed previous results 299 (Fig. 13). In xenotransplants, an oncRAS-mediated 
downregulation of GLI1 was also observed, which however was very weak and not 
significant. This effect can be explained by the tumor microenvironment, which is missing in 
cell culture. 
Similar to RMS cell lines, a suppressive effect of oncKRAS on GLI1 expression has been 
described for pancreatic cancer cells 84. However, these findings are in contrast to other 
studies, which show that oncNRAS or oncHRAS can stimulate expression of GLI1. This has 
been shown in melanoma cells 75. Additionally, oncHRAS and oncKRAS increase GLI1 in 
thyroid cancer cells 298. This shows that oncRAS-mediated modulation of GLI1 can have 
oppositional effects in different tumor entities. Indeed, this is also suggested by the current 
experiments that show that oncRAS downregulate GLI1 in RMS cell lines, but not in the MB 
cell line Daoy. 
DISCUSSION | 127 
7.1.2.1 ERMS cell lines do not secrete HH ligands and are not HH-responsive 
The ERMS cell lines TE617.T, RUCH-2 and RD generally express SHH but were not able to 
secrete this ligand, regardless if they harbor an oncRAS mutation or not (Fig. 16, Fig. 17 
and 299). In contrast, data published for pancreatic cancer cell lines suggest that onKRAS 
induces SHH expression and secretion, which results in activation of HH signaling activity in 
neighboring cells 84. However, this was not the case in ERMS cell lines. One possible 
explanation is that cholesterol-dependent binding of SHH to DISP or an autocatalytic 
cleavage of the HH ligand (that is required for ligand secretion 355), do not occur in ERMS cell 
lines. To test this hypothesis, a Western Blot to detect cleaved and precursor HH ligands 
could be performed with lysates from cells cultured in cholesterol-lacking or cholesterol-
supplemented media. An additional explanation could be the lack of extracellular Scube 
proteins in the used ERMS cell lines. This group of proteins enhances the solubility of the 
cholesterol-modified HH ligands and is necessary for HH ligand secretion 355. Western Blot 
analyses for Scube proteins could shed light on this question. Moreover, it is possible that 
the SHH protein is degraded in ERMS cell lines and therefore is not secreted. This could be 
tested in experiments with proteasome inhibitors, e.g. Bortezomib, which then should 
increase the intracellular level of SHH and could allow for SHH secretion as well. 
Vice versa, stimulation with SHH did not significantly activate HH signaling in RUCH-2 cells 
with and without oncRAS mutation (Fig. 18). This was also seen in RD cells, which neither 
react to stimulation with SHH-CM nor to the SMO agonist SAG at the level of GLI1, HHIP or 
PTCH 159. However, it has been reported that in RD cells, depletion of IHH or DHH results in 
a decrease of GLI1, whereas SHH downregulation does not affect GLI1 expression 150. 
Therefore, it is possible that IHH and DHH are more important in RMS than SHH. 
Nevertheless, the current data and data from our group using SMO inhibitors indicate that 
canonical HH signaling only plays a subordinate role in ERMS cell lines 159,337, regardless if 
they harbor an oncRAS mutation or not. This is partially conflicting with the expression of IHH 
and DHH in ERMS 150 (see above) and with other reports, showing that especially ERMS 
display elevated expression level of GLI1, GLI2, GLI3 and PTCH, which actually is indicative 
for an active canonical HH signaling cascade 141,142. However, HH target gene expression not 
always stands for an active HH signaling cascade, because the respective genes can also be 
regulated non-canonically (compare section 2.2.2). Indeed and as recently described by our 
group, a non-canonical regulation of the HH signaling pathway is supported by the fact that 
RUCH-2 and RD cells rarely develop cilia 159. Cilia play a central role in canonical HH signal 
transduction 356. Consequently, canonical HH signaling cannot be properly activated in RD 
and RUCH-2 cells. 
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7.1.2.2 OncRAS mutations decrease GLI1/GLI1 expression via the MEK/ERK axis in 
ERMS cells 
The fact that it is not possible to stimulate or inhibit canonical HH signaling via the 
PTCH/SMO axis led to the hypothesis that oncRAS isoforms decrease the expression of 
GLI1 in a non-canonical i.e. HH/PTCH/SMO-independent manner. Consequently, the 
expression of GLI1 was measured in TE617.T and RUCH-2 cell lines with and without 
oncRAS after application of PI-103, UO126 or SCH772984 (Fig. 21, Fig. 22). Additionally, 
SCH772984 was applied to RD cells (Fig. 23). Finally, the expression of GLI1 was measured 
after incubation of the cells with HhA. Ahead of the experiments, the inhibitor functionality 
was validated, and results are described and explained in section 6.1.4. 
Treatment with HhA failed to decrease GLI1 in any of the TE617.T cell lines. Similar results 
have been obtainend in other RMS cell lines 337, including RUCH-2 control cells. Since HhA 
is a SMO inhibitor, these observations underline the hypothesis, that canonical HH signaling 
plays only a minor role in ERMS cell lines (see section 7.1.2.1). Likewise, the application of 
PI-103 did not influence GLI1 in any of the TE617.T cells. In contrast, treatment with UO126 
or SCH772984 resulted in a significant increase of GLI1 expression in all TE617.T cells. 
However, this is independent of oncRAS mutations, since the effect was also observed in 
control TE617.T cells. This might depend on the MAP3K1 mutation in these cells. Assuming 
that this mutation is an activating one, this would result in an increased basal activation of 
ERK and consequently in an ERK-dependent suppression of GLI1 in TE617.T control cells. 
The stable transduction with oncRAS isoforms could additionally increase ERK activity and 
thus strengthen the decrease of GLI1. Consequently, the application of SCH772984 would 
result in an increase of GLI1 in all TE617.T cells. If this hypothesis is true, it would support 
the assumption that oncRAS isoforms downregulate GLI1 expression and thus the HH 
signaling pathway through activation of the ERK axis. 
Indeed, in RUCH-2 cells, in which HhA activates ERK, GLI1 expression was downregulated. 
This effect was significant for oncRAS-expressing cells, but was also seen as a trend in wt 
cells. Nevertheless, downregulation of GLI1 can also depend on SMO inhibition. Finally, it 
also can be explained by toxic effects of the drug because the used concentration of 10 µM 
decreases cell viability (measured by WST-1 assay) of oncRAS-expressing RUCH-2 299,337. In 
contrast, application of HhA to TE617.T cells did not influence cell viability (data not shown). 
A treatment with PI-103 decreased GLI1 mRNA expression in RUCH-2 cell lines with and 
without oncRAS. This indicates that PI3K/mTOR signaling in general activates the 
expression of GLI1 in RUCH-2 cells and is not involved in oncRAS-mediated downregulation 
of GLI1. It is possible that PI-103 decreases GLI1 via AKT or S6, which are downstream of 
the inhibited kinases PI3K and mTOR. Thus, AKT can inactivate GSK3 and PKA and thereby 
decrease the inhibitory effects of these kinases on GLI1/2 activity 54,79,357. In addition, S6 
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triggers S6K1-dependent phosphorylation of GLI1 and induced the release of GLI1 from 
SUFU 79. On the other hand, downregulation of GLI1 by PI-103 could be a toxic effect, 
because the same concentration of PI-103 decreased cell viability (measured by WST-1 
assay) in oncRAS-expressing RUCH-2 cells 299. However, because PI-103 also decreases 
cell viability of TE617.T cells (data not shown), but not the expression of GLI1 (see above) 
the latter explanation this is rather unlikely. Finally, inhibition of ERK restored oncRAS-
induced downregulation of GLI1 back to basal level of RUCH-2 control cells. Similar results 
were obtained on protein level. Thus, oncRAS decreased the GLI1 protein level, which was 
reversed by ERK inhibition irrespective of the cellular compartment (Fig. 33). This confirms 
that oncRAS-mediated decrease of GLI1/GLI1 can be regulated by ERK in ERMS, which 
thus is different from pancreatitic ductal epithel cells, in which oncRAS (or at least oncKRAS) 
stabilizes GLI1 protein 297. 
Like in oncRAS-expressing RUCH-2 cells, ERK also inhibited GLI1 expression in RD cells 
(Fig. 23). This was supported by the fact that the transcriptional activity of a GLI reporter 
significantly increased after incubation with SCH772984 (Fig. 32). 
Together, these data indicate an ERK-dependent regulation of GLI1 in RUCH-2 and RD 
cells. Indeed and as already mentioned, non-canonical interactions between the HH and 
RAS signaling pathways via the MEK/ERK pathway have been described 71,284,343. Thus, Gli1 
was identified as a potential substrate of Erk and supposedly can be phosphorylated by this 
kinase in a Mek-dependent manner 286-288. Therefore it was first hypothesized that ERK 
regulates GLI1 through phosphorylation in ERMS and thereby prevents the translocation of 
the GLI transcrition factors into the nucleus. However, no differences between the GLI level 
in cytosol and nucleus were observed, at least not in RUCH-2 cells (Fig. 33, Fig. 34). 
Consequently, the oncRAS-dependent downregulation of GLI1 is most likely not due to the 
translocation of GLIA and GLIR forms into the nucleus. This result is in contrast to findings 
from melanoma model systems where oncNRAS or oncHRAS stimulate nuclear localization 
of GLI1 75. However, and as already described in the results section, GLI2 and GLI3 protein 
level were highly variable between biological replicates and were probably not regulated by 
the oncRAS/ERK axis. Thus, it is possible that GLI1 is selectively degradated by the 
proteasom in an ERK-dependent manner. This is supported by the finding that the MEK/ERK 
pathway can lead to selective protein degradation in other cellular settings 187. To test this 
hypothesis, expression of GLI proteins in ERMS cell lines should be measured within time 
row experiments after application of a proteasome inhibitor. Another explanation for the 
decrease of GLI1/GLI1 in oncRAS-expressing RUCH-2 is an ERK-dependent regulation of 
GLI1 transcription. This is even more likely than a proteasome-dependent regulation of GLI1, 
because GLI2 and GLI3 are in most likeliness not regulated by ERK. ERK itself, or its 
downstream targets ETS-like gene tyrosine kinase 1 (Elk1), c-Fos and c-Jun, that activate 
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the AP1 transcription factor 358, can regulate transcriptional activity of ERK target genes. 
However, it remains to be elucidated if the GLI1 promotor is a direct target of ERK signaling. 
To confirm this hypothesis, the GLI1 promotor sequence should be screened for ERK-
specific (or Elk1-, c-Fos- c-Jun or AP1-specific) binding sites. Additionally, respective 
chromatin immunoprecipitation (ChIP) assays can be performed. 
7.1.3 Influence of oncRAS mutations on expression of other genes implicated 
in the HH signaling cascade 
In TE617.T cells, there is an insignificant trend for an oncKRAS- or oncH-/NRAS-dependent 
decrease of GLI2 or PTCH, respectively, without affecting HHIP expression level (Fig. 14). 
ERK inhibits PTCH in TE617.T cells irrespective of an oncRAS mutation, whereas its impact 
in regulation of GLI2 is not clear-cut (Fig. 24, Fig. 25, Fig. 26). In xenografts derived from 
TE617.T cells that express oncKRAS or oncH-/NRAS isoforms, the tumorintrinsic expression 
of hGLI2 is not affected (Fig. 37). However, this differences might be explained by the 
presence of tumorextrinsic effects in xenografts through the tumor’s micorenvironment. 
In RUCH-2 cells, oncRAS isoforms reduce GLI2 expression without affecting HHIP 
expression level (Fig. 15). Additionally, oncHRAS and oncKRAS increase PTCH expression 
in cultured RUCH-2 cells (Fig. 15) and ERK is not involved in the regulation of PTCH 
expression in this very cell line (Fig. 28, Fig. 29, Fig. 30). However and in contrast to cell cell 
culture experiments, oncKRAS or oncNRAS did not significantly decrease hGLI2 in 
xenografts (Fig. 39, Fig. 40), which might be an effect of the xenograft microenvironment.  
GLI1, PTCH and HHIP are considered to be mammalian HH target genes and GLI2 is a 
positive regulator of HH signaling 31,69. In a canonical regulation of GLI1 through HH 
signaling, an oncRAS-dependent decrease of GLI1 would be probably accompanied by a 
downregulation of PTCH, HHIP and also of GLI2. However, this was not the case, neither in 
cell culture nor in xenotransplants derived neither from TE617.T nor in RUCH-2 cells. These 
observations together with the fact that it is rather impossible to stimulate or to inhibit 
canonical HH signaling via the PTCH/SMO axis (see also chapter 7.1.2.1) strengthens the 
hypothesis, that oncRAS isoforms decrease the expression of GLI1/GLI1 in a non-canonical 
i.e. HH/PTCH/SMO-independent manner. 
Moreover, the expression of GLI3 was decreased in an oncNRAS-dependent manner in 
TE617.T and RUCH-2 cells (Fig. 14, Fig. 15). However and in contrast to GLI1, GLI3 is not a 
HH target gene. In TE617.T and RUCH-2 cells, the oncNRAS-dependent downregulation of 
GLI3 is independent of ERK (Fig. 26, Fig. 30). This is in contrast to RD cells, where ERK 
inhibits GLI3 (Fig. 31). The differences between the cell lines might rely on cell line specific 
mutations (see section 7.1). 
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Despite a lack of HH ligand secretion, all ERMS cell lines show basal mRNA expression of 
SHH. In oncRAS-transduced TE617.T cell lines the expression of SHH was decreased in 
comparison to control cells (Fig. 14). Additionally, xenografts derived from TE617.T cells with 
oncKRAS or oncH-/NRAS also showed decreased tumorintrinsic expression of hSHH, which 
was however only significant for oncH-/NRAS tumors (Fig. 37). In general, transcriptional 
regulation of SHH is mechanistically not fully understood. However, it can be mediated via 
NFκB, which normally induces SHH expression 359-362. Additionally, it is known that oncRAS 
isoforms can induce the activation of NFκB through the NIK(MAP3K14)/IKK-pathway 363,364. 
In addition, NIK also can influence phosphorylation and thus activity of ERK 365. The 
regulation becomes even more complicated because ERK can activate NFκB by IKK 366,367 or 
inhibit NFκB-driven transcription, which is dependent on the cellular context 368. Thus, it is 
possible that the MAP3K14 (NIK) mutation in TE617.T impairs the activity of both NFκB and 
ERK, which could also affect SHH expression in a specific, but so far unknown mechanism. 
In contrast, RUCH-2 cells show an oncRAS-dependent increase of SHH in cell culture 
(Fig. 15). This similar to pancreatic cancer cells, in which oncKRAS also upregulates the 
expression of SHH 84,295. Additionally, the data from this work show that this increase is ERK-
dependent (Fig. 28, Fig. 29, Fig. 30). This is in line with findings from the literature, in which 
an enhanced SHH expression correlates with the oncRAS mutational status 84,369. In contrast 
to the observation in cell culture, xenografts derived from RUCH-2 cells with oncKRAS or 
oncNRAS show a slightly decreased tumorintrinsic SHH expression (Fig. 39, Fig. 40). The 
discrepancy between SHH expression in cell culture experiments and xenografts can also be 
explained by microenvironmental effects that occur only in the in vivo setting. However, it is 
also possible that this relies on a difference in transcriptional regulation of the SHH promotor, 
which could be different between cultured and transplanted cells.  
Despite the tumorintrinsic decrease of SHH, tumorextrinsic mGli2 expression is increased in 
oncKRAS-expressing RUCH-2 xenografts. This indicates that the transplanted tumor cells 
may indeed secrete SHH (despite being downregulated). Nevertheless, this is against the 
finding, that mGli1 is not upregulated in the tumor stroma and that RUCH-2 cells in general 
do not secrete SHH. However, and as already mentioned in section 7.1.2.1, it is still possible 
that RUCH-2 secrete IHH or DHH. 
Besides the impact on HH signaling genes, these experiments show that different RAS 
proteins can have non-redundant (oncNRAS decreases GLI3 expression in TE617.T and 
RUCH-2 cells, whereas oncH/-KRAS do not) or partially overlapping functions (both 
oncHRAS and oncKRAS increase the expression of PTCH in RUCH-2 cells) in ERMS cell 
lines. Isoform-specific functions of RAS proteins have also been described in other tumor 
entities. It is hypothesized that this is due to the different intracellular distribution of RAS 
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isoforms or to the induction of different biological responses through diverse downstream 
effectors 174,208,211-215 (compare also section 2.3.1). 
Taken together, these results show that an ERK-dependent downregulation of GLI1 is a 
common feature in ERMS cell lines with oncRAS mutation (compare section 7.1.2), whereas 
the expression of other HH target genes such as PTCH, GLI2 or HHIP are either inhibited, 
activated or not affected by ERK. This depends on the used cell line and on the respective 
oncRAS isoform. Furthermore, these results are in support of a RAS/ERK-dependent 
regulation of GLI1 expression on transcriptional level, which is independent of the 
SHH/PTCH/SMO/GLI2-3 axis (Fig. 59). One possibility to verify that the oncRAS-dependent 
regulation of GLI1 is indeed non-canonical, the experiments could be repeated after inhibition 
of SUFU, a negative regulator of canonical HH signaling 59. 
Finally, the differences between TE617.T, RUCH-2 and RD cell lines are hard to explain. 
Most likely they depend on the different activation status of the MAPK signaling pathway 
within the cells. As already mentioned, RD cells and oncRAS-expressing RUCH-2 cells show 
hyperactive MEK/ERK signaling, whereas oncRAS does not affect phosphorylation of ERK in 
TE617.T cells. However, TE617.T cells harbor protein-changing mutations in MAP3K14 and 
MAP3K1 345,349. These mutations might alter activation of ERK and of JNK, as well as of 
NFκB. Consequently, it is possible that the effects of oncRAS mutations or of MEK/ERK-
inhibition are masked in this very cell line. This also would fit to the observation that 
oncRAS/MEK/ERK-associated downregulation of GLI1 in TE617.T is weaker than in the 
other cell lines (Fig. 13). It is possible that elevated level of pERK were not detected in the 
TE617.T cell line due to a lack of sensitivity of the Western Blot. Immunoprecipitation of 
active ERK and in vitro kinase activity assays could help to prove this assumption. 
The differences between RUCH-2 and RD cell lines in oncRAS-mediated regulation of other 
HH targets than GLI1 can also be explained by the mutational status of the cell lines. For 
example, RD cells harbor a TP53 mutation 16,275,312,326,351. In melanoma, p53 can suppress 
GLI1 activity and GLI1 expression 72 and a mutation in p53 would consequently increase 
GLI1 transcription. On the other hand, MEK and ERK can transcriptionally activate p53 370,371, 
which thus may contribute to suppression of GLI1 transcription. However, the a final 
statement about the precise role of the p53 tumor suppressor in combination with oncRAS 
mutations in ERMS cell lines needs further investigations. Nevertheless, mutations such as 
TP53 are likely to influence cellular signaling networks and thus may influence the effect of 
oncRAS mutations in ERMS. 
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Figure 59: Model system for HH/RAS interactions in ERMS with oncRAS mutations 
In ERMS with activating RAS mutations, the MEK/ERK axis is hyperactivated and GLI1/GLI1 is suppressed. 
Thereby the MEK/ERK axis negatively regulates GLI1 transcription and GLI1 protein expression, whereas the 
PI3K/AKT/mTOR axis may positively regulate GLI1 transcription (at least in RD and RUCH-2 cells). Canonical HH 
signaling seems to play a subordinate role in regulation of GLI1/GLI1 (dashed arrow). For more details, see text. 
7.1.4 Influence of oncRAS mutations on proliferation 
OncRas isoforms can promote deregulation of cell cycle progression and can have positive 
or negative effects on the regulation of apoptosis, depending on the cell type and other 
cellular factors 184,372. Additionally, oncRas can promote malignant transformation, 
characterized by increased proliferation and desensitization to apoptosis 167. However, 
oncRAS isoforms do not induce apoptosis and do not alter the cell cycle distribution in RMS 
cell lines (Fig. 10, Fig. 12). Nevertheless, the cells show a more aggressive phenotype as 
measured by proliferative capacity in cell culture (Fig. 35 and 299) and tumorigenicity in 
xenografts (Fig. 36, Fig. 38 and 299). 
In TE617.T cells oncRAS isoforms strongly induce proliferation (Fig. 35) and additionally 
increase growth and weight of xenografts (Fig. 36). However, oncRAS do not change the cell 
cycle distribution in this cell line (Fig. 12). Experiments with RMS-13 cells showed similar 
results (Fig. 12 and 299). These inconsistent results (i.e. strongly induced proliferation and 
tumorigenicity, but lack of increased cell numbers in S phase) can be explained by the fact 
that the cells were not synchronized ahead of the cell cycle analyses. During synchronization 
(e.g. by serum starvation or a double thymidine block 373) distinct subpopulations of cells are 
in the same stages of the cell cycle, which makes shifts in cell cycle distribution more 
evident. Additionally, the protocol for cell cycle analyses should be optimized e.g. by 
inclusion of BrdU labeling of proliferating cells. This would make the analyses more precise 
because both, cell cycle distribution and the percentage of proliferating cells would be 
investigated 374. 
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RUCH-2 cells grow slowly in comparison to other RMS cell lines. OncHRAS or oncKRAS 
increased proliferation of cultured RUCH-2 cells, whereas oncNRAS had no impact on 
proliferation (Fig. 35). These findings are in contrast to previous observations from our group, 
in which oncRAS decreased proliferation 24 h after seeding 299. However and as shown here, 
at least 48 – 72 hours are needed to detect an oncRAS-dependent increase of proliferation in 
this very cell line. For oncNRAS transduced cells an even a longer period might be 
necessary. Indeed, RUCH-2 xenografts that express oncKRAS or oncNRAS show a strongly 
increased growth and weight of the tumors (Fig. 38). Additionally, RUCH-2 xenotransplants 
with and without oncRAS mutations grow very efficiently when injected within a matrigel 
matrix but do marginally grow when injected in PBS (data not shown). This shows that 
microenvironmental effects might improve attachment and growth of RUCH-2 cells more 
efficiently than regular cell culture medium. Besides, these experiments verify the finding that 
oncRAS isoforms can increase proliferation of RUCH-2 cell lines. 
It has to be mentioned that oncHRAS-expressing RUCH-2 cells did not grow in vivo (Fig. 38). 
In most likelyhood this observation is due to an experimental failure. However, it could also 
rely on oncHRAS-induced senescence, which has been described for the HRASG12V 
mutation 174. The induction of senescence occurs downstream of RAS, most likely via the 
p53/p19ARF and/or p16INK4A pathways and requires a high cell density 185. Indeed, the cell 
density of oncHRAS-expressing cells is strongly elevated within tumor xenografts in 
comparison to cell culture experiments. This might explain why the cells grew normal in cell 
culture but failed to establish tumors in Nu/Nu mice. To test if oncHRAS-induced senescence 
indeed hampered tumor growth of RUCH-2 cells, tumor sections should be examined for 
senescence-associated β-galactosidase activity with X-Gal staining. Nevertheless, the 
transplantation experiment using oncHRAS-transduced RUCH-2 cells needs to be repeated. 
The fact that all oncRAS mutations (with the exception of transplanted RUCH-2 oncHRAS 
cells; see above) strongly induce proliferation despite downregulation of GLI1/GLI1 indicate 
that the HH signaling pathway is not the main driver of growth and aggressiveness of cell 
lines derived from sporadic ERMS, like the TE617.T and RUCH-2 cells. However, aberrant 
activation of the HH pathway can drive the initiation of RMS, since heterozygous loss of 
PTCH/Ptch in humans and mice is associated with ERMS development 21,99,100,108,324,325,375. 
On the other hand, PTCH mutations are a very rare event in human ERMS (compare 
section 2.2.4). Nevertheless, also established ERMS show high level of GLI1 and PTCH, 
which is indicative for an active HH signaling cascade 141,142. However, ERMS are insensitive 
to SMO-inhibition, at least if they do not harbor a mutation in PTCH 158,159. Interestingly, they 
are sensitive to the specific GLI1/2 inhibitor GANT61, which reduces growth of ERMS cells in 
vitro and in vivo 155. This indicates that GLI transcription factors indeed drive proliferative 
processes of ERMS, which are most likely independent of canonical HH signaling. 
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In this context and at the first glance, the results showing that oncRAS-mediated 
downregulation of GLI1/GLI1 is associated with a more aggressive ERMS growth, seems to 
be paradox. However, it is possible that oncRAS is such a potent proliferative stimulus that 
permits simultaneous downregulation of other proliferative stimuli such as GLI1/GLI1. Of 
whether a complete GLI1 knockdown would still allow for oncRAS-driven ERMS proliferation 
is unclear. This question could be answered by transfection of oncRAS-expressing ERMS 
cell lines with e.g. GLI1 specific siRNA or by incubation of the cells with GANT61. In addition, 
it also would be interesting to see if the proliferative capacity of ERMS cell lines is dependent 
on the MEK/ERK axis. This could be done by inhibition of either MEK or ERK. To exclude 
that other signaling pathways are involved in cellular proliferation, GLI and MEK/ERK should 
be blocked simultaneously. If the cells indeed will stop to proliferate upon this co-treatment, 
this combinatory treatment should be tested as a therapeutic approach in e.g. ERMS 
xenografts. 
Taken together, oncRAS isoforms increase proliferation despite a decrease of GLI1 
expression in human RMS cell lines. In the ERMS cell lines RUCH-2 and RD the 
downregulation of GLI1 is ERK-dependent. Hence, it would be highly valuable to analyze, if 
the occurrence of high RAS signaling with concurrent low HH signaling is a general feature in 
human ERMS. This could be done by analysis of public available RMS microarray datasets, 
like 275. If these data are consistent with the findings from cell culture, ERK should be 
considered as a target in future therapies in ERMS. 
7.2 Specific oncRas mutations can increase Hh/Ptch-driven ERMS 
incidence and growth when expressed at an early tumor stage 
To investigate the role of Ras signaling in Hh/Ptch-driven ERMS in an immunocompetent in 
vivo setting, a genetic approach was pursued. For this purpose, Ptchdel/+ mice, which 
spontaneously develop ERMS-like tumors with active Hh signaling 137,143,323,324, were bred to 
mice, which conditionally express one of the oncRas genes 220,303,304 and to Myf5CreER deleter 
mice 305. The resulting Ptchdel/+oncRasfl/+Myf5CreER/+ mice were used to study the effect of 
oncRAS mutations in ERMS precursor lesions and full-blown ERMS. 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice are a suitable model to analyze Ras signaling in Hh/Ptch-
driven ERMS because their tumors express wtHRas, wtKRas and wtNRas and because the 
Myf5CreER driver induces tamoxifen-mediated recombination primarily in tumor tissue (Fig. 41, 
Fig. 42). This was crucial because the expression of Myf5 is detected in different muscle 
populations but is also found in non-muscle tissues, such as preadipocytes and neurons 376-
378. Indeed, an experiment utilizing R26R reporter mice, which conditionally can express lacZ 
and basically can show high β-galactosidase activity in every organ of the body 306, indicated 
that the tamoxifen-inducible Myf5CreER driver is primarily active in tumor tissue without 
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leakiness. However, the galactosidase activity visualized by X-Gal staining was not as strong 
as expected from literature 305. This is most likely due to technical issues, such as an 
incorrect pH or temperature of the staining solutions or too much contact to light (X-gal is 
light sensitive). In addition to its ERMS-specificity, the Myf5CreER driver also efficiently 
mediated recombination at the different Ras loci (Fig. 43, Fig. 44, Fig. 45). This was 
important, because differently floxed loci have different sensitivities to cre-mediated 
recombination 339,379. Additionally, increased Ras activity was verified in ERMS of tamoxifen-
treated Ptchdel/+oncRasfl/+Myf5CreER/+ mice (Fig. 46). Finally, the results revealed that 
tamoxifen itself (which is necessary to activate the CreER) has no impact on median overall 
survival, median tumor latency time, mean ERMS-free survival, tumor incidence or tumor 
multiplicity (Fig. 47, Tab. 25). Together, these experiments indicate that 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice are a suitable model to study the role of Ras signaling in 
Hh/Ptch-driven ERMS. 
7.2.1 Influence of oncRas mutations on Hh/Ptch-associated ERMS precursor 
lesions 
The 3 different oncRas mutations were induced in ERMS precursor lesions of 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice. Interestingly, oncHRas and oncKRas mutations influence 
the tumor growth, whereas oncNRas does not (Fig. 48, Fig. 49, Fig. 50). Thus, activation of 
oncHRas in ERMS precursor lesions significantly increased the tumor incidence and resulted 
in a trend to decrease mean ERMS-free survival. It however did not influence median overall 
survival, median tumor latency time or tumor multiplicity (Fig. 48, Tab. 26). In contrast, 
activation of oncKRas significantly decreased median overall survival, median tumor latency 
time, mean ERMS-free survival and significantly increases tumor incidence without affecting 
tumor multiplicity (Fig. 49, Tab. 27). These data indicate that both oncKRas and oncHRas 
increase the susceptibility to HH-associated ERMS formation. OncKRas also accelerates 
ERMS formation and thus decreases the ERMS-free survival and latency time until tumor 
detection. In addition, it significantly decreased the life span of the mice. At the first glance, 
these differences point out diverse roles or functions of the HRas and KRas oncogenes in 
ERMS pathogenesis. One explanation is the different expression levels of the Ras genes in 
SM and ERMS. Thus, the level of HRas expression are similar in SM and RMS, whereas 
KRas level are higher in RMS compared to SM (Fig. 42). A higher level of KRas most likely 
also results in a higher level of oncKRas, which may explain the faster tumor growth and thus 
the reduction of the latency time when the mutation was set in ERMS precursors. However, it 
is also possible that the tumor detection in the HRas cohort by manual palpation was not as 
efficient as in the KRas cohort, because several experimenters were involved in the tumor 
monitoring of the HRas cohort. Indeed, like ERMS with oncKRas, paraffin sections of ERMS 
with oncHRas show a significantly higher amount of Ki67+ nuclei than the respective controls, 
suggesting a faster tumor growth of the tumors with oncHRas. Unfortunately, the final tumor 
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size and tumor weight were not recorded, for neither the HRas nor the KRas cohorts. 
Consequently, it is very hard to judge if an oncKRas mutation indeed induces an ERMS 
growth behavior that is different from that of an oncHRas mutation. Nevertheless, oncKRas 
mutations in ERMS precursor lesions decreased the median overall survival, which was not 
observed in mice with oncHRas mutations. Since other tumors than ERMS occurred at 
similar numbers in both cohorts and since all mice were sacrificed when the tumors reached 
a size of 1.5 cm, the data indeed favor the idea that oncKRas induces a more aggressive 
ERMS growth compared to oncHRas. 
In contrast, oncNRas mutations neither influenced median overall survival, median tumor 
latency time, mean ERMS-free survival, tumor incidence, tumor multiplicity nor proliferation 
of ERMS in Ptchdel/+ mice (Fig. 50, Tab. 28, Fig. 51). These results highlight that oncNRas 
mutations, which are set at a very early ERMS stages do not alter the aggressiveness of the 
tumors. This is similar to a mouse model for colon cancers, where oncKRas stimulates 
hyperproliferation in the colonic epithelium, whereas oncNRas does not alter the growth 
properties of the tissue 220. Similar differences between Ras isoforms have been described 
for endodermal progenitor cells. OncKRas promotes proliferation and maintains stem cell 
characteristics and oncHRas promotes differentiation and growth arrest. In contrast, 
oncNRas has no impact on any of these parameters 221. These findings underline that 
different oncRas isoforms can lead to different cellular fates. This can be due to collaborative 
effects between oncRas and different wtRas proteins, which contribute for the cancer 
phenotype 236,238,239. For example, wtKRas and wtNRas promote oncHRas-dependent 
papilloma development 239. However, in other settings, wtRas can act as a tumor suppressor 
in oncRas-expressing cancers 239-241. An additional explanation for this non-redundant 
functions is the different cellular compartmentalization of Ras isoforms, which can influence 
the ability of Ras proteins to activate their downstream effectors 206. However, whether one of 
these mechanisms is also involved in ERMS precursor lesions is not clear so far. 
The observation that oncNRas mutations do not influence the growth of ERMS precursor 
lesions of Ptchdel/+ mice is suprising, because in human RMS, oncNRAS mutations are the 
most frequent RAS mutations 14,15,141. However, it is possible that this modification is due to 
species-specific differences in tumor pathobiology. This has already been described for 
several other knockout mouse models 380. For example, loss of the RB gene is associated 
with the development of retinoblastomas and osteosarcomas in humans, whereas mice that 
have a Rb deletion fail to develop these tumor types 381. Similar, NF2 mutations in humans 
lead to schwannomas, whereas conventional Nf2 knockout mice develop osteosarcomas 382. 
It has to be noted that tamoxifen-treated Ptchdel/+oncRasfl/+Myf5CreER/+ mice show similar 
tumor incidences (oncHRas: 74 %, oncKRas: 76 %, oncNRas: 71 %). However, whereas the 
tumor incidence of the oncHRas and oncKRas cohorts differed from the respective control 
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cohorts, that of the oncNRas cohort did not. This finding indicates that untreated 
Ptchdel/+NRasfl/+Myf5CreER/+ mice develop more tumors than other untreated 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice. The underlying reason in most likelihood is the genetic 
background of the NRas cohort, since leakiness of the Myf5CreER deleter and spontaneous 
recombination at the floxed NRas locus were precluded. In addition, all mice with suspect 
genotypes or recombination patterns (regardless of which cohort) were excluded from the 
analyses. The finding that ERMS from tamoxifen-treated Ptchdel/+NRasfl/+Myf5CreER/+ mice did 
not show a higher proliferation rate than ERMS from untreated mice together with the fact 
that the proliferation rate was similar to untreated Ptchdel/+HRasfl/+Myf5CreER/+ and 
Ptchdel/+KRasfl/+Myf5CreER/+ mice (Fig. 51) supports the conclusion that oncNRas mutations do 
not accelerate formation of (Ptch/Hh-associated) ERMS. Hence, the presence of an 
oncNRas mutation in ERMS does not necessarily reflect the individual tumor’s 
aggressiveness, which could also be true for human tumors. Nevertheless, when considering 
the high prevalence of NRAS mutations in human ERMS, it is also possible that the 
NRasG12D mutation in the mouse model is simply not functional. However, the fact that 
tumors, in which the oncNRas mutation was induced with tamoxifen, showed a higher Ras 
activity than the controls, strongly argues against this assumption (Fig. 46). Furthermore, it is 
also possible that the expression of the NRasQ61H mutation, which is frequently seen in 
human ERMS 267, will be a more potent oncogene than the NRasG12D mutation. However, the 
fact that the expression level of the muscle differentiation markers Myogenin and 
Tropomyosin 3 were significantly higher in tamoxifen-treated Ptchdel/+NRasfl/+Myf5CreER/+ mice 
compared to the other cohorts (Fig. 53), strongly argues for the conclusion that oncNRas 
mutations indeed do not accelerate formation of (Ptch/Hh-associated) ERMS, at least in 
mice. It however induces myogenic differentiation, because myogenin is a reliable and 
specific marker for rhabdomyoblastic differentiation 383 and Tropomyosin 3 encodes for a 
sarcomeric protein implicated in in skeletal muscle cell differentiation 384. This is not the case 
for ERMS expressing oncHRas or oncKRas mutations (Fig. 53). Hence, oncNRas mutations 
may have a different role than oncHRas and oncKRas in ERMS. This would be similar to 
colonic tumors, in which oncKRas and oncNRas have differential effects on proliferation, 
differentiation and tumor progression. Thus, expression of oncKRasG12D in the colonic 
epithelium stimulates hyperproliferation, whereas oncNRasG12D does not alter the growth 
properties of the epithelium, but is able to confer resistance to apoptosis 220. If oncNRas 
indeed has a different function than the other oncRas isoforms in Ptch/Hh-associated ERMS, 
this would be different from fusion-negative RMS cell lines, in which all oncRAS isoforms 
inhibit myogenic differentiation through an ERK-dependent inhibition of the myogenic 
transcription factor MYOG 385. 
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7.2.1.1 OncRas mutations do not influence the expression of Hh signaling genes or 
the phosphorylation status of Erk, Akt and S6 in ERMS 
All oncRas-expressing ERMS show a moderate downregulation of Gli1 when compared to 
the control. This is similar to cell culture and xenotransplantation experiments discussed in 
section 7.1.2. However, these results did not reach significance in murine ERMS. Thus, it is 
rather unlikely that oncRas mutations altered the Hh signaling pathway in the mouse, 
especially because the expression of Gli2, Gli3, Ptch and Hhip was also not modified in SM 
and RMS tissue samples (Fig. 52). Additionally, the phosphorylation status of Erk, Akt and 
S6 was very heterogeneous in in ERMS from mice with and without oncRas mutation (Fig. 
54). The final statemant from Western Blot analyses, that phosphorylation of these proteins 
is generally higher in tumors compared to normal skeletal muscle, is similar to findings from 
the literature 138. 
The result that oncRas isoforms rather do not influence Hh signaling or the mRNA 
expression of Hh signaling members in murine ERMS is in contrast to findings from cultured 
human ERMS cells. It is possible that this relies on the mutational status of the systems or on 
the tumor microenvironment. However, it is also possible that oncRas mutations simply do 
not play a role in regulation of Hh signaling genes in Hh/Ptch-associated ERMS. This 
suggests that the oncRAS-mediated changes of the tumor phenotype must be driven by 
other molecular mechanisms, which could be analyzed by RNA sequencing (RNAseq) of 
tumor samples from tamoxifen-treated, solvent-treated and untreated 
Ptchdel/+oncRasfl/+Myf5CreER/+ mice. 
7.2.2 Influence of oncRas mutations on Hh/Ptch-associated full-blown ERMS 
The impact of oncRas mutations was also analyzed in full-blown ERMS. For this purpose the 
expression of oncRas was induced in palpable tumors of Ptchdel/+HRasfl/+Myf5CreER/+, 
Ptchdel/+KRasfl/+Myf5CreER/+ or Ptchdel/+NRasfl/+Myf5CreER/+ mice. Controls were solvent-treated 
siblings of the same genotype, solvent-treated or tamoxifen-treated Ptchdel/+ mice, which all 
had palpable ERMS of approximately the same size. In this setting, none of the oncRas 
mutations did influence tumor growth (Fig. 55). OncRas mutations also did not alter 
proliferation of the tumors (Fig. 56). They also did not modulate the expression of the Hh 
target genes Gli1 and Gli2 (Fig. 57) or of muscle differentiation markers (Fig. 58). 
7.2.2.1 Comparison of the role of oncRAS in Hh/Ptch-associated ERMS precursor 
lesions and full-blown ERMS 
Together, the data from Ptchdel/+oncRasfl/+Myf5CreER/+ mice indicate that oncRAS mutations 
influence growth of Hh/Ptch-associated ERMS precursor lesion but not of full blown ERMS. 
This favors the hypothesis that oncRas are early events in ERMS development and that they 
might be a driver mutation in ERMS. However, oncRAS germline mutations do not 
predispose mice to the development of ERMS 277. This strongly argues against the “ERMS-
140 | DISCUSSION 
driver” hypothesis (for further discussion see also section 7.3). In contrast, Hh/Ptch-
associated ERMS of mice are initiated before birth 386, showing that Ptch mutations can be 
“ERMS-drivers”. Nevertheless, in general oncRas mutations also seem to be early events in 
different other tumor entities. For example, HRAS mutations are early events during 
development and progression of bladder cancer 387. Additionally, KRAS mutations occur in 
early stages during colorectal carcinoma progression 388. Likewise, NRAS mutations are 
early events during melanoma development 389. 
In contrast to Hh/Ptch-driven ERMS precursor lesions, full-blown ERMS do not care about 
the expression of oncRAS mutations. This indicates that ERMS cells at later stages of tumor 
progression are insensitive to oncRAS mutations because of their specific genetic make-up. 
However, it is also possible that this insensitivity is a matter of the used animal model or of 
e.g. the tumor stem cell population (for further discussion see section 7.3). Finally, it has to 
mentioned that oncHRas and oncKRas increase ERMS formation from Hh/Ptch-associated 
precursor lesions and increase the proliferative capacity of the tumors, without notably 
affecting the Hh signaling pathway. This again indicate that HH/Hh signaling is extremely 
important for growth of Hh/Ptch-mutant ERMS. 
7.3 Potential roles of active Ras or Hh signaling in ERMS initiation 
and progression 
As stated above, oncRas mutations differently affect aggressiveness of ERMS of Ptchdel/+ 
mice, cell culture experiments and xenografts. All oncRAS isoforms increase proliferation 
and tumorigenicity of cultured cells derived from sporadic ERMS (Fig. 35, Fig. 36, Fig. 38), 
whereas oncKRas and oncHRas accelerate growth of Hh/Ptch-driven ERMS precursor 
lesions (Fig. 48, Fig. 49) but not of full-blown ERMS (Fig. 55). This indicates that oncRas 
mutations differently effect diverse developmental stages of ERMS as discussed above. 
Similarly, oncRAS mutations inhibit GLI1 expression in a non-canonical manner in cell lines 
derived from sporadic ERMS, whereas this is rather not seen in Hh/Ptch-associated ERMS 
of Ptchdel/+ mice. These findings are summarized in Tab. 29. 
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Table 29: Overview of oncRas-dependent effects in cell lines derived from sporadic ERMS, Hh/Ptch-driven 
ERMS precursor lesions and full-blown ERMS 
This table summarizes the discussed effects of different oncRas isoforms in ERMS. For more details, see 
sections 7.1 (ERMS cell lines), 7.2.1 (ERMS precursor lesions) and 7.2.2 (full-blown ERMS). 
↑: increase; ↓: decrease; ↔: no effect 
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One hypothesis for the discrepancy of the role of oncRAS between sporadic and Hh/Ptch-
driven tumors may be the mode of tumor formation. Whereas Ptchdel/+ mice develop ERMS 
due to a heterozygous Ptch mutation 21, activating mutations in PTCH or other genes of the 
HH pathway are very rare in sporadic ERMS. PTCH mutations have been excluded in RD 
cells and probably also do not occur in TE617.T and RUCH-2 cells 15,142,144,145,147,155. 
Therefore, it is possible that the growth of already established HH/PTCH (Hh/Ptch)-
associated tumors solely depend on active canonical HH/Hh signaling, whereas this pathway 
rather plays a subsidiary role in ERMS without PTCH/Ptch mutations. Indeed, recent work 
from our lab shows that full-blown Hh/Ptch-associated ERMS cells react to SMO inhibitors, 
whereas those without PTCH mutations do not 159. Vice versa, it is possible that RAS 
mutations elicit different cellular responses in ERMS cells with and without PTCH mutation. 
However, this is pure speculation and should be verified by e.g. a PTCH knock-down in 
TE617.T and RUCH-2 cells with and without oncRAS mutations or in the RD cell line. 
However and as already mentioned above, it is likely that canonical HH signaling plays a 
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subordinate role in ERMS cell lines, which are wt for PTCH. Indeed, oncRAS decrease the 
expression of the main HH target GLI1/GLI1 in a non-canonical manner via ERK, whereas 
cell proliferation is strongly enhanced. This shows that the HH pathway or at least GLI1 is not 
the main driver of ERMS that are wt for PTCH. 
The data from the genetic experiments are highly interesting. The findings indicate that 
oncHRas and oncKRas mutations increase the aggressiveness of Hh-associated ERMS 
precursor lesions but do not affect proliferation of full-blown ERMS. In contrast, oncNRas 
does not influence proliferation and aggressiveness of ERMS in any of these settings, while 
inducing a more differentiated ERMS phenotype when activated in precursor lesion. 
Together, these findings indicate that oncRAS mutations in different isoforms affect diverse 
developmental stages of ERMS in a different manner. In the case of the oncNRas mutation it 
must be noticed that ERMS in the Ptchdel/+ model are derived from Delta1-positive, Myf5-
negative, Myogenin-negative and Pax3-negative mesodermal progenitors that can undergo 
myogenic differentiation but lack stable lineage commitment 386. Therefore it is possible that 
oncNRas pushes the cells into myogenic differentiation, whereas oncHRas and oncKRas 
rather keep the cells in a more undifferentiated stages and push proliferation of the ERMS 
precursors. The underlying molecular mechanisms must be specific for very early ERMS, 
because they do not operate at an advanced tumor stage. 
In addition, and since RAS mutations usually occur at a very early stage during tumor 
development (see above) it is tempting to speculate that oncRas mutations are driver 
mutations. Indeed, this also has been suggested for ERMS. For example, oncRas mutations 
were proposed to be necessary to convert normal primary human skeletal muscle myoblasts 
into tumorigenic cells mimicking ERMS 278 (compare section 2.3.4). This is in line with 
genetic syndromes e.g. Costello and Noonan syndrome, in which RAS germline mutations 
can confer susceptibility to ERMS development 242,243. However, this is apparently different in 
the mouse, in which Ras germline mutations do not result in ERMS 277. It is also different 
from several reports, indicating that RAS mutations are rather modifiers in ERMS. Thus 
microarray-based data of human RMS samples show that an oncRAS signature only occurs 
in combination with other pathway signatures 275. Nevertheless, the increased ERMS 
susceptibility in patients with e.g. Noonan syndrome strongly favors the “driver” hypothesis. 
However, the Noonan syndrome can be caused by KRASP34R, KRASD153V and KRASF156L 
mutations in the KRAS protein 256 or by NRASG60E, NRAST71A, NRASC101T, NRASC149T or 
NRASG179A mutations in the NRAS protein 257,390. These mutations are different from the 
oncRASG12, oncRASG13 and oncRASQ61 mutations, which commonly occur in cancer 231,233. 
This observation together with the fact, that mice with oncRas mutations alone do not 
develop ERMS 277, opens the intriguing possibility that the oncRAS mutations found in 
human sporadic ERMS are not ERMS driver mutations, but rather passenger mutations that, 
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dependent on the tumor stage or the affected cell subpopulation, can either accelerate or 
decelerate tumor progression. Indeed, whereas Xia et al. 20 and Chen et al. 15 reported a 
worse prognosis in ERMS patients with RAS mutations, another study shows the opposite. 
Martinelli et al. showed that gain-of-function mutations within the RAS genes occur more 
frequently in ERMS patients with a better outcome 267. Similar findings were described for 
NRAS mutations in melanoma patients 391. 
Hh/Ptch-associated ERMS of mice are initiated before birth. Thus, deletion of a single copy 
of the Ptch allele at E9.5 results in a tumor incidence of 88% but reaches only 44% and 12% 
when the Ptch allele is inactivated at E11.5 and E13.5, respectively 323. Similarly, induction of 
the Ptch mutation at E9.5 also significantly shortens ERMS-free survival and results in an 
increased tumor multiplicity 323. This shows that Ptch mutations are real ERMS-driver 
mutations, at least in the mouse. In contrast, oncRas mutations rather act as some kind of 
“passenger” mutations in ERMS. Thus, as already stated several times, they by themselves 
do not initiate ERMS at least not in the mouse. However, they can accelerate tumor growth 
or modify tumor differentiation of already initiated ERMS precursor lesions (oncHRas and 
oncKRas or oncNRas, respectively). They also can accelerate growth of cultured cells or 
xenotransplants derived from sporadic ERMS. This may indicate that oncRas mutations only 
affect already initiated ERMS precursor cells and/or cancer stem cells (CSCs) within the 
heterogeneous tumor mass, whereas they do not affect the total cancer cell population. This 
would be in line with oncRas being not an ERMS-predisposing mutation, but rather an 
advantageous mutation for ERMS. As suggested by Kuhner and colleagues, a mutation 
which is advantageous but not predisposing, is a mutation that occurs in a specific somatic 
cell and confers growth or survival advantage on this very cell lineage, but otherwise does 
not contribute to tissue invasion or metastasis 392. These cells then might be selectively 
favored early during tumor development. If this hypothesis is true for ERMS, it could explain 
the high number of tumors showing RAS mutations (12 % 16, 22 % 266, 35 % 267 or even 
46 % 141 of RMS, depending on the analyzed tumor subset). Intriguingly, one study shows 
that all ERMS (or fusion-negative RMS) with RAS mutations show LOH of 11p15.5 393. LOH 
results from uniparental disomy or trisomy, which is usually associated with loss of maternal 
genetic information and duplication of the paternal one 394. 11p15.5 is the location of the 
IGF2 gene, which is normally imprinted and is exclusively expressed from the paternal allele. 
Almost all RMS overexpress IGF2 395,396, which is due either to loss of imprinting with re-
expression of IGF2 from the normally silent maternal allele or results from LOH with paternal 
disomy or trisomy 4. Although both, LOH of 11p15.5 and RAS mutations, apparently are very 
early events in the evolutionary history of fusion-negative RMS 393, it is possible that LOH 
with overexpression of IGF2 is the ERMS initiating event, whereas the RAS mutations are 
advantageous for ERMS growth. This could also be true for recurrent gains of chromosome 8 
that are also described for all ERMS with RAS mutations 14. 
144 | DISCUSSION 
It is also possible that RAS mutations only are advantageous when they occur in CSCs. 
CSCs are tumor cells that show self-renewal, clonal tumor initiation and clonal long-term 
repopulation potential 397. In this context, it is interesting to know that Hh and Egfr signaling 
synergistically contribute to oncogenic transformation of keratinocytes via the Raf/Mek/Erk 
axis 289-291. Thereby the pathways synergistically regulate the expression of the stem cell 
markers Sox2, Sox9 and Cxcr4, which are also required for growth of BCC cells 292. The total 
number of CSCs is variable depending on the cell line and tissue 397,398. We assume that 
human ERMS cell lines derived from sporadic tumors carry a relatively high number of 
CSCs. Indeed, preliminary data of our lab using the putative CSCs marker in sarcoma cells 
CD133 399,400 suggest the presence of a subpopulation with stem cell characteristics. Thus, 
transduction of ERMS cell lines with oncRAS might have targeted many CSCs, which could 
be selectively favored during tumor development. This can explain the increased proliferative 
capacity of oncRAS cells both in vitro and in vivo settings. However, if this is true, one would 
expect that targeting oncRas mutations to full-blown ERMS of Ptchdel/+oncRasfl/+Myf5CreER/+ 
mice would similarly enhance ERMS growth. However, this was not the case (see 
section 7.2.2.1). There are several explanations for this circumstance. One the one hand, it is 
possible that only few CSCs exist in Hh/Ptch-driven full-blown ERMS (whereas many of them 
exist in precursor lesions). On the other hand, it is possible that CSCs do not express Myf5. 
This would prevent the induction of oncRAS in these cells. Indeed, CSCs usually show a 
different gene expression pattern than the bulk tumor mass 401-403. Finally, it is possible that 
CSCs in Hh/Ptch-driven ERMS are solely dependent on Hh signaling (the role of Hh 
signaling in CSCs is described in detail in 404-406). To verify the existence of CSCs in full-
blown ERMS of Ptchdel/+ mice the tumors should be screened for CD133, aldehyde 
dehydrogenase 1 (Aldh1) or Sox2 expression, which are all established CSCs marker for 
ERMS 400,407-409. In addition and to verify the hypothesis that oncRAS/oncRas mutations 
selectively favor ERMS growth from CSCs, but not from the bulk tumor mass, one should 
test the proliferative capacity of CSCs and the bulk cells from ERMS cell lines with and 
without oncRas mutation. This can be done by FACS sorting of living cells and by 
subsequent BrdU proliferation assays and transplantation studies of the sorted cells. 
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8 Summary and Conclusion 
This work aimed for a deeper unterstandig of the role of RAS signaling in HH/PTCH-
associated ERMS and to study potential interactions between both pathways. Sporadic 
ERMS usually show high expression of HH target genes despite lacking mutations in 
members of the HH pathway. However, subsets of ERMS are HH-driven by e.g. inactivating 
PTCH mutations, which is mimicked in mice that are heterozygous for Ptch. The data from 
this work show that oncRAS mutations decrease the expression of the major HH target GLI1 
in cell lines that are derived from 3 sporadic ERMS and 1 sporadic ARMS. Furthermore, 
oncRAS can also regulate the expression of PTCH, GLI2, GLI3 and SHH, which depends on 
the oncRAS isoform and the individual cell line, e.g. all oncRAS isoforms increase or 
decrease GLI2 and SHH, respectively, in the ERMS cell line RUCH-2. Although oncRAS 
mutations can modify the expression of SHH, ERMS cell lines (TE617.T, RUCH-2 and RD) 
are in all likelihood not able to secret HH ligands. They are also not responsive to a HH 
stimulus. Together with results from other lab members, these data suggest a subordinate 
role of canonical HH/PTCH/SMO signaling in sporadic ERMS. They also suggest an 
oncRAS-dependent, non-canonical regulation of GLI1 expression in ERMS. Indeed, 
experiments utilizing several kinase inhibitors show that the oncRAS-mediated 
downregulation of GLI1 in RD and RUCH-2 cell lines is ERK-dependent. Similarly, oncRAS-
mediated downregulation of GLI1 in TE617.T also depends on ERK. However, this cell line 
already shows an intrinsic block of GLI1 expression. Subsequent experiments revealed that 
the oncRAS/ERK-mediated downregulation of GLI1 is also seen on protein level and occurs 
in the cytoplasm and in the nucleus of RUCH-2 cells. This indicates that oncRAS/ERK 
regulate GLI1/GLI1 levels probably on transcriptional level. ERK is also involved in regulation 
of other HH pathway members (GLI2, GLI3, PTCH and SHH), which however is cell line-
specific and probably depends on the individual genetic make-up of the individual cell line. 
Further experiments are needed to prove the latter findings and to complete the knowledge 
about the role of oncRAS isoforms in regulation of HH targets in sporadic ERMS. 
Interestingly, oncRAS mutations induce proliferation of TE617.T and RUCH-2 cell lines 
despite downregulation of GLI1/GLI1 in cell culture. Increased proliferation is also seen in the 
respective xenografts. This indicates that GLI1/GLI1, and thereby HH signaling activity, is not 
associated with the proliferative capacity of ERMS cells. In addition, in xenotransplants, 
oncRAS isoforms tend to decrease tumorintrinsic GLI1 and SHH expression, whereas 
tumorextrinsic expression of Gli2 is increased in oncKRAS-expressing RUCH-2 xenografts. 
This indicates that specific oncRAS mutations might affect HH signaling activity in the tumor 
microenvironment. Further experiments are needed to verify this assumption. 
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In Hh/Ptch-driven ERMS of Ptchdel/+ mice, oncKRas and oncHRas accelerate Hh-associated 
ERMS formation as measured by tumor incidence, ERMS-free survival and the proliferation 
marker Ki67, whereas oncNRas does not. However, oncNRas induces myogenic 
differentiation. This indicates that oncRas isoform have divergent tumorigenic functions. 
Interestingly, and in contrast to ERMS precursor lesions, oncRas mutations do not influence 
growth and proliferation of full-blown tumors in Ptchdel/+ mice. This underlines that oncRas 
mutations have a different impact on different developmental stages of ERMS. However, 
irrespective of the tumor developmental stage, oncRas do not significantly modulate Hh 
signaling in murine ERMS, suggesting that the growth of the tumors depend on the latter 
pathway. 
Since oncRas mutation themselves do not drive ERMS formation but can enhance tumor 
progression of ERMS precursor lesions, it is possible that oncRAS mutations act as a 
“passenger“ mutations in ERMS, which modulate the tumor’s aggressiveness at early stages 
of tumor development. This is different from Ptch mutations that drive ERMS formation. In 
already established ERMS, Ras mutations have no or only a minor impact on tumor 
aggressiveness. However, this has to be verified e.g. by treatment of ERMS-bearing mice 
with RAS inhibitors. 
Finally, the difference of the oncRAS-mediated impact on growth of ERMS cell lines derived 
from sporadic full-blown ERMS and on full-blown Hh/Ptch-driven ERMS must be noted. At 
the first glance, it is tempting to speculate that this discrepancy is caused by the Ptch/PTCH 
mutation status of the tumors. However, the differences might also dependent on the impact 
of oncRAS/oncRas mutation on CSC subpopulations within ERMS cell lines and murine 
ERMS, which again fosters the “passenger” hypothesis. However, this must be elucidated in 
further experiment.
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